zyne_Current Folio

0001558370-18-008905.txt : 20181108 0001558370-18-008905.hdr.sgml : 20181108 20181108084030 ACCESSION NUMBER: 0001558370-18-008905 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181108 DATE AS OF CHANGE: 20181108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zynerba Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001621443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260389433 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37526 FILM NUMBER: 181168321 BUSINESS ADDRESS: STREET 1: 80 W. LANCASTER AVENUE STREET 2: SUITE 300 CITY: DEVON STATE: PA ZIP: 19333 BUSINESS PHONE: 484-581-7505 MAIL ADDRESS: STREET 1: 80 W. LANCASTER AVENUE STREET 2: SUITE 300 CITY: DEVON STATE: PA ZIP: 19333 FORMER COMPANY: FORMER CONFORMED NAME: Zynerba Pharmeceuticals, Inc. DATE OF NAME CHANGE: 20141003 10-Q 1 zyne-20180930x10q.htm 10-Q zyne_Current Folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-37526

Zynerba Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware (State or other jurisdiction of incorporation or organization)		26-0389433 (I.R.S. Employer Identification Number)

80 W. Lancaster Avenue, Suite 300 Devon, PA (Address of principal executive offices)		19333 (Zip Code)

(484) 581-7505
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐		Accelerated filer ☒
		Smaller reporting company ☐
Non-accelerated filer ☐		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 5, 2018, there were 17,626,873 shares of Common Stock, $0.001 par value per share, outstanding.

Table of Contents

TABLE OF CONTENTS


PART I—FINANCIAL INFORMATION		4

Item 1.	Consolidated Financial Statements (Unaudited)	4

	Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017 (Unaudited)	4

	Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2018 and 2017 (Unaudited)	5

	Consolidated Statement of Stockholders’ Equity for the Nine Months Ended September 30, 2018 (Unaudited)	6

	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017 (Unaudited)	7

	Notes to Unaudited Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22

Item 4.	Controls and Procedures	23

PART II—OTHER INFORMATION		23

Item 1.	Legal Proceedings	23

Item 1A.	Risk Factors	23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

Item 3.	Defaults Upon Senior Securities	23

Item 4.	Mine Safety Disclosures	23

Item 5.	Other Information	23

Item 6.	Exhibits	24

	Signatures	25

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements made in this Quarterly Report that are not statements of historical or current facts, such as those under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning.

Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct.

You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:

our estimates regarding expenses, future revenue, capital requirements and timing and availability of and the need for additional financing;

the results, cost and timing of our preclinical studies and clinical trials, including any delays to such clinical trials relating to enrollment or site initiation, as well as the number of required trials for regulatory approval and the criteria for success in such trials;

our dependence on third parties in the conduct of our preclinical studies and clinical trials;

legal and regulatory developments in the United States and foreign countries, including any actions or advice that may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials;

the difficulties and expenses associated with obtaining and maintaining regulatory approval of our product candidates, and the indication and labeling under any such approval;

our plans and ability to develop and commercialize our product candidates;

the successful development of our commercialization capabilities, including medical affairs and sales and marketing capabilities, whether alone or with potential future collaborators;

the size and growth of the potential markets for our product candidates, the rate and degree of market acceptance of our product candidates and our ability to serve those markets;

the success of competing therapies and products that are or become available;

our ability to limit our exposure under product liability lawsuits;

our ability to obtain and maintain intellectual property protection for our product candidates;

recently enacted and future legislation regarding the healthcare system, including changes to the Patient Protection and Affordable Care Act;

our ability to obtain and maintain third-party manufacturing for our product candidates on commercially reasonable terms;

delays, interruptions or failures in the manufacture and supply of our product candidates;

the performance of third parties upon which we depend, including contract research organizations, or CROs, contract manufacturing organizations, or CMO’s, contractor laboratories and independent contractors;

our ability to recruit or retain key scientific, commercial or management personnel or to retain our executive officers; and

the other risks, uncertainties and factors discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, or our 2017 Annual Report, under the caption “Item 1.A Risk Factors”.

In light of these risks and uncertainties, expected results or other anticipated events or circumstances discussed in this Form 10-Q (including the exhibits hereto) might not occur. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements (Unaudited)

ZYNERBA PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS

(UNAUDITED)


	September 30,		December 31,
	2018		2017
Assets
Current assets:
Cash and cash equivalents	$	66,177,376	$	62,510,277
Incentive and tax receivables		3,095,195		3,983,604
Prepaid expenses and other current assets		3,413,029		1,733,701
Total current assets		72,685,600		68,227,582
Property and equipment, net		248,741		164,527
Other assets		—		662,200
Total assets	$	72,934,341	$	69,054,309
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	3,553,350	$	3,355,255
Accrued expenses		5,415,742		3,915,491
Deferred grant revenue		171,975		171,975
Total current liabilities		9,141,067		7,442,721
Deferred grant revenue, long-term		—		662,000
Total liabilities		9,141,067		8,104,721
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding		—		—
Common stock, $0.001 par value; 200,000,000 shares authorized; 17,623,873 shares issued and outstanding at September 30, 2018 and 13,553,873 shares issued and outstanding at December 31, 2017		17,623		13,554
Additional paid-in capital		173,877,449		138,916,900
Accumulated deficit		(110,101,798)		(77,980,866)
Total stockholders' equity		63,793,274		60,949,588
Total liabilities and stockholders' equity	$	72,934,341	$	69,054,309

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)


	Three months ended				Nine months ended
	September 30,				September 30,
	2018		2017		2018		2017
Operating expenses:
Research and development	$	4,859,902	$	5,753,764	$	22,368,881	$	16,978,016
General and administrative		3,125,780		2,795,839		9,982,743		7,640,489
Total operating expenses		7,985,682		8,549,603		32,351,624		24,618,505
Loss from operations		(7,985,682)		(8,549,603)		(32,351,624)		(24,618,505)
Other income (expense):
Interest income		278,214		161,930		639,702		363,350
Foreign exchange (loss) gain		(99,897)		76,468		(409,010)		361,450
Total other income (expense)		178,317		238,398		230,692		724,800
Net loss	$	(7,807,365)	$	(8,311,205)	$	(32,120,932)	$	(23,893,705)

Net loss per share basic and diluted	$	(0.47)	$	(0.63)	$	(2.21)	$	(1.87)
Basic and diluted weighted average shares outstanding		16,587,353		13,098,914		14,531,272		12,743,332

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(UNAUDITED)


								Total
	Common stock			Additional		Accumulated		stockholders'
	Shares	Amount		paid-capital		deficit		equity
Balance at December 31, 2017	13,553,873	$	13,554	$	138,916,900	$	(77,980,866)	$	60,949,588
Issuance of common stock, net of issuance costs	4,062,500		4,062		29,933,443		—		29,937,505
Issuance of restricted stock	7,500		7		(7)		—		—
Stock-based compensation expense	—		—		5,027,113		—		5,027,113
Net loss	—		—		—		(32,120,932)		(32,120,932)
Balance at September 30, 2018	17,623,873	$	17,623	$	173,877,449	$	(110,101,798)	$	63,793,274

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Nine months ended September 30,
	2018		2017
Cash flows from operating activities:
Net loss	$	(32,120,932)	$	(23,893,705)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		73,195		68,368
Stock-based compensation		5,027,113		4,266,716
Changes in operating assets and liabilities:
Incentive and tax receivables		888,409		(4,013)
Prepaid expenses and other assets		(1,017,128)		(914,554)
Deferred grant revenue		(662,000)		—
Accounts payable		121,583		1,154,109
Accrued expenses		1,500,251		194,385
Net cash used in operating activities		(26,189,509)		(19,128,694)
Cash flows from investing activities:
Purchases of property and equipment		(157,409)		(91,070)
Net cash used in investing activities		(157,409)		(91,070)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of offering costs		30,014,017		54,245,579
Payment of financing costs		—		(175,011)
Proceeds from the exercise of stock options		—		434,691
Net cash provided by financing activities		30,014,017		54,505,259
Net increase in cash and cash equivalents		3,667,099		35,285,495
Cash and cash equivalents at beginning of period		62,510,277		30,965,791
Cash and cash equivalents at end of period	$	66,177,376	$	66,251,286

Supplemental disclosures of cash flow information:
Deferred financing costs included in accounts payable and accrued expenses	$	76,512	$	89,621
Changes in property and equipment acquired but not paid	$	—	$	24,286

See accompanying notes to unaudited consolidated financial statements

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(1) Nature of Business and Liquidity

Zynerba Pharmaceuticals, Inc., together with its subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Company” or “we”), is a clinical stage pharmaceutical company focused on the development of pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome and refractory epilepsies. The Company was incorporated on January 31, 2007 under the laws of the State of Delaware as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.

The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $110.1 million as of September 30, 2018. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company's primary source of liquidity has been the issuance of equity securities.

In June 2017, the Company entered into the Open Market Sales Agreement (the “Sales Agreement”) with Jefferies LLC, (“Jefferies”) pursuant to which the Company may sell, from time to time, up to $50.0 million of its common stock. During 2017, the Company sold and issued 296,594 shares of its common stock in the open market at a weighted average selling price of $10.74 per share, for gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018.

In July 2018, the Company completed a follow-on public offering, selling 4,062,500 shares of its common stock at an offering price of $8.00 per share, resulting in gross proceeds of $32.5 million. Net proceeds received after deducting underwriting discounts and commissions and offering expenses were $29.9 million.

Management believes that current cash and cash equivalents are sufficient to fund operations and capital requirements into the first half of 2020. Substantial additional financings will be needed by the Company to fund its operations, to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.

The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

(2) Summary of Significant Accounting Policies

a. Basis of Presentation

The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The interim unaudited consolidated financial statements have been prepared on the same basis as the consolidated financial statements as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Annual Report”), filed with the Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company's financial position as of September 30, 2018 its results of operations for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017. Operating results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2017 Annual Report.

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

b. Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from such estimates.

c. Incentive and Tax Receivables

The Company’s subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Subsidiary”), is incorporated in Australia. The Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, the Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by the Subsidiary in Australia. The cash refund is available to eligible companies with an annual aggregate revenue of less than $20.0 million (Australian) during the reimbursable period. The Company’s estimate of the amount of cash refund it expects to receive related to the Australian research and development tax incentive program is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, the Company’s estimate of the amount of cash refund it expects to receive in 2019 for 2018 eligible spending as part of this incentive program was $2.7 million and was recorded as a current asset. During the three months ended September 30, 2018, the Company received $3.6 million in research and development tax incentive refunds related to qualified Australian expenses incurred during the year ended December 31, 2017.

In addition, the Subsidiary incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an Australian entity, the Subsidiary is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST incurred is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, incentive and tax receivables included $0.4 million for refundable GST on expenses incurred with Australian vendors during the three months ended September 30, 2018.

d. Research and Development

Research and development costs are expensed as incurred and are primarily comprised of external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMO’s”), consultants and employee-related expenses including salaries and benefits. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Research and development expenses are recorded net of expected refunds of eligible research and development costs paid to Australian vendors pursuant to the Australian research and development tax incentive program and GST incurred on services provided by Australian vendors.

e. Net Loss Per Share

Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as restricted stock and stock options, which would result in the issuance of incremental shares of common stock. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of restricted stock and stock options would be anti-dilutive.

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The following potentially dilutive securities outstanding as of September 30, 2018 and 2017 have been excluded from the computation of diluted weighted average shares outstanding, as their effects on net loss per share for the periods presented would be anti-dilutive:


	September 30,
	2018	2017
Stock options	3,158,531	2,369,296
Unvested restricted stock	7,500	144,972
	3,166,031	2,514,268

f. Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, which requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The pronouncement is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. The Company will adopt the new leasing standards using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which provides specific guidance related to eight cash flow classification issues. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-15 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which requires changes in restricted cash and restricted cash equivalents to be explained on the statement of cash flows by including restricted cash and restricted cash equivalents in the beginning-of-period and end-of-period total cash and cash equivalents shown on the statement of cash flows. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-18 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with Accounting Standards

Codification (“ASC”) 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 — Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3 — Valuations based on unobservable inputs and models that are supported by little or no market activity.

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The following fair value hierarchy tables present information about each major category of financial assets measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017:



			Fair Value Measurement
	Carrying amount		as of September 30, 2018
	as of September 30, 2018		Level 1		Level 2		Level 3
Cash equivalents (money market accounts)	$	62,316,686	$	62,316,686	$	—	$	—
	$	62,316,686	$	62,316,686	$	—	$	—



			Fair Value Measurement
	Carrying amount		as of December 31, 2017
	as of December 31, 2017		Level 1		Level 2		Level 3
Cash equivalents (money market accounts)	$	61,133,457	$	61,133,457	$	—	$	—
Certificate of deposit (included in prepaid expenses and other current assets)		20,171		20,171		—		—
	$	61,153,628	$	61,153,628	$	—	$	—

(4) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following as of September 30, 2018 and December 31, 2017:


	September 30,		December 31,
	2018		2017
Prepaid development expenses	$	2,376,965	$	907,028
Prepaid insurance		535,722		355,838
Deferred financing costs		195,754		240,439
Other current assets		304,588		230,396
Total prepaid expenses and other current assets	$	3,413,029	$	1,733,701

(5) Property and Equipment

Property and equipment consisted of the following as of September 30, 2018 and December 31, 2017:


	Estimated
	useful life	September 30,		December 31,
	(in years)	2018		2017
Equipment	2-5	$	85,417	$	85,417
Computer equipment	3-5		30,319		30,319
Furniture and fixtures	3-5		300,407		199,016
Leasehold improvements	various		68,881		12,863
Total cost			485,024		327,615
Less accumulated depreciation			(236,283)		(163,088)
Property and equipment, net		$	248,741	$	164,527

Depreciation expense was $25,043 and $24,773 for the three months ended September 30, 2018 and 2017, respectively, and $73,195 and $68,368 for the nine months ended September 30, 2018 and 2017, respectively.

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(6) Accrued Expenses

Accrued expenses consisted of the following as of September 30, 2018 and December 31, 2017:


	September 30,		December 31,
	2018		2017
Accrued compensation	$	1,786,098	$	1,503,615
Accrued research and development		2,490,658		2,059,536
Grants payable		661,952		—
Other		477,034		352,340
Total accrued expenses	$	5,415,742	$	3,915,491

As of December 31, 2017, there was $0.7 million included in deferred grant revenue, long-term and other assets for prepaid research and development contracts related to a federal grant. During the three months ended September 30, 2018, the Company discontinued the research and development program associated with the grant and received a refund for certain prepaid research and development costs. The Company will be required to return grant monies to the grantor. As of September 30, 2018, the Company reclassified the $0.7 million deferred grant revenue to accrued expense to reflect this future payment to the grantor.

(7) Common Stock

In June 2017, the Company entered into the Sales Agreement with Jefferies pursuant to which the Company may sell, from time to time, up to $50.0 million of its common stock. As of September 30, 2018, cumulative shares sold in the open market under the Sales Agreement were 296,594 shares, resulting in gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018.

(8) Stock-Based Compensation

The Company maintains the Amended and Restated 2014 Omnibus Incentive Compensation Plan, as amended (the “2014 Plan”), which allows for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, performance units and other stock‑based awards to employees, officers, non-employee directors, consultants, and advisors. In addition, the 2014 Plan provides selected executive employees with the opportunity to receive bonus awards that are considered qualified performance‑based compensation. The 2014 Plan is subject to automatic annual increases in the number of shares authorized for issuance under the 2014 Plan on the first trading day of January each year equal to the lesser of 1.5 million shares or 10% of the number of shares of common stock outstanding on the last trading day of December of the preceding year. As of January 1, 2018, the number of shares of common stock that may be issued under the 2014 Plan was automatically increased by 1,355,387 shares, increasing the number of shares of common stock reserved for issuance under the 2014 Plan to 4,804,869 shares. As of September 30, 2018, 1,150,545 shares are available for issuance under the 2014 Plan.

Options issued under the 2014 Plan have a contractual life of 10 years and may be exercisable in cash or as otherwise determined by the board of directors. The Company has granted options to employees and non‑employee directors. Stock options granted to employees vest 25% upon the first anniversary of the grant date and the balance of unvested options vests in quarterly installments over a three-year period. Stock options granted annually to non-employee directors vest on the earlier of the one-year anniversary of the grant date, or the date of the Company’s next annual stockholders’ meeting that occurs after the grant date. The Company’s non-employee director compensation policy enables directors to receive stock options in lieu of quarterly cash payments. Any option granted to the directors in lieu of cash compensation vests in full on the date of grant.

The Company granted 83,280 performance-based stock options to certain employees in January 2018. These

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

performance options have a 10-year life and an exercise price equal to the fair value of the Company’s stock at the grant date. Vesting of these performance options is dependent on meeting certain performance conditions, which relate to the Company’s research and development progress, which were established by the Company’s board of directors. The Company’s board of directors determines if the performance conditions have been met. Stock-based compensation expense for these options is recorded when management estimates that the vesting of these options is probable based on the status of the Company’s research and development programs and other relevant factors. For the nine months ended September 30, 2018, none of the performance-based metrics were deemed probable. Any change in these estimates will result in a cumulative adjustment in the period in which the estimate is changed, so that as of the end of a period, the cumulative compensation expense recognized for an award or grant equals the amount that would be recognized on a straight-line basis as if the current estimates had been utilized since the beginning of the service period. The aggregate estimated grant date fair value of options for which the satisfaction of the related-performance conditions have not been deemed probable is $663,484.

For the nine months ended September 30, 2018 and 2017, the Company recorded stock-based compensation expense related to its stock option grants and restricted stock awards, as follows:


	Stock Option Grants				Restricted stock awards				Total
	2018		2017		2018		2017		2018			2017
Research and development	$	2,096,710	$	1,604,346	$	171,073	$	118,110	$	2,267,783	$	1,722,456
General and administrative		2,712,517		2,482,490		46,813		61,770		2,759,330		2,544,260
	$	4,809,227	$	4,086,836	$	217,886	$	179,880	$	5,027,113	$	4,266,716

The following table summarizes the stock option activity for the nine months ended September 30, 2018:


		Weighted-		Weighted-
		Average		Average	Aggregate
	Number	Exercise		Contractual	Intrinsic
	of Shares	Price		Life (in Years)	Value
Outstanding as of December 31, 2017	2,386,538	$	12.53
Granted	837,930	$	11.50
Expired	(65,937)	$	13.76
Outstanding as of September 30, 2018	3,158,531	$	12.23	7.76	$	2,290,510
Exercisable as of September 30, 2018	1,709,384	$	11.12	6.95	$	2,287,810
Vested and expected to vest as of September 30, 2018	3,114,781	$	12.22

The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 and 2017 was $7.94 and $13.08, respectively. During the nine months ended September 30, 2018, stock option grants included 6,030 stock options that were granted to certain members of the Company’s board of directors, at their election, in lieu of quarterly cash payments.

The fair values of stock options granted were calculated using the Black-Scholes option pricing model with the following weighted-average assumptions:


	Nine months ended September 30,
	2018	2017
Weighted-average risk-free interest rate	2.51%	2.11%
Expected term of options (in years)	6.13	6.13
Expected stock price volatility	78.00%	77.00%
Expected dividend yield	0%	0%

As of September 30, 2018, excluding performance-based stock options that have not been deemed probable, there was $11.1 million of unrecognized stock-based compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.44 years.

Table of Contents

ZYNERBA PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The following table summarizes the restricted stock award activity under the 2014 Plan for the nine months ended September 30, 2018:


		Weighted
		Average
		Grant Date
	Shares	Fair Value
Unvested as of December 31, 2017	108,730	$	1.65
Granted	7,500		12.99
Vested	(108,730)		1.65
Unvested as of September 30, 2018	7,500	$	12.99

As of September 30, 2018, there was $25,792 of unrecognized stock-based compensation expense related to unvested restricted stock awards, which is expected to be recognized over a weighted-average period of 0.25 years. The Company expects all 7,500 unvested restricted stock awards to vest.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited interim consolidated financial statements and related notes appearing elsewhere in this Quarterly Report and the audited consolidated financial statements and notes thereto for the year ended December 31, 2017 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our 2017 Annual Report. The following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of many factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this Quarterly Report, including those set forth under “Cautionary Note Regarding Forward-looking Statements” and “Risk Factors” in this Quarterly Report and our 2017 Annual Report.

Overview

Company Overview

We are the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, or FXS, and refractory epilepsies.

We are currently evaluating ZYN002, a patent protected transdermal cannabidiol, or CBD, gel for the treatment of FXS, developmental and epileptic encephalopathy, or DEE, and adult refractory epilepsy. In 2017, we completed three Phase 2 clinical trials for ZYN002 and two of those studies have open-label extensions that are ongoing. In April 2018, we initiated a Phase 2 clinical trial evaluating ZYN002 in DEE in children and adolescent patients, and in July 2018, we initiated what we believe will be a pivotal clinical trial evaluating ZYN002 in children and adolescents with FXS. In the second half of 2018, we plan to initiate a Phase 2b clinical trial evaluating ZYN002 for the treatment of refractory focal seizures in adults with epilepsy.

Our pipeline also included ZYN001, a pro-drug of ∆9-tetrahydrocannabinol, or THC, which we were previously evaluating for the treatment of Tourette Syndrome, or TS. In July 2018, we decided to discontinue the development of ZYN001 and focus our development efforts and investments on our development programs for ZYN002 for the treatment of FXS, DEE and refractory focal seizures in adults with epilepsy.

Cannabinoids are a class of compounds derived from Cannabis plants. The two primary cannabinoids contained in Cannabis are CBD and THC. Clinical and preclinical data suggest that CBD has positive effects on treating behavioral symptoms of FXS and epilepsy. We believe ZYN002 may potentially offer first-line therapies to patients suffering from FXS, DEE and focal seizures in adults with epilepsy.

ZYN002

ZYN002 is the first and only pharmaceutically-produced CBD formulated as a permeation-enhanced gel for transdermal delivery, and is patent protected through 2030. CBD is the primary non-psychoactive component of Cannabis. In preclinical animal studies, ZYN002’s permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. These preclinical studies suggest increased bioavailability, consistent plasma levels and the avoidance of first-pass liver metabolism of CBD when delivered transdermally. In addition, an in vitro study published in Cannabis and Cannabinoid Research in April 2016 demonstrated that CBD is degraded to THC in an acidic environment such as the stomach. We believe such degradation may lead to increased psychoactive effects if CBD is delivered orally and may be avoided with the transdermal delivery of ZYN002, which maintains CBD in a neutral pH. ZYN002, which is being developed as a clear gel with once- or twice-daily dosing, is targeting treatment of behavioral symptoms of FXS, DEE in pediatric and adolescent patients, and refractory focal seizures in adults with epilepsy. We have been granted orphan drug designation from the FDA for the use of CBD for the treatment of FXS. In our Phase 1 program, ZYN002 was demonstrated to be safe and well tolerated, provided a favorable CBD pharmacokinetic profile, and no THC was detected in plasma or urine. As of June 2018, the ZYN002 safety database across all clinical studies conducted by us includes data from 570 volunteers and patients. Across these clinical studies, ZYN002 has been well tolerated and consistent with previously reported data.

Table of Contents

In April 2018, we initiated the Phase 2 BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial, a six-month open label multi-dose clinical trial designed to evaluate the efficacy and safety of ZYN002 in children and adolescents (three to 17 years) with DEE as classified by the International League Against Epilepsy (ILAE) (Scheffer et al. 2017). Approximately 50 patients with confirmed DEE will be enrolled in the clinical trial, up to half of whom may have either Dravet or Lennox-Gastaut syndrome. Enrolled patients will receive weight-based initial doses of 125 mg BID (250 mg daily) or 250 mg BID (500 mg daily) of ZYN002 CBD gel. The primary endpoint is change in seizure frequency from baseline. We expect to report top line results from the BELIEVE 1 trial in 2019.

In July 2018, we initiated the CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X) clinical trial, a multi-national randomized, double-blind, placebo-controlled, 14-week study that will assess the efficacy and safety of ZYN002 in children and adolescents ages three to 17 years who have full mutation of the FMR1 gene. Approximately 200 male and female patients with FXS will be enrolled at approximately 20 clinical sites in the United States, Australia, and New Zealand. The study is being conducted in the United States under an Investigational New Drug (IND) application opened with the FDA. Patients will be randomized 1:1 to either trial drug or placebo. Randomization will be stratified by gender, weight, and investigator geographic region. The primary endpoint is the change from baseline to the end of the treatment period in the Aberrant Behavior Checklist-Community FXS Specific (ABC-CFXS) Social Avoidance subscale. Key secondary endpoints are the change from baseline to the end of the treatment period in the ABC-CFXS Irritability subscale score, the ABC-CFXS Socially Unresponsive/Lethargic subscale score, and improvement in Clinical Global Impression - Improvement (CGI-I) at the end of the treatment period. Based on discussions with the FDA, we will anchor the CGI-I scale to behavioral symptoms of FXS. Consistent with recent guidance from the FDA on capturing the voice of the patient in drug development, additional qualitative data on the clinical relevance of various FXS behaviors to caregivers and patients will be collected. If we obtain positive results from this trial, we plan to request a meeting with the FDA to determine the acceptability of these data as the basis for an NDA filing. We expect to report top line results from the CONNECT-FX trial in the second half of 2019.

ZYN002 Clinical Development Timelines

Our key development programs and expected timelines for the development of ZYN002 are shown in the chart below:

cid:image001.jpg@01D46A16.025D9820

We have never been profitable and have incurred net losses since inception. Our net losses were $32.1 million and $23.9 million for the nine months ended September 30, 2018 and 2017, respectively. As of September 30, 2018, our

Table of Contents

accumulated deficit was $110.1 million. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.

Financial Operations Overview

The following discussion sets forth certain components of our consolidated statements of operations as well as factors that impact those items.

Revenue

Historically, our revenue consisted of state and federal research grants and fees received from research services for third-party product development. We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured.

Research and Development Expenses

Our research and development expenses relating to our product candidates consist of the following:

expenses associated with preclinical development and clinical trials;

personnel-related expenses, such as salaries, benefits, travel and other related expenses, including stock-based compensation;

payments to third-party CROs, CMO’s, contractor laboratories and independent contractors; and

depreciation, maintenance and other facility-related expenses.

We expense all research and development costs as incurred. Clinical development expenses for our product candidates are a significant component of our current research and development expenses. Expenses associated with clinical trials will increase as our clinical trials progress. Product candidates in later stage clinical development generally have higher research and development expenses than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We track and record information regarding external research and development expenses for each grant, study or trial that we conduct. We use third-party CROs, CMO’s, contractor laboratories and independent contractors in preclinical studies and clinical trials. We recognize the expenses associated with third parties performing these services for us in our preclinical studies and clinical trials based on the percentage of each study completed at the end of each reporting period.

For the nine months ended September 30, 2018 and 2017, we recognized research and development expenses of $22.4 million and $17.0 million, respectively, which were net of $2.8 million and $3.3 million, respectively, associated with the Australian research and development tax incentive program. As part of this program, we are eligible to receive a cash refund from the Australian Taxation Office for a percentage of our research and development costs expended by Zynerba Pharmaceuticals Pty Ltd, our Australian subsidiary.

We expect research and development expenses in future years to continue to increase as we continue our clinical trials and begin new phases for each of our product candidates. These expenditures are subject to numerous uncertainties regarding timing and cost to completion. Completion of our preclinical development and clinical trials may take several years or more and the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:

the number of sites included in the clinical trials;

the length of time required to enroll suitable patients;

the size of patient populations participating in the clinical trials;

Table of Contents

the duration of patient follow-ups;

the development stage of the product candidates; and

the efficacy and safety profile of the product candidates.

Due to the early stages of our research and development, we are unable to determine the duration or completion costs of our development of our product candidates. As a result of the difficulties of forecasting research and development costs of our product candidates as well as the other uncertainties discussed above, we are unable to determine when and to what extent we will generate revenue from the commercialization and sale of an approved product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our executive, finance, legal, human resource, investor relations and commercial functions. Our general and administrative expenses also include facility and related costs not included in research and development expenses, professional fees for legal services, including patent-related expenses, consulting, tax and accounting services, insurance, market research and general corporate expenses. We expect that our general and administrative expenses will increase for the next several years as we increase our headcount with the continued development and potential commercialization of our product candidates.

Interest Income

Interest income primarily consists of interest earned on balances maintained in our money market bank account.

Foreign Exchange (Loss) Gain

Foreign exchange (loss) gain relates to the effect of exchange rates on transactions incurred by our Australian subsidiary.

Critical Accounting Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reported period. In accordance with GAAP, we base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We define our critical accounting policies as those that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations as well as the specific manner in which we apply those principles. Critical accounting estimates and the accounting policies critical to the process of making significant judgments and estimates in the preparation of our consolidated financial statements are discussed in our 2017 Annual Report under Part I, Item 7, “Critical Accounting Policies and Use of Estimates”. During the nine months ended September 30, 2018, there have been no material changes to the critical accounting estimates or critical accounting policies discussed in our 2017 Annual Report.

Results of Operations

Comparison of the Three Months Ended September 30, 2018 and 2017

Research and Development Expenses

Research and development expenses decreased by $0.9 million, or 16%, to $4.9 million for the three months ended

Table of Contents

September 30, 2018 from $5.8 million for the three months ended September 30, 2017. The decrease was primarily related to manufacturing costs, predominantly due to the discontinuation of the ZYN001 program, and a decrease in non-clinical trial costs related to our ZYN002 program; these decreases were partially offset by increased personnel costs, including stock-based compensation expense.

General and Administrative Expenses

General and administrative expenses increased by $0.3 million, or 12%, to $3.1 million for the three months ended September 30, 2018 from $2.8 million for the three months ended September 30, 2017. The increase was primarily related to increases in expenses associated with personnel costs and an increase in pre-commercialization expense for our product candidates.

Other Income (Expense)

During the three months ended September 30, 2018 and 2017, we recognized $0.3 million and $0.2 million, respectively, in interest income. The increase in interest income was primarily related to a higher average interest rate earned on our investments. During the three months ended September 30, 2018 and 2017, we recognized a foreign currency loss of $0.1 million and a foreign currency gain of $0.1 million, respectively. Foreign currency gains and losses are due primarily to the remeasurement of our Australian subsidiary’s assets and liabilities that are denominated in the local currency to the subsidiary’s functional currency, which is the U.S. dollar.

Comparison of the Nine Months Ended Months Ended September 30, 2018 and 2017

Research and Development Expenses

Research and development expenses increased by $5.4 million, or 32%, to $22.4 million for the nine months ended September 30, 2018 from $17.0 million for the nine months ended September 30, 2017. The increase was primarily related to increased manufacturing and clinical trial costs related to our product candidates; and increased personnel costs, including stock-based compensation expense.

General and Administrative Expenses

General and administrative expenses increased by $2.3 million, or 31%, to $10.0 million for the nine months ended September 30, 2018 from $7.6 million for the nine months ended September 30, 2017. The increase was primarily related to increases in expenses associated with personnel costs, including stock-based compensation expense, and an increase in pre-commercialization expense for our product candidates.

Other Income (Expense)

During the nine months ended September 30, 2018 and 2017, we recognized $0.6 million and $0.4 million, respectively, in interest income. The increase in interest income was primarily related to a higher average interest rate earned on our investments. During the nine months ended September 30, 2018 and 2017, we recognized a foreign currency loss of $0.4 million and a foreign currency gain of $0.4 million, respectively. Foreign currency gains and losses are due primarily to the remeasurement of our Australian subsidiary’s assets and liabilities that are denominated in the local currency to the subsidiary’s functional currency, which is the U.S. dollar.

Liquidity and Capital Resources

Since our inception in 2007, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of equity securities (most notably our IPO in 2015, sales under our “at-the-market” offering in 2016 and 2017, and our follow-on public offerings in the first quarter of 2017 and the third quarter of 2018; the 2017 and 2018 transactions are described below under Equity Financings) and convertible promissory notes, state and federal grants and research services.

To date, we have not generated any revenue from the sale of products, and we do not anticipate generating any revenue from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from

Table of Contents

operations since inception. As of September 30, 2018, our principal source of liquidity was our cash and cash equivalents of $66.2 million. Our working capital was $63.5 million as of September 30, 2018.

Management believes that current cash and cash equivalents are sufficient to fund operations and capital requirements into the first half of 2020. Substantial additional financings will be needed to fund our operations and to complete clinical development of and to commercially develop our product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.

Equity Financings

In the first quarter of 2017, we completed a follow-on public offering, selling 3,220,000 shares of our common stock at an offering price of $18.00 per share, resulting in gross proceeds of $58.0 million. Net proceeds received after deducting underwriting and commissions and offering expenses were $54.2 million.

In June 2017, we entered into an Open Market Sales Agreement, or Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which we may sell, from time to time, up to $50 million of our common stock. During 2017, we sold and issued 296,594 shares of our common stock in the open market at a weighted average selling price of $10.74 per share, for gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018.

In July 2018, we completed a follow-on public offering, selling 4,062,500 shares of our common stock at an offering price of $8.00 per share, resulting in gross proceeds of $32.5 million. Net proceeds received after deducting underwriting discounts and commissions and offering expenses were $29.9 million.

Debt

We had no debt outstanding as of September 30, 2018 or December 31, 2017.

Future Capital Requirements

During the nine months ended September 30, 2018, net cash used in operating activities was $26.2 million, and our accumulated deficit as of September 30, 2018 was $110.1 million. Our expectations regarding future cash requirements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make in the future. To the extent that we enter into any of those types of transactions, we may need to raise substantial additional capital.

We expect to continue to incur substantial additional operating losses for at least the next several years as we continue to develop our product candidates and seek marketing approval and, subject to obtaining such approval, the eventual commercialization of our product candidates. If we obtain marketing approval for either of our product candidates, we will incur significant sales, marketing and manufacturing expenses. In addition, we expect to incur additional expenses to add operational, financial and information systems and personnel, including personnel to support our planned product commercialization efforts. We also expect to incur significant costs to comply with corporate governance, internal controls and similar requirements associated with operating as a public reporting company.

Our future use of operating cash and capital requirements will depend on many forward-looking factors, including the following:

the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates;

the clinical development plans we establish for these product candidates;

the number and characteristics of product candidates that we develop or may in-license;

the terms of any collaboration agreements we may choose to execute;

the outcome, timing and cost of meeting regulatory requirements established by the United States Drug

Table of Contents

Enforcement Agency, the FDA, the European Medicines Agency or other comparable foreign regulatory authorities;

the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;

the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;

costs and timing of the implementation of commercial scale manufacturing activities; and

the cost of establishing, or outsourcing, sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.

To the extent that our capital resources are insufficient to meet our future operating and capital requirements, we will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.

If we raise additional funds by issuing equity securities, our stockholders will experience dilution.

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities for the nine months ended September 30, 2018 and 2017.


	Nine Months Ended September 30,
	2018		2017
Statement of Cash Flows Data:
Total net cash (used in) provided by:
Operating activities	$	(26,189,509)	$	(19,128,694)
Investing activities		(157,409)		(91,070)
Financing activities		30,014,017		54,505,259
Net increase in cash and cash equivalents	$	3,667,099	$	35,285,495

Operating Activities

For the nine months ended September 30, 2018, cash used in operating activities was $26.2 million compared to $19.1 million for the nine months ended September 30, 2017. The increase from the comparable 2017 period was primarily the result of increased research and development activities related to the clinical trials of our product candidates, and an increase in personnel costs.

We expect cash used in operating activities to continue to increase throughout the remainder 2018 as compared to 2017 due to an expected increase in our operating losses associated with ongoing development of our product candidates.

Investing Activities

For the nine months ended September 30, 2018 and 2017 cash used in investing activities represented the cost of computer equipment, furniture and fixtures and leasehold improvements associated with our corporate headquarters.

Financing Activities

Cash provided by financing activities for the nine months ended September 30, 2018 primarily consisted of $29.9 million in net proceeds from sales of our shares of common stock under a follow-on public offering. Cash provided by financing activities for the nine months ended September 30, 2017 consisted of $54.2 million in proceeds from sales of our shares of common stock under a follow-on public offering and $0.4 million in proceeds from the exercise of employee stock options.

Table of Contents

Contractual Obligations

Our material contractual obligations consist of commitments under operating lease agreements and the related amounts of our obligations as of December 31, 2017 were disclosed in “Contractual Obligations” in Part I, Item 7 in our 2017 Annual Report. Since December 31, 2017, no material changes in our contractual obligations have occurred.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, except for operating leases, or relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.

Recent Accounting Pronouncements

For descriptions of recently issued accounting pronouncements, see “Note 2 – Summary of Significant Accounting Policies – Recent Accounting Pronouncements” of our Notes to Unaudited Consolidated Financial Statements included above in Part I of this report.

JOBS Act

We are an “emerging growth company” as defined under the Jumpstart Our Business Startups Act of 2012, or JOBS Act. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." As an "emerging growth company," we have elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision not to take advantage of the extended transition period is irrevocable.

Subject to certain conditions set forth in the JOBS Act, as an "emerging growth company," we are not required to, among other things, (i) provide an auditor's attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation. These exemptions will apply until December 31, 2020 or until we no longer meet the requirements for being an “emerging growth company,” whichever occurs first.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to various market risks, which may result in potential losses arising from adverse changes in market rates, such as interest rates and foreign exchange rates. We do not enter into derivative instruments or other financial instruments for trading or speculative purposes nor do we engage in any hedging activities. As of September 30, 2018, we had cash and cash equivalents of $66.2 million consisting primarily of cash and money market account balances. Because of the short-term maturities of our cash and cash equivalents, we do not believe that an immediate 10% increase in interest rates would have any significant impact on the realized value of our investments. Accordingly, we do not believe we are exposed to material market risk with respect to our cash and cash equivalents.

We have engaged third parties to manufacture our product candidates in Australia, Canada and Europe and to conduct clinical trials for our product candidates in Australia and New Zealand. Manufacturing and research costs related to these operations are paid for in a combination of U.S. dollars and local currencies, limiting our foreign currency exchange rate risk. Accordingly, we do not believe our foreign currency exchange rate risk is significant due to the limited extent of our operations in foreign currencies; however, if we conduct clinical trials and seek to manufacture a more significant portion of our product candidates outside of the United States in the future, we could incur significant foreign currency exchange rate risk.

Table of Contents

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2018. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms, promulgated by the Securities and Exchange Commission. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2018, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the nine months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently a party to any legal proceedings.

Item 1A. Risk Factors.

You should carefully consider the risk factors described in our December 31, 2017 Annual Report, under the caption “Item 1.A “Risk Factors”. There have been no material changes to the risk factors disclosed in our 2017 Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

None.

Purchase of Equity Securities

We did not purchase any of our registered equity securities during the period covered by this Quarterly Report on Form 10-Q.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

Not applicable

Table of Contents

Item 6. Exhibits.

The following exhibits are being filed herewith:

E
		EXHIBIT INDEX
	Exhibit No.	Exhibit
	31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
	31.2	Certification of Chief Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
	32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
	32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
	101 INS	XBRL Instance Document (filed herewith).
	101 SCH	XBRL Taxonomy Extension Schema Document (filed herewith).
	101 CAL	XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith).
	101 DEF	XBRL Taxonomy Extension Definition Linkbase Document (filed herewith).
	101 LAB	XBRL Taxonomy Extension Label Linkbase Document (filed herewith).
	101 PRE	XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith).

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	ZYNERBA PHARMACEUTICALS, INC.

Date: November 8, 2018	By:	/s/ ARMANDO ANIDO
		Armando Anido
		Chief Executive Officer
		(Principal executive officer)

Date: November 8, 2018	By:	/s/ JAMES E. FICKENSCHER
		James E. Fickenscher
		Chief Financial Officer
		(Principal financial and accounting officer)

EX-31.1 2 zyne-20180930ex3113f5d24.htm EX-31.1 zyne_Ex31_1

Exhibit 31.1

CERTIFICATION

I, Armando Anido, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zynerba Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By: /s/ Armando Anido

Name: Armando Anido

Title: Chairman and Chief Executive Officer

Dated: November 8, 2018

EX-31.2 3 zyne-20180930ex312c1b721.htm EX-31.2 zyne_Ex31_2

Exhibit 31.2

CERTIFICATION

I, James E. Fickenscher, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zynerba Pharmaceuticals, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By: /s/ James E. Fickenscher

Name: James E. Fickenscher

Title: Chief Financial Officer

Dated: November 8, 2018

EX-32.1 4 zyne-20180930ex321b8b198.htm EX-32.1 zyne_Ex32_1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Zynerba Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Armando Anido, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Armando Anido

Armando Anido

Chairman and Chief Executive Officer

Dated: November 8, 2018

EX-32.2 5 zyne-20180930ex3228589f4.htm EX-32.2 zyne_Ex32_2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Zynerba Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James E. Fickenscher, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James E. Fickenscher

James E. Fickenscher

Chief Financial Officer

Dated: November 8, 2018

GRAPHIC 6 zyne20180930x10q001.jpg GRAPHIC begin 644 zyne20180930x10q001.jpg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�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end EX-101.INS 7 zyne-20180930.xml EX-101.INS 0001621443 zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-01-01 0001621443 us-gaap:AustralianTaxationOfficeMember 2018-07-01 2018-09-30 0001621443 zyne:OpenMarketOfferingMember 2017-06-30 0001621443 zyne:IncentiveAndTaxReceivablesCurrentCaptionMember us-gaap:AustralianTaxationOfficeMember 2018-09-30 0001621443 us-gaap:AustralianTaxationOfficeMember 2018-01-01 2018-09-30 0001621443 zyne:OpenMarketOfferingMember 2018-01-01 2018-09-30 0001621443 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001621443 us-gaap:RetainedEarningsMember 2018-09-30 0001621443 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001621443 us-gaap:RetainedEarningsMember 2017-12-31 0001621443 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001621443 us-gaap:CommonStockMember 2018-09-30 0001621443 us-gaap:CommonStockMember 2017-12-31 0001621443 zyne:FollowOnPublicOfferingMember 2018-07-31 0001621443 us-gaap:PerformanceSharesMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-12-31 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember us-gaap:DirectorMember 2018-01-01 2018-09-30 0001621443 zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-09-30 0001621443 zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 0001621443 zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-01-01 0001621443 us-gaap:PerformanceSharesMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-01-31 0001621443 us-gaap:RestrictedStockMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-12-31 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember us-gaap:MaximumMember us-gaap:DirectorMember 2018-01-01 2018-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember zyne:EmployeesMember 2018-01-01 2018-09-30 0001621443 us-gaap:LeaseholdImprovementsMember 2018-09-30 0001621443 us-gaap:FurnitureAndFixturesMember 2018-09-30 0001621443 us-gaap:EquipmentMember 2018-09-30 0001621443 us-gaap:ComputerEquipmentMember 2018-09-30 0001621443 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001621443 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001621443 us-gaap:EquipmentMember 2017-12-31 0001621443 us-gaap:ComputerEquipmentMember 2017-12-31 0001621443 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2018-01-01 2018-09-30 0001621443 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2018-01-01 2018-09-30 0001621443 us-gaap:EquipmentMember us-gaap:MinimumMember 2018-01-01 2018-09-30 0001621443 us-gaap:EquipmentMember us-gaap:MaximumMember 2018-01-01 2018-09-30 0001621443 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2018-01-01 2018-09-30 0001621443 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2018-01-01 2018-09-30 0001621443 us-gaap:LeaseholdImprovementsMember 2018-01-01 2018-09-30 0001621443 zyne:FollowOnPublicOfferingMember 2018-07-01 2018-07-31 0001621443 zyne:OpenMarketOfferingMember 2017-06-01 2018-09-30 0001621443 zyne:OpenMarketOfferingMember 2017-01-01 2017-12-31 0001621443 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-09-30 0001621443 us-gaap:RestrictedStockMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-09-30 0001621443 2018-07-01 2018-09-30 0001621443 2017-07-01 2017-09-30 0001621443 2017-09-30 0001621443 2016-12-31 0001621443 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001621443 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0001621443 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001621443 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember 2018-01-01 2018-09-30 0001621443 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember 2017-01-01 2017-09-30 0001621443 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001621443 2017-01-01 2017-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember us-gaap:ResearchAndDevelopmentExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember us-gaap:GeneralAndAdministrativeExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 us-gaap:RestrictedStockMember us-gaap:ResearchAndDevelopmentExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 us-gaap:RestrictedStockMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 us-gaap:ResearchAndDevelopmentExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 us-gaap:GeneralAndAdministrativeExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2018-01-01 2018-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember us-gaap:ResearchAndDevelopmentExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember us-gaap:GeneralAndAdministrativeExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 us-gaap:RestrictedStockMember us-gaap:ResearchAndDevelopmentExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 zyne:EmployeeAndNonemployeeStockOptionsMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 us-gaap:RestrictedStockMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 us-gaap:ResearchAndDevelopmentExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 us-gaap:GeneralAndAdministrativeExpenseMember zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 zyne:AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember 2017-01-01 2017-09-30 0001621443 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001621443 2018-09-30 0001621443 2017-12-31 0001621443 2018-11-05 0001621443 2018-01-01 2018-09-30 iso4217:AUD xbrli:pure iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 Q3 2018 2018-09-30 10-Q 0001621443 17626873 Yes Accelerated Filer Zynerba Pharmaceuticals, Inc. 3355255 3553350 3915491 5415742 1503615 1786098 163088 236283 138916900 173877449 5027113 5027113 4266716 2544260 1722456 179880 4086836 61770 118110 2482490 1604346 5027113 2759330 2267783 217886 4809227 46813 171073 2712517 2096710 2514268 144972 2369296 3166031 7500 3158531 69054309 72934341 68227582 72685600 61153628 61153628 62316686 62316686 <div> <div>   a. Basis of Presentation   The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The interim unaudited consolidated financial statements have been prepared on the same basis as the consolidated financial statements as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Annual Report”), filed with the Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company's financial position as of September 30, 2018 its results of operations for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017. Operating results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2017 Annual Report.   <div /></div> </div> 62510277 66177376 61133457 61133457 62316686 62316686 30965791 66251286 62510277 66177376 35285495 3667099 0.001 0.001 200000000 200000000 13553873 17623873 13553873 17623873 13554 17623 171975 171975 662000 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.74%;"> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid development expenses </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,376,965 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 907,028 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid insurance </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 535,722 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 355,838 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Deferred financing costs </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 195,754 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 240,439 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other current assets </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 304,588 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 230,396 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total prepaid expenses and other current assets </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,413,029 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,733,701 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> 240439 195754 68368 24773 73195 25043 <div> <div> (8) Stock-Based Compensation   The Company maintains the Amended and Restated 2014 Omnibus Incentive Compensation Plan, as amended (the “2014 Plan”), which allows for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, performance units and other stock‑based awards to employees, officers, non-employee directors, consultants, and advisors. In addition, the 2014 Plan provides selected executive employees with the opportunity to receive bonus awards that are considered qualified performance‑based compensation. The 2014 Plan is subject to automatic annual increases in the number of shares authorized for issuance under the 2014 Plan on the first trading day of January each year equal to the lesser of 1.5 million shares or 10% of the number of shares of common stock outstanding on the last trading day of December of the preceding year. As of January 1, 2018, the number of shares of common stock that may be issued under the 2014 Plan was automatically increased by 1,355,387 shares, increasing the number of shares of common stock reserved for issuance under the 2014 Plan to 4,804,869 shares. As of September 30, 2018, 1,150,545 shares are available for issuance under the 2014 Plan.   Options issued under the 2014 Plan have a contractual life of 10 years and may be exercisable in cash or as otherwise determined by the board of directors. The Company has granted options to employees and non‑employee directors. Stock options granted to employees vest 25% upon the first anniversary of the grant date and the balance of unvested options vests in quarterly installments over a three-year period. Stock options granted annually to non-employee directors vest on the earlier of the one-year anniversary of the grant date, or the date of the Company’s next annual stockholders’ meeting that occurs after the grant date. The Company’s non-employee director compensation policy enables directors to receive stock options in lieu of quarterly cash payments. Any option granted to the directors in lieu of cash compensation vests in full on the date of grant.   The Company granted 83,280 performance-based stock options to certain employees in January 2018. These performance options have a 10-year life and an exercise price equal to the fair value of the Company’s stock at the grant date. Vesting of these performance options is dependent on meeting certain performance conditions, which relate to the Company’s research and development progress, which were established by the Company’s board of directors. The Company’s board of directors determines if the performance conditions have been met. Stock-based compensation expense for these options is recorded when management estimates that the vesting of these options is probable based on the status of the Company’s research and development programs and other relevant factors. For the nine months ended September 30, 2018,  none of the performance-based metrics were deemed probable. Any change in these estimates will result in a cumulative adjustment in the period in which the estimate is changed, so that as of the end of a period, the cumulative compensation expense recognized for an award or grant equals the amount that would be recognized on a straight-line basis as if the current estimates had been utilized since the beginning of the service period. The aggregate estimated grant date fair value of options for which the satisfaction of the related-performance conditions have not been deemed probable is $663,484.   For the nine months ended September 30, 2018 and 2017, the Company recorded stock-based compensation expense related to its stock option grants and restricted stock awards, as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Option Grants </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Restricted stock awards </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,096,710 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,604,346 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 171,073 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 118,110 </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,267,783 </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,722,456 </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,712,517 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">     </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,482,490 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46,813 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61,770 </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,759,330 </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,544,260 </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,809,227 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,086,836 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 217,886 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,880 </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,027,113 </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,266,716 </td> </tr> </table></div>   The following table summarizes the stock option activity for the nine months ended September 30, 2018:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 90.00%;"> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Shares </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Life (in Years) </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:11.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of December 31, 2017 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,386,538 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12.53 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 837,930 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11.50 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expired </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (65,937) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13.76 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding as of September 30, 2018 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,158,531 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.23 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.76 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,290,510 </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable as of September 30, 2018 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,709,384 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.12 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.95 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,287,810 </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and expected to vest as of September 30, 2018 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,114,781 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.22 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 and 2017 was $7.94 and $13.08, respectively. During the nine months ended September 30, 2018, stock option grants included 6,030 stock options that were granted to certain members of the Company’s board of directors, at their election, in lieu of quarterly cash payments.   The fair values of stock options granted were calculated using the Black-Scholes option pricing model with the following weighted-average assumptions:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30, </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average risk-free interest rate </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.51% </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.11% </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected term of options (in years) </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.13 </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.13 </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected stock price volatility </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78.00% </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77.00% </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0% </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0% </td> </tr> </table></div>   As of September 30, 2018,  excluding performance-based stock options that have not been deemed probable, there was $11.1 million of unrecognized stock-based compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.44 years. The following table summarizes the restricted stock award activity under the 2014 Plan for the nine months ended September 30, 2018:     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 85.00%;"> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Grant Date </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested as of December 31, 2017 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 108,730 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.99 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (108,730) </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested as of September 30, 2018 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.99 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of September 30, 2018, there was $25,792 of unrecognized stock-based compensation expense related to unvested restricted stock awards, which is expected to be recognized over a weighted-average period of 0.25 years. The Company expects all 7,500 unvested restricted stock awards to vest. <div /></div> </div> -1.87 -0.63 -2.21 -0.47 <div> <div> e. Net Loss Per Share   Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as restricted stock and stock options, which would result in the issuance of incremental shares of common stock. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of restricted stock and stock options would be anti-dilutive. The following potentially dilutive securities outstanding as of September 30, 2018 and 2017 have been excluded from the computation of diluted weighted average shares outstanding, as their effects on net loss per share for the periods presented would be anti-dilutive: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:25.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,158,531 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,369,296 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested restricted stock </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 144,972 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,166,031 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,514,268 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> P3M P2Y5M9D 25792 11100000 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurement </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:21.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Carrying amount </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of September 30, 2018 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:21.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of September 30, 2018 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents (money market accounts) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 62,316,686 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 62,316,686 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,316,686 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,316,686 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurement </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Carrying amount </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of December 31, 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of December 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents (money market accounts) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,133,457 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,133,457 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Certificate of deposit (included in prepaid expenses and other current assets) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20,171 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20,171 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,153,628 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,153,628 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> <div> <div> (3) Fair Value Measurements   The Company measures certain assets and liabilities at fair value in accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:   Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.   Level 2 — Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.   Level 3 — Valuations based on unobservable inputs and models that are supported by little or no market activity.   The following fair value hierarchy tables present information about each major category of financial assets measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurement </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:21.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Carrying amount </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of September 30, 2018 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:21.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of September 30, 2018 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents (money market accounts) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 62,316,686 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 62,316,686 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,316,686 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,316,686 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurement </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Carrying amount </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of December 31, 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of December 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents (money market accounts) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,133,457 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,133,457 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Certificate of deposit (included in prepaid expenses and other current assets) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20,171 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20,171 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,153,628 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 61,153,628 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> 361450 76468 -409010 -99897 7640489 2795839 9982743 3125780 1154109 121583 194385 1500251 914554 1017128 363350 161930 639702 278214 8104721 9141067 69054309 72934341 7442721 9141067 <div> <div> (1) Nature of Business and Liquidity<a name="Notes"></a>   Zynerba Pharmaceuticals, Inc., together with its subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Company” or “we”), is a clinical stage pharmaceutical company focused on the development of pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome and refractory epilepsies. The Company was incorporated on January 31, 2007 under the laws of the State of Delaware as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.   The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $110.1 million as of September 30, 2018. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company's primary source of liquidity has been the issuance of equity securities.   In June 2017, the Company entered into the Open Market Sales Agreement (the “Sales Agreement”) with Jefferies LLC, (“Jefferies”) pursuant to which the Company may sell, from time to time, up to $50.0 million of its common stock. During 2017, the Company sold and issued 296,594 shares of its common stock in the open market at a weighted average selling price of $10.74 per share, for gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018.   In July 2018, the Company completed a follow-on public offering, selling 4,062,500 shares of its common stock at an offering price of $8.00 per share, resulting in gross proceeds of $32.5 million. Net proceeds received after deducting underwriting discounts and commissions and offering expenses were $29.9 million.    Management believes that current cash and cash equivalents are sufficient to fund operations and capital requirements into the first half of 2020. Substantial additional financings will be needed by the Company to fund its operations, to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.   The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. <div /></div> </div> 54505259 30014017 -91070 -157409 -19128694 -26189509 -32120932 -32120932 -23893705 -8311205 -32120932 -7807365 <div> <div> f. Recent Accounting Pronouncements   In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, which requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The pronouncement is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. The Company will adopt the new leasing standards using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019.   In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which provides specific guidance related to eight cash flow classification issues. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-15 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.   In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which requires changes in restricted cash and restricted cash equivalents to be explained on the statement of cash flows by including restricted cash and restricted cash equivalents in the beginning-of-period and end-of-period total cash and cash equivalents shown on the statement of cash flows. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-18 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.  <div /></div> </div> 724800 238398 230692 178317 24618505 8549603 32351624 7985682 -24618505 -8549603 -32351624 -7985682 352340 477034 230396 304588 662200 <div> <div>   (4) Prepaid Expenses and Other Current Assets   Prepaid expenses and other current assets consisted of the following as of September 30, 2018 and December 31, 2017:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.74%;"> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid development expenses </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,376,965 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 907,028 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid insurance </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 535,722 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 355,838 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Deferred financing costs </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 195,754 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 240,439 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other current assets </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 304,588 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 230,396 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total prepaid expenses and other current assets </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,413,029 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,733,701 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> 175011 91070 157409 0.001 0.001 10000000 10000000 0 0 0 0 1733701 3413029 355838 535722 3200000 3200000 32500000 434691 -23893705 -32120932 <div> <div> (5) Property and Equipment   Property and equipment consisted of the following as of September 30, 2018 and December 31, 2017:     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Estimated </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> useful life </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Equipment </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2-5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 85,417 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 85,417 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Computer equipment </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3-5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 30,319 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 30,319 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Furniture and fixtures </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3-5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 300,407 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 199,016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> various </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,881 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,863 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cost </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 485,024 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 327,615 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less accumulated depreciation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (236,283) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (163,088) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Property and equipment, net </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 248,741 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 164,527 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Depreciation expense was $25,043 and $24,773 for the three months ended September 30, 2018 and 2017, respectively, and $73,195 and $68,368 for the nine months ended September 30, 2018 and 2017, respectively.     <div /></div> </div> various P5Y P3Y P5Y P2Y P5Y P3Y 327615 30319 85417 199016 12863 485024 30319 85417 300407 68881 164527 248741 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Estimated </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> useful life </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Equipment </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2-5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 85,417 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 85,417 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Computer equipment </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3-5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 30,319 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 30,319 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Furniture and fixtures </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3-5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 300,407 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 199,016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> various </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,881 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,863 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cost </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 485,024 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 327,615 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less accumulated depreciation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (236,283) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (163,088) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Property and equipment, net </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 248,741 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 164,527 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> 16978016 5753764 22368881 4859902 <div> <div> d. Research and Development   Research and development costs are expensed as incurred and are primarily comprised of external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMO’s”), consultants and employee-related expenses including salaries and benefits. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Research and development expenses are recorded net of expected refunds of eligible research and development costs paid to Australian vendors pursuant to the Australian research and development tax incentive program and GST incurred on services provided by Australian vendors. <div /></div> </div> -77980866 -110101798 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,786,098 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,503,615 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,490,658 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,059,536 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Grants payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 661,952 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 477,034 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 352,340 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total accrued expenses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,415,742 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,915,491 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> <div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:25.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,158,531 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,369,296 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested restricted stock </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 144,972 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,166,031 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,514,268 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Option Grants </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Restricted stock awards </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,096,710 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,604,346 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 171,073 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 118,110 </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,267,783 </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,722,456 </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,712,517 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">     </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,482,490 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46,813 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61,770 </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,759,330 </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,544,260 </td> </tr> <tr> <td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,809,227 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,086,836 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 217,886 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,880 </td> <td valign="bottom" style="width:05.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,027,113 </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,266,716 </td> </tr> </table></div>   <div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 85.00%;"> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Grant Date </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested as of December 31, 2017 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 108,730 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.99 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (108,730) </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested as of September 30, 2018 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.99 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> <div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 90.00%;"> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of Shares </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Life (in Years) </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:11.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of December 31, 2017 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,386,538 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12.53 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 837,930 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11.50 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expired </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (65,937) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13.76 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding as of September 30, 2018 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,158,531 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.23 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.76 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,290,510 </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable as of September 30, 2018 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,709,384 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.12 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.95 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,287,810 </td> </tr> <tr> <td valign="bottom" style="width:51.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and expected to vest as of September 30, 2018 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,114,781 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.22 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> <div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30, </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average risk-free interest rate </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.51% </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.11% </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected term of options (in years) </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.13 </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.13 </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected stock price volatility </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78.00% </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77.00% </td> </tr> <tr> <td valign="bottom" style="width:69.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0% </td> <td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0% </td> </tr> </table></div>   <div /></div> </div> 4266716 5027113 P3Y P1Y 0.25 7500 12.99 108730 7500 1.65 12.99 108730 1.65 P10Y P10Y 0.0000 0.0000 P6Y1M17D P6Y1M17D 0.7700 0.7800 0.0211 0.0251 1355387 4804869 1150545 2287810 1709384 11.12 65937 83280 837930 6030 13.08 7.94 2290510 2386538 3158531 12.53 12.23 P7Y9M4D P6Y11M12D 3114781 12.22 0 13.76 11.50 8.00 13553873 17623873 <div> <div> (2) Summary of Significant Accounting Policies   a. Basis of Presentation   The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The interim unaudited consolidated financial statements have been prepared on the same basis as the consolidated financial statements as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Annual Report”), filed with the Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company's financial position as of September 30, 2018 its results of operations for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017. Operating results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2017 Annual Report.   b. Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from such estimates.   c. Incentive and Tax Receivables   The Company’s subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Subsidiary”), is incorporated in Australia. The Subsidiary is eligible to participate in an Australian research and development tax incentive program.  As part of this program, the Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by the Subsidiary in Australia. The cash refund is available to eligible companies with an annual aggregate revenue of less than $20.0 million (Australian) during the reimbursable period. The Company’s estimate of the amount of cash refund it expects to receive related to the Australian research and development tax incentive program is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, the Company’s estimate of the amount of cash refund it expects to receive in 2019 for 2018 eligible spending as part of this incentive program was $2.7 million and was recorded as a current asset. During the three months ended September 30, 2018, the Company received $3.6 million in research and development tax incentive refunds related to qualified Australian expenses incurred during the year ended December 31, 2017. . In addition, the Subsidiary incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an Australian entity, the Subsidiary is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST incurred is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, incentive and tax receivables included $0.4 million for refundable GST on expenses incurred with Australian vendors during the three months ended September 30, 2018.       d. Research and Development   Research and development costs are expensed as incurred and are primarily comprised of external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMO’s”), consultants and employee-related expenses including salaries and benefits. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Research and development expenses are recorded net of expected refunds of eligible research and development costs paid to Australian vendors pursuant to the Australian research and development tax incentive program and GST incurred on services provided by Australian vendors.   e. Net Loss Per Share   Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as restricted stock and stock options, which would result in the issuance of incremental shares of common stock. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of restricted stock and stock options would be anti-dilutive. The following potentially dilutive securities outstanding as of September 30, 2018 and 2017 have been excluded from the computation of diluted weighted average shares outstanding, as their effects on net loss per share for the periods presented would be anti-dilutive: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:25.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,158,531 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,369,296 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested restricted stock </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 144,972 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,166,031 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,514,268 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   f.  Recent Accounting Pronouncements   In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, which requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The pronouncement is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. The Company will adopt the new leasing standards using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019.   In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which provides specific guidance related to eight cash flow classification issues. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-15 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.   In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which requires changes in restricted cash and restricted cash equivalents to be explained on the statement of cash flows by including restricted cash and restricted cash equivalents in the beginning-of-period and end-of-period total cash and cash equivalents shown on the statement of cash flows. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-18 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.  <div /></div> </div> 60949588 138916900 13554 -77980866 63793274 173877449 17623 -110101798 <div> <div> (7) Common Stock   In June 2017, the Company entered into the Sales Agreement with Jefferies pursuant to which the Company may sell, from time to time, up to $50.0 million of its common stock. As of September 30, 2018, cumulative shares sold in the open market under the Sales Agreement were 296,594 shares, resulting in gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018.   In July 2018, the Company completed a follow-on public offering, selling 4,062,500 shares of its common stock at an offering price of $8.00 per share, resulting in gross proceeds of $32.5 million. Net proceeds received after deducting underwriting discounts and commissions and offering expenses were $29.9 million.   <div /></div> </div> 296594 296594 4062500 0 4062500 7500 29937505 29933443 4062 -7 7 <div> <div> b. Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from such estimates. <div /></div> </div> 12743332 13098914 14531272 16587353 <div> <div> (6) Accrued Expenses   Accrued expenses consisted of the following as of September 30, 2018 and December 31, 2017:     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,786,098 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,503,615 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,490,658 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,059,536 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Grants payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 661,952 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 477,034 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 352,340 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total accrued expenses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,415,742 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,915,491 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of December 31, 2017, there was $0.7 million included in deferred grant revenue, long-term and other assets for prepaid research and development contracts related to a federal grant. During the three months ended September 30, 2018, the Company discontinued the research and development program associated with the grant and received a refund for certain prepaid research and development costs. The Company will be required to return grant monies to the grantor. As of September 30, 2018, the Company reclassified the $0.7 million deferred grant revenue to accrued expense to reflect this future payment to the grantor.   <div /></div> </div> 2059536 2490658 20000000 20171 20171 24286 89621 76512 400000 2700000 661952 <div> <div> c. Incentive and Tax Receivables   The Company’s subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Subsidiary”), is incorporated in Australia. The Subsidiary is eligible to participate in an Australian research and development tax incentive program.  As part of this program, the Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by the Subsidiary in Australia. The cash refund is available to eligible companies with an annual aggregate revenue of less than $20.0 million (Australian) during the reimbursable period. The Company’s estimate of the amount of cash refund it expects to receive related to the Australian research and development tax incentive program is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, the Company’s estimate of the amount of cash refund it expects to receive in 2019 for 2018 eligible spending as part of this incentive program was $2.7 million and was recorded as a current asset. During the three months ended September 30, 2018, the Company received $3.6 million in research and development tax incentive refunds related to qualified Australian expenses incurred during the year ended December 31, 2017. . In addition, the Subsidiary incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an Australian entity, the Subsidiary is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST incurred is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, incentive and tax receivables included $0.4 million for refundable GST on expenses incurred with Australian vendors during the three months ended September 30, 2018. <div /></div> </div> 4013 -888409 -662000 50000000 907028 2376965 54245579 3000000 3000000 30014017 29900000 3600000 663484 7500 3983604 3095195 1500000 0.10 10.74 EX-101.SCH 8 zyne-20180930.xsd EX-101.SCH 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Liquidity link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Other (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock-Based Compensation - Stock Based Compensation Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Stock-Based Compensation - Options Activity, Unrecognized Costs, Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Stock-Based Compensation - Restricted Stock Activity, Unrecognized Costs (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 zyne-20180930_cal.xml EX-101.CAL EX-101.DEF 10 zyne-20180930_def.xml EX-101.DEF EX-101.LAB 11 zyne-20180930_lab.xml EX-101.LAB N/A Document And Entity Information Abstract Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONSOLIDATED BALANCE SHEETS Assets. Assets Current assets: Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Represents the incentive and tax receivables due within a future period of one year or the normal operating cycle. Tax Incentive Receivable Current Incentive and tax receivables Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Partners’ Capital Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Total accrued expenses Accrued expenses Contract With Customer Liability, Current Deferred grant revenue Liabilities, Current Total current liabilities Contract with Customer, Liability, Noncurrent Deferred grant revenue, long-term Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding Common Stock, Value, Issued Common stock, $0.001 par value; 200,000,000 shares authorized; 17,623,873 shares issued and outstanding at September 30, 2018 and 13,553,873 shares issued and outstanding at December 31, 2017 Additional Paid-In Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Income Expense Nonoperating Net Interest income Foreign Currency Transaction Gain (Loss), before Tax Foreign exchange (loss) gain Other Nonoperating Income (Expense) Total other income (expense) Net Income (Loss) Available to Common Stockholders, Basic Net loss Earnings Per Share, Basic and Diluted Net loss per share basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted weighted average shares outstanding CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity (Deficit) Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock, net of issuance costs Stock Issued During Period, Shares, New Issues Shares issued Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of restricted stock Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of restricted stock (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Net Income (Loss) Attributable to Parent Net loss CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation Depreciation expense Share-based Compensation Stock-based compensation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Represents the increase (decrease) in incentive and tax receivables. Increase Decrease Incentive And Tax Receivable Incentive and tax receivables Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. Increase (Decrease) in Contract with Customer, Liability Deferred grant revenue Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: The cash inflow (outflow) from the additional capital contribution to the entity, net of issuance costs. Proceeds From Issuance Of Common Stock Net Of Issuance Costs Proceeds from the issuance of common stock, net of offering costs Payments of Stock Issuance Costs Payment of financing costs Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information: Future cash outflow to pay for financing costs deferred and included in accounts payable and accrued expenses. Deferred Financing Costs Incurred But Not Yet Paid Deferred financing costs included in accounts payable and accrued expenses Change in future cash outflow to pay for purchases of fixed assets that have occurred. Change In Capital Expenditures Incurred But Not Yet Paid Change in property and equipment acquired but not yet paid Nature of Business and Liquidity Nature of Operations [Text Block] Nature of Business and Liquidity Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Accrued Expenses The entire disclosure for accrued liabilities at the end of the reporting period. Accrued Liabilities Disclosure [Text Block] Accrued Expenses Common Stock Stockholders' Equity Note Disclosure [Text Block] Common Stock Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of the accounting policy for research and development tax incentive program and tax receivables expected to be collected. Incentive And Tax Receivable Policy [Policy Text Block] Incentive and Tax Receivables Research and Development Expense, Policy [Policy Text Block] Research and Development Earnings Per Share, Policy [Policy Text Block] Net Loss per Share New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of financial assets measured at fair value on a recurring basis Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of prepaid expenses and other current assets Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of stock-based compensation expense Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions used to calculate fair values of stock options Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Summary of restricted stock activity Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Sales of Stock Represents the maximum aggregate price of common stock offering. Maximum Aggregate Value Of Common Stock Offering Maximum aggregate value of common stock available for offering Shares Issued, Price Per Share Offering price per share Represents the weighted average price per share amount of equity securities issued. Weighted Average Shares Issued Price Per Share Weighted average selling price per share Proceeds from Issuance of Common Stock Gross proceeds from issuance of common stock Schedule of information pertaining to accounting policies. Significant Accounting Policies [Table] Represents the line items for the significant accounting policies. Significant Accounting Policies [Line Items] Significant Accounting Policies No definition available. Incentive And Tax Receivable [Abstract] Incentive and Tax Receivable Represents the aggregate revenue maximum for companies to to be eligible to receive a cash refund for research and development costs. Aggregate Revenue Maximum For Research And Development Costs Cash Refund Aggregate revenue maximum to be eligible to receive a cash refund The cash inflow of research and development tax incentive refunds. Research and Development Tax Incentive Refund Research and development tax incentive refunds Represents the amount of incentive expected to be collected as part of the incentive program, as of the balance sheet date. Estimated Incentive Receivable Estimated incentive receivable Represents the estimated cash refund from Goods and Services Taxes paid as of the balance sheet date. Estimated Cash Refund Goods And Services Tax Paid Estimated GST receivable Property, Plant and Equipment, Estimated Useful Lives Estimated useful life (in years) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value on a recurring basis Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents (money market accounts) Fair value portion of certificate of deposit, included in prepaid expenses and other current assets. Certificate Of Deposits Fair Value Disclosure Certificate of deposit (included in prepaid expenses and other current assets) Assets, Fair Value Disclosure Total Amount of asset related to consideration paid in advance for preclinical trial expenses that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Preclinical Trial Expenses Prepaid development expenses Prepaid Insurance Prepaid insurance Deferred Offering Costs Deferred financing costs Other Assets, Current Other current assets Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment Property, Plant and Equipment, Gross Total cost Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accrued Salaries, Current Accrued compensation Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from Accrued research and development expenses. Accrued Research And Development Expenses Current Accrued research and development Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from grants. Grants Payable Current Grants payable Other Accrued Liabilities, Current Other Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-Based Compensation Represents the threshold amount of authorized share-base compensation shares to be increased under the 2014 Plan. Threshold Increase Of Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Threshold increase of authorized shares for issuance Represents the threshold percentage of common stock outstanding for an increase in the number of authorized shares available for issuance under the 2014 Plan. Threshold Percentage of Common Stock Outstanding For Increase Of Number Of Shares Authorized For Share Based Compensation Arrangement Threshold increase of authorized shares for issuance (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional number of shares authorized for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares reserved for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for issuance Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Contractual life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Shares options vested based upon performance-based metrics Represents the total fair value of options granted during the reporting period. Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value Aggregate fair value Allocated Share-based Compensation Expense Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Balance (in shares) Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price per share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance (in dollars per shares) Balance (in dollars per shares) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per shares) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired (in dollars per shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options exercisable (in dollars per shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options Outstanding Weighted Average Contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Options Vested and Expected to Vest Weighted Average Contractual Life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options Outstanding Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options Exercisable Aggregate Intrinsic Value Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Expected stock based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Recognition period for compensation costs Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions and Methodology Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted average risk-free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term of options (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted stock award activity Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested balance (in shares) Unvested balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unvested balance (in dollars per share) Unvested balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Unrecognized compensation expense related to unvested awards As of the balance sheet date, the number of shares into which expected to vest stock-based awards outstanding can be converted under the plan. Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options Expected to Vest, Outstanding, Number Unvested restricted stock awards expected to vest (in shares) Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common stock Additional Paid In Capital [Member] Additional paid-capital Retained Earnings [Member] Accumulated deficit Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] Information pertaining to sale of the entity's stock in a follow-on public offering. Follow On Public Offering [Member] Follow On Public Offering Information pertaining to sale of the entity's stock in the open market. Open Market Offering [Member] Open Market Offering Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Primary financial statement caption encompassing incentive and tax receivables. Incentive And Tax Receivables Caption [Member] Incentive and Tax Receivables Primary financial statement caption encompassing current incentive and tax receivables. Incentive And Tax Receivables Current Caption [Member] Incentive and Tax Receivables Current Income Tax Authority, Name [Axis] Income Tax Authority Name [Domain] Income Tax Authority, Name [Domain] Australian Taxation Office [Member] Australian Taxation Office Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Computer Equipment [Member] Computer equipment Equipment [Member] Equipment Furniture And Fixtures [Member] Furniture and fixtures Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] An arrangement whereby an employee or nonemployee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Nonemployees may include, but are not limited to, directors, consultants and advisors. Excludes performance-based stock options. Employee And Nonemployee Stock Options [Member] Stock options Restricted Stock [Member] Restricted stock Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring Measurement Basis [Axis] Portion At Fair Value Fair Value Disclosure [Member] Portion at Fair Value Measurement [Member] Carrying Reported Amount Fair Value Disclosure [Member] Carrying value Estimate Of Fair Value Fair Value Disclosure [Member] Fair Value Measurement Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Level 1 Leasehold Improvements [Member] Leasehold improvements Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Represents information pertaining to the Amended and Restated 2014 Omnibus Incentive Compensation Plan (the "2014 Plan"). Amended And Restated2014 Omnibus Incentive Compensation Plan [Member] 2014 Plan Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Performance Shares [Member] Performance-based Stock options Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Relationship to Entity [Domain] Represents information pertaining to Employees member. Employees [Member] Employees Director [Member] Board of Directors Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research And Development Expense [Member] Research and development General And Administrative Expense [Member] General and administrative EX-101.PRE 12 zyne-20180930_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2018

Nov. 05, 2018

Document And Entity Information Abstract

Entity Registrant Name Zynerba Pharmaceuticals, Inc.

Entity Central Index Key 0001621443

Document Type 10-Q

Document Period End Date Sep. 30, 2018

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Current Reporting Status Yes

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 17,626,873

Document Fiscal Year Focus 2018

Document Fiscal Period Focus Q3

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
N/A
+ References
No definition available.
+ Details

Name: zyne_DocumentAndEntityInformationAbstract

Namespace Prefix: zyne_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1

CONSOLIDATED BALANCE SHEETS - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Current assets:

Cash and cash equivalents $ 66,177,376 $ 62,510,277

Incentive and tax receivables 3,095,195 3,983,604

Prepaid expenses and other current assets 3,413,029 1,733,701

Total current assets 72,685,600 68,227,582

Property and equipment, net 248,741 164,527

Other assets 662,200

Total assets 72,934,341 69,054,309

Current liabilities:

Accounts payable 3,553,350 3,355,255

Accrued expenses 5,415,742 3,915,491

Deferred grant revenue 171,975 171,975

Total current liabilities 9,141,067 7,442,721

Deferred grant revenue, long-term 662,000

Total liabilities 9,141,067 8,104,721

Stockholders' equity:

Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding

Common stock, $0.001 par value; 200,000,000 shares authorized; 17,623,873 shares issued and outstanding at September 30, 2018 and 13,553,873 shares issued and outstanding at December 31, 2017 17,623 13,554

Additional paid-in capital 173,877,449 138,916,900

Accumulated deficit (110,101,798) (77,980,866)

Total stockholders' equity 63,793,274 60,949,588

Total liabilities and stockholders' equity $ 72,934,341 $ 69,054,309

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the incentive and tax receivables due within a future period of one year or the normal operating cycle.
+ References
No definition available.
+ Details

Name: zyne_TaxIncentiveReceivableCurrent

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 15 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Sep. 30, 2018

Dec. 31, 2017

CONSOLIDATED BALANCE SHEETS

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 200,000,000 200,000,000

Common stock, shares issued 17,623,873 13,553,873

Common stock, shares outstanding 17,623,873 13,553,873

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Operating expenses:

Research and development $ 4,859,902 $ 5,753,764 $ 22,368,881 $ 16,978,016

General and administrative 3,125,780 2,795,839 9,982,743 7,640,489

Total operating expenses 7,985,682 8,549,603 32,351,624 24,618,505

Loss from operations (7,985,682) (8,549,603) (32,351,624) (24,618,505)

Other income (expense):

Interest income 278,214 161,930 639,702 363,350

Foreign exchange (loss) gain (99,897) 76,468 (409,010) 361,450

Total other income (expense) 178,317 238,398 230,692 724,800

Net loss $ (7,807,365) $ (8,311,205) $ (32,120,932) $ (23,893,705)

Net loss per share basic and diluted $ (0.47) $ (0.63) $ (2.21) $ (1.87)

Basic and diluted weighted average shares outstanding 16,587,353 13,098,914 14,531,272 12,743,332

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of nonoperating interest income (expense).
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeExpenseNonoperatingNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 17 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1

CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (DEFICIT) - 9 months ended Sep. 30, 2018 - USD ($)

Common stock

Additional paid-capital

Accumulated deficit

Total

Balance at Dec. 31, 2017 $ 13,554 $ 138,916,900 $ (77,980,866) $ 60,949,588

Balance (in shares) at Dec. 31, 2017 13,553,873

Increase (Decrease) in Stockholders' Equity (Deficit)

Issuance of common stock, net of issuance costs $ 4,062 29,933,443 29,937,505

Issuance of common stock, net of issuance costs (in shares) 4,062,500

Issuance of restricted stock $ 7 (7)

Issuance of restricted stock (in shares) 7,500

Stock-based compensation expense 5,027,113 5,027,113

Net loss (32,120,932) (32,120,932)

Balance at Sep. 30, 2018 $ 17,623 $ 173,877,449 $ (110,101,798) $ 63,793,274

Balance (in shares) at Sep. 30, 2018 17,623,873

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=96864182&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=96864182&loc=d3e11178-113907
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate value of stock related to Restricted Stock Awards issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Cash flows from operating activities:

Net loss $ (32,120,932) $ (23,893,705)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation $ 25,043 $ 24,773 73,195 68,368

Stock-based compensation 5,027,113 4,266,716

Changes in operating assets and liabilities:

Incentive and tax receivables 888,409 (4,013)

Prepaid expenses and other assets (1,017,128) (914,554)

Deferred grant revenue (662,000)

Accounts payable 121,583 1,154,109

Accrued expenses 1,500,251 194,385

Net cash used in operating activities (26,189,509) (19,128,694)

Cash flows from investing activities:

Purchases of property and equipment (157,409) (91,070)

Net cash used in investing activities (157,409) (91,070)

Cash flows from financing activities:

Proceeds from the issuance of common stock, net of offering costs 30,014,017 54,245,579

Payment of financing costs (175,011)

Proceeds from the exercise of stock options 434,691

Net cash provided by financing activities 30,014,017 54,505,259

Net increase in cash and cash equivalents 3,667,099 35,285,495

Cash and cash equivalents at beginning of period 62,510,277 30,965,791 $ 30,965,791

Cash and cash equivalents at end of period $ 66,177,376 $ 66,251,286 66,177,376 66,251,286 $ 62,510,277

Supplemental disclosures of cash flow information:

Deferred financing costs included in accounts payable and accrued expenses $ 76,512 89,621

Change in property and equipment acquired but not yet paid $ 24,286

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=SL79508275-113901
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Change in future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
No definition available.
+ Details

Name: zyne_ChangeInCapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Future cash outflow to pay for financing costs deferred and included in accounts payable and accrued expenses.
+ References
No definition available.
+ Details

Name: zyne_DeferredFinancingCostsIncurredButNotYetPaid

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
No definition available.
+ Details

Name: zyne_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the increase (decrease) in incentive and tax receivables.
+ References
No definition available.
+ Details

Name: zyne_IncreaseDecreaseIncentiveAndTaxReceivable

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow (outflow) from the additional capital contribution to the entity, net of issuance costs.
+ References
No definition available.
+ Details

Name: zyne_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1

Nature of Business and Liquidity
9 Months Ended

Sep. 30, 2018

Nature of Business and Liquidity

Nature of Business and Liquidity

(1) Nature of Business and Liquidity

Zynerba Pharmaceuticals, Inc., together with its subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Company” or “we”), is a clinical stage pharmaceutical company focused on the development of pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome and refractory epilepsies. The Company was incorporated on January 31, 2007 under the laws of the State of Delaware as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.

The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $110.1 million as of September 30, 2018. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company's primary source of liquidity has been the issuance of equity securities.

In June 2017, the Company entered into the Open Market Sales Agreement (the “Sales Agreement”) with Jefferies LLC, (“Jefferies”) pursuant to which the Company may sell, from time to time, up to $50.0 million of its common stock. During 2017, the Company sold and issued 296,594 shares of its common stock in the open market at a weighted average selling price of $10.74 per share, for gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018.

In July 2018, the Company completed a follow-on public offering, selling 4,062,500 shares of its common stock at an offering price of $8.00 per share, resulting in gross proceeds of $32.5 million. Net proceeds received after deducting underwriting discounts and commissions and offering expenses were $29.9 million.

Management believes that current cash and cash equivalents are sufficient to fund operations and capital requirements into the first half of 2020. Substantial additional financings will be needed by the Company to fund its operations, to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.

The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

a. Basis of Presentation

The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The interim unaudited consolidated financial statements have been prepared on the same basis as the consolidated financial statements as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Annual Report”), filed with the Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company's financial position as of September 30, 2018 its results of operations for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017. Operating results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2017 Annual Report.

b. Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from such estimates.

c. Incentive and Tax Receivables

The Company’s subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Subsidiary”), is incorporated in Australia. The Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, the Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by the Subsidiary in Australia. The cash refund is available to eligible companies with an annual aggregate revenue of less than $20.0 million (Australian) during the reimbursable period. The Company’s estimate of the amount of cash refund it expects to receive related to the Australian research and development tax incentive program is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, the Company’s estimate of the amount of cash refund it expects to receive in 2019 for 2018 eligible spending as part of this incentive program was $2.7 million and was recorded as a current asset. During the three months ended September 30, 2018, the Company received $3.6 million in research and development tax incentive refunds related to qualified Australian expenses incurred during the year ended December 31, 2017.

.

In addition, the Subsidiary incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an Australian entity, the Subsidiary is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST incurred is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, incentive and tax receivables included $0.4 million for refundable GST on expenses incurred with Australian vendors during the three months ended September 30, 2018.

d. Research and Development

Research and development costs are expensed as incurred and are primarily comprised of external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMO’s”), consultants and employee-related expenses including salaries and benefits. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Research and development expenses are recorded net of expected refunds of eligible research and development costs paid to Australian vendors pursuant to the Australian research and development tax incentive program and GST incurred on services provided by Australian vendors.

e. Net Loss Per Share

Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as restricted stock and stock options, which would result in the issuance of incremental shares of common stock. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of restricted stock and stock options would be anti-dilutive.

The following potentially dilutive securities outstanding as of September 30, 2018 and 2017 have been excluded from the computation of diluted weighted average shares outstanding, as their effects on net loss per share for the periods presented would be anti-dilutive:

September 30,

2018

2017

Stock options

3,158,531

2,369,296

Unvested restricted stock

7,500

144,972

3,166,031

2,514,268

f. Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, which requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The pronouncement is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. The Company will adopt the new leasing standards using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which provides specific guidance related to eight cash flow classification issues. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-15 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which requires changes in restricted cash and restricted cash equivalents to be explained on the statement of cash flows by including restricted cash and restricted cash equivalents in the beginning-of-period and end-of-period total cash and cash equivalents shown on the statement of cash flows. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-18 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements
9 Months Ended

Sep. 30, 2018

Fair Value Measurements

Fair Value Measurements

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with Accounting Standards

Codification (“ASC”) 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 — Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3 — Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following fair value hierarchy tables present information about each major category of financial assets measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017:

Fair Value Measurement

Carrying amount

as of September 30, 2018



as of September 30, 2018



Level 1



Level 2



Level 3

Cash equivalents (money market accounts)

$

62,316,686

$

62,316,686

$

—

$

—



$

62,316,686



$

62,316,686

$

—

$

—



Fair Value Measurement

Carrying amount

as of December 31, 2017



as of December 31, 2017



Level 1



Level 2



Level 3

Cash equivalents (money market accounts)

$

61,133,457

$

61,133,457

$

—

$

—

Certificate of deposit (included in prepaid expenses and other current assets)

20,171

20,171

—

—

$

61,153,628

$

61,153,628

$

—

$

—

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1

Prepaid Expenses and Other Current Assets
9 Months Ended

Sep. 30, 2018

Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

(4) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following as of September 30, 2018 and December 31, 2017:



September 30,



December 31,

2018

2017

Prepaid development expenses

$

2,376,965

$

907,028

Prepaid insurance

535,722

355,838

Deferred financing costs

195,754

240,439

Other current assets

304,588

230,396

Total prepaid expenses and other current assets

$

3,413,029

$

1,733,701

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other current assets.
+ References
No definition available.
+ Details

Name: us-gaap_OtherCurrentAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1

Property and Equipment
9 Months Ended

Sep. 30, 2018

Property and Equipment

Property and Equipment

(5) Property and Equipment

Property and equipment consisted of the following as of September 30, 2018 and December 31, 2017:



Estimated





useful life

September 30,

December 31,

(in years)

2018

2017

Equipment

2-5

$

85,417

$

85,417

Computer equipment

3-5

30,319

30,319

Furniture and fixtures

3-5

300,407

199,016

Leasehold improvements

various

68,881

12,863

Total cost

485,024

327,615

Less accumulated depreciation

(236,283)

(163,088)

Property and equipment, net

$

248,741

$

164,527

Depreciation expense was $25,043 and $24,773 for the three months ended September 30, 2018 and 2017, respectively, and $73,195 and $68,368 for the nine months ended September 30, 2018 and 2017, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1

Accrued Expenses
9 Months Ended

Sep. 30, 2018

Accrued Expenses

Accrued Expenses

(6) Accrued Expenses

Accrued expenses consisted of the following as of September 30, 2018 and December 31, 2017:



September 30,



December 31,

2018

2017

Accrued compensation

$

1,786,098

$

1,503,615

Accrued research and development

2,490,658

2,059,536

Grants payable

661,952

—

Other

477,034

352,340

Total accrued expenses

$

5,415,742

$

3,915,491

As of December 31, 2017, there was $0.7 million included in deferred grant revenue, long-term and other assets for prepaid research and development contracts related to a federal grant. During the three months ended September 30, 2018, the Company discontinued the research and development program associated with the grant and received a refund for certain prepaid research and development costs. The Company will be required to return grant monies to the grantor. As of September 30, 2018, the Company reclassified the $0.7 million deferred grant revenue to accrued expense to reflect this future payment to the grantor.

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for accrued liabilities at the end of the reporting period.
+ References
No definition available.
+ Details

Name: zyne_AccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: zyne_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1

Common Stock
9 Months Ended

Sep. 30, 2018

Common Stock

Common Stock

(7) Common Stock

In June 2017, the Company entered into the Sales Agreement with Jefferies pursuant to which the Company may sell, from time to time, up to $50.0 million of its common stock. As of September 30, 2018, cumulative shares sold in the open market under the Sales Agreement were 296,594 shares, resulting in gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018.

In July 2018, the Company completed a follow-on public offering, selling 4,062,500 shares of its common stock at an offering price of $8.00 per share, resulting in gross proceeds of $32.5 million. Net proceeds received after deducting underwriting discounts and commissions and offering expenses were $29.9 million.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stock-Based Compensation
9 Months Ended

Sep. 30, 2018

Stock-Based Compensation

Stock-Based Compensation

(8) Stock-Based Compensation

The Company maintains the Amended and Restated 2014 Omnibus Incentive Compensation Plan, as amended (the “2014 Plan”), which allows for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, performance units and other stock‑based awards to employees, officers, non-employee directors, consultants, and advisors. In addition, the 2014 Plan provides selected executive employees with the opportunity to receive bonus awards that are considered qualified performance‑based compensation. The 2014 Plan is subject to automatic annual increases in the number of shares authorized for issuance under the 2014 Plan on the first trading day of January each year equal to the lesser of 1.5 million shares or 10% of the number of shares of common stock outstanding on the last trading day of December of the preceding year. As of January 1, 2018, the number of shares of common stock that may be issued under the 2014 Plan was automatically increased by 1,355,387 shares, increasing the number of shares of common stock reserved for issuance under the 2014 Plan to 4,804,869 shares. As of September 30, 2018, 1,150,545 shares are available for issuance under the 2014 Plan.

Options issued under the 2014 Plan have a contractual life of 10 years and may be exercisable in cash or as otherwise determined by the board of directors. The Company has granted options to employees and non‑employee directors. Stock options granted to employees vest 25% upon the first anniversary of the grant date and the balance of unvested options vests in quarterly installments over a three-year period. Stock options granted annually to non-employee directors vest on the earlier of the one-year anniversary of the grant date, or the date of the Company’s next annual stockholders’ meeting that occurs after the grant date. The Company’s non-employee director compensation policy enables directors to receive stock options in lieu of quarterly cash payments. Any option granted to the directors in lieu of cash compensation vests in full on the date of grant.

The Company granted 83,280 performance-based stock options to certain employees in January 2018. These performance options have a 10-year life and an exercise price equal to the fair value of the Company’s stock at the grant date. Vesting of these performance options is dependent on meeting certain performance conditions, which relate to the Company’s research and development progress, which were established by the Company’s board of directors. The Company’s board of directors determines if the performance conditions have been met. Stock-based compensation expense for these options is recorded when management estimates that the vesting of these options is probable based on the status of the Company’s research and development programs and other relevant factors. For the nine months ended September 30, 2018, none of the performance-based metrics were deemed probable. Any change in these estimates will result in a cumulative adjustment in the period in which the estimate is changed, so that as of the end of a period, the cumulative compensation expense recognized for an award or grant equals the amount that would be recognized on a straight-line basis as if the current estimates had been utilized since the beginning of the service period. The aggregate estimated grant date fair value of options for which the satisfaction of the related-performance conditions have not been deemed probable is $663,484.

For the nine months ended September 30, 2018 and 2017, the Company recorded stock-based compensation expense related to its stock option grants and restricted stock awards, as follows:

Stock Option Grants

Restricted stock awards

Total



2018



2017

2018

2017

2018



2017

Research and development

$

2,096,710



$

1,604,346

$

171,073

$

118,110

$

2,267,783

$

1,722,456

General and administrative

2,712,517



2,482,490

46,813

61,770

2,759,330

2,544,260

$

4,809,227

$

4,086,836

$

217,886

$

179,880

$

5,027,113

$

4,266,716

The following table summarizes the stock option activity for the nine months ended September 30, 2018:





Weighted-



Weighted-

Average

Average

Aggregate

Number

Exercise

Contractual

Intrinsic

of Shares

Price

Life (in Years)



Value

Outstanding as of December 31, 2017

2,386,538

$

12.53

Granted

837,930

$

11.50

Expired

(65,937)

$

13.76

Outstanding as of September 30, 2018

3,158,531

$

12.23

7.76

$

2,290,510

Exercisable as of September 30, 2018

1,709,384

$

11.12

6.95

$

2,287,810

Vested and expected to vest as of September 30, 2018

3,114,781

$

12.22

The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 and 2017 was $7.94 and $13.08, respectively. During the nine months ended September 30, 2018, stock option grants included 6,030 stock options that were granted to certain members of the Company’s board of directors, at their election, in lieu of quarterly cash payments.

The fair values of stock options granted were calculated using the Black-Scholes option pricing model with the following weighted-average assumptions:

Nine months ended September 30,

2018

2017

Weighted-average risk-free interest rate

2.51%

2.11%

Expected term of options (in years)

6.13

6.13

Expected stock price volatility

78.00%

77.00%

Expected dividend yield

0%

0%

As of September 30, 2018, excluding performance-based stock options that have not been deemed probable, there was $11.1 million of unrecognized stock-based compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.44 years.

The following table summarizes the restricted stock award activity under the 2014 Plan for the nine months ended September 30, 2018:

Weighted

Average

Grant Date



Shares



Fair Value

Unvested as of December 31, 2017

108,730

$

1.65

Granted

7,500

12.99

Vested

(108,730)

1.65

Unvested as of September 30, 2018

7,500

$

12.99

As of September 30, 2018, there was $25,792 of unrecognized stock-based compensation expense related to unvested restricted stock awards, which is expected to be recognized over a weighted-average period of 0.25 years. The Company expects all 7,500 unvested restricted stock awards to vest.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-URI http://asc.fasb.org/subtopic&trid=2208855
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Basis of Presentation

a. Basis of Presentation

The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The interim unaudited consolidated financial statements have been prepared on the same basis as the consolidated financial statements as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Annual Report”), filed with the Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company's financial position as of September 30, 2018 its results of operations for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017. Operating results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2017 Annual Report.

Use of Estimates

b. Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from such estimates.

Incentive and Tax Receivables

c. Incentive and Tax Receivables

The Company’s subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Subsidiary”), is incorporated in Australia. The Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, the Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by the Subsidiary in Australia. The cash refund is available to eligible companies with an annual aggregate revenue of less than $20.0 million (Australian) during the reimbursable period. The Company’s estimate of the amount of cash refund it expects to receive related to the Australian research and development tax incentive program is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, the Company’s estimate of the amount of cash refund it expects to receive in 2019 for 2018 eligible spending as part of this incentive program was $2.7 million and was recorded as a current asset. During the three months ended September 30, 2018, the Company received $3.6 million in research and development tax incentive refunds related to qualified Australian expenses incurred during the year ended December 31, 2017.

.

In addition, the Subsidiary incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an Australian entity, the Subsidiary is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST incurred is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. As of September 30, 2018, incentive and tax receivables included $0.4 million for refundable GST on expenses incurred with Australian vendors during the three months ended September 30, 2018.

Research and Development

d. Research and Development

Research and development costs are expensed as incurred and are primarily comprised of external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMO’s”), consultants and employee-related expenses including salaries and benefits. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Research and development expenses are recorded net of expected refunds of eligible research and development costs paid to Australian vendors pursuant to the Australian research and development tax incentive program and GST incurred on services provided by Australian vendors.

Net Loss per Share

e. Net Loss Per Share

Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as restricted stock and stock options, which would result in the issuance of incremental shares of common stock. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of restricted stock and stock options would be anti-dilutive.

The following potentially dilutive securities outstanding as of September 30, 2018 and 2017 have been excluded from the computation of diluted weighted average shares outstanding, as their effects on net loss per share for the periods presented would be anti-dilutive:

September 30,

2018

2017

Stock options

3,158,531

2,369,296

Unvested restricted stock

7,500

144,972

3,166,031

2,514,268

Recent Accounting Pronouncements

f. Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, which requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The pronouncement is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. The Company will adopt the new leasing standards using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which provides specific guidance related to eight cash flow classification issues. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-15 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which requires changes in restricted cash and restricted cash equivalents to be explained on the statement of cash flows by including restricted cash and restricted cash equivalents in the beginning-of-period and end-of-period total cash and cash equivalents shown on the statement of cash flows. The pronouncement is effective for interim and annual periods beginning after December 15, 2017. The adoption of the guidance in ASU No. 2016-18 in the first quarter of 2018 did not have an impact on the Company’s consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6132-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of the accounting policy for research and development tax incentive program and tax receivables expected to be collected.
+ References
No definition available.
+ Details

Name: zyne_IncentiveAndTaxReceivablePolicyPolicyTextBlock

Namespace Prefix: zyne_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Summary of potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding

September 30,

2018

2017

Stock options

3,158,531

2,369,296

Unvested restricted stock

7,500

144,972

3,166,031

2,514,268

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2018

Fair Value Measurements

Summary of financial assets measured at fair value on a recurring basis

Fair Value Measurement

Carrying amount

as of September 30, 2018



as of September 30, 2018



Level 1



Level 2



Level 3

Cash equivalents (money market accounts)

$

62,316,686

$

62,316,686

$

—

$

—



$

62,316,686



$

62,316,686

$

—

$

—



Fair Value Measurement

Carrying amount

as of December 31, 2017



as of December 31, 2017



Level 1



Level 2



Level 3

Cash equivalents (money market accounts)

$

61,133,457

$

61,133,457

$

—

$

—

Certificate of deposit (included in prepaid expenses and other current assets)

20,171

20,171

—

—

$

61,153,628

$

61,153,628

$

—

$

—

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1

Prepaid Expenses and Other Current Assets (Tables)
9 Months Ended

Sep. 30, 2018

Prepaid Expenses and Other Current Assets

Schedule of prepaid expenses and other current assets



September 30,



December 31,

2018

2017

Prepaid development expenses

$

2,376,965

$

907,028

Prepaid insurance

535,722

355,838

Deferred financing costs

195,754

240,439

Other current assets

304,588

230,396

Total prepaid expenses and other current assets

$

3,413,029

$

1,733,701

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1

Property and Equipment (Tables)
9 Months Ended

Sep. 30, 2018

Property and Equipment

Schedule of property and equipment



Estimated





useful life

September 30,

December 31,

(in years)

2018

2017

Equipment

2-5

$

85,417

$

85,417

Computer equipment

3-5

30,319

30,319

Furniture and fixtures

3-5

300,407

199,016

Leasehold improvements

various

68,881

12,863

Total cost

485,024

327,615

Less accumulated depreciation

(236,283)

(163,088)

Property and equipment, net

$

248,741

$

164,527

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1

Accrued Expenses (Tables)
9 Months Ended

Sep. 30, 2018

Accrued Expenses

Schedule of accrued expenses



September 30,



December 31,

2018

2017

Accrued compensation

$

1,786,098

$

1,503,615

Accrued research and development

2,490,658

2,059,536

Grants payable

661,952

—

Other

477,034

352,340

Total accrued expenses

$

5,415,742

$

3,915,491

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stock-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2018

Stock-Based Compensation

Schedule of stock-based compensation expense

Stock Option Grants

Restricted stock awards

Total



2018



2017

2018

2017

2018



2017

Research and development

$

2,096,710



$

1,604,346

$

171,073

$

118,110

$

2,267,783

$

1,722,456

General and administrative

2,712,517



2,482,490

46,813

61,770

2,759,330

2,544,260

$

4,809,227

$

4,086,836

$

217,886

$

179,880

$

5,027,113

$

4,266,716

Summary of stock option activity





Weighted-



Weighted-

Average

Average

Aggregate

Number

Exercise

Contractual

Intrinsic

of Shares

Price

Life (in Years)



Value

Outstanding as of December 31, 2017

2,386,538

$

12.53

Granted

837,930

$

11.50

Expired

(65,937)

$

13.76

Outstanding as of September 30, 2018

3,158,531

$

12.23

7.76

$

2,290,510

Exercisable as of September 30, 2018

1,709,384

$

11.12

6.95

$

2,287,810

Vested and expected to vest as of September 30, 2018

3,114,781

$

12.22

Schedule of weighted-average assumptions used to calculate fair values of stock options

Nine months ended September 30,

2018

2017

Weighted-average risk-free interest rate

2.51%

2.11%

Expected term of options (in years)

6.13

6.13

Expected stock price volatility

78.00%

77.00%

Expected dividend yield

0%

0%

Summary of restricted stock activity

Weighted

Average

Grant Date



Shares



Fair Value

Unvested as of December 31, 2017

108,730

$

1.65

Granted

7,500

12.99

Vested

(108,730)

1.65

Unvested as of September 30, 2018

7,500

$

12.99

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1

Nature of Business and Liquidity (Details) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended 16 Months Ended

Jul. 31, 2018

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Sep. 30, 2018

Jun. 30, 2017

Sales of Stock

Accumulated deficit $ 110,101,798 $ 77,980,866 $ 110,101,798

Proceeds from the issuance of common stock, net of offering costs $ 30,014,017 $ 54,245,579

Follow On Public Offering

Sales of Stock

Shares issued 4,062,500

Offering price per share $ 8.00

Gross proceeds from issuance of common stock $ 32,500,000

Proceeds from the issuance of common stock, net of offering costs $ 29,900,000

Open Market Offering

Sales of Stock

Maximum aggregate value of common stock available for offering $ 50,000,000

Shares issued 0 296,594 296,594

Weighted average selling price per share $ 10.74

Gross proceeds from issuance of common stock $ 3,200,000 $ 3,200,000

Proceeds from the issuance of common stock, net of offering costs $ 3,000,000 $ 3,000,000

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SubsidiarySaleOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the maximum aggregate price of common stock offering.
+ References
No definition available.
+ Details

Name: zyne_MaximumAggregateValueOfCommonStockOffering

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow (outflow) from the additional capital contribution to the entity, net of issuance costs.
+ References
No definition available.
+ Details

Name: zyne_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the weighted average price per share amount of equity securities issued.
+ References
No definition available.
+ Details

Name: zyne_WeightedAverageSharesIssuedPricePerShare

Namespace Prefix: zyne_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=zyne_FollowOnPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=zyne_OpenMarketOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies - Other (Details) - Australian Taxation Office
$ in Millions, $ in Millions
3 Months Ended 9 Months Ended

Sep. 30, 2018

USD ($)

Sep. 30, 2018

AUD ($)

Incentive and Tax Receivable

Aggregate revenue maximum to be eligible to receive a cash refund $ 20.0

Research and development tax incentive refunds $ 3.6

Incentive and Tax Receivables Current

Incentive and Tax Receivable

Estimated incentive receivable 2.7

Estimated GST receivable $ 0.4

X

- Definition
Represents the aggregate revenue maximum for companies to to be eligible to receive a cash refund for research and development costs.
+ References
No definition available.
+ Details

Name: zyne_AggregateRevenueMaximumForResearchAndDevelopmentCostsCashRefund

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the estimated cash refund from Goods and Services Taxes paid as of the balance sheet date.
+ References
No definition available.
+ Details

Name: zyne_EstimatedCashRefundGoodsAndServicesTaxPaid

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the amount of incentive expected to be collected as part of the incentive program, as of the balance sheet date.
+ References
No definition available.
+ Details

Name: zyne_EstimatedIncentiveReceivable

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: zyne_IncentiveAndTaxReceivableAbstract

Namespace Prefix: zyne_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow of research and development tax incentive refunds.
+ References
No definition available.
+ Details

Name: zyne_ResearchAndDevelopmentTaxIncentiveRefund

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=zyne_IncentiveAndTaxReceivablesCurrentCaptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies - Anti-dilutive securities (Details) - shares
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Antidilutive Securities Excluded from Computation of Earnings Per Share

Anti-dilutive securities 3,166,031 2,514,268

Stock options

Antidilutive Securities Excluded from Computation of Earnings Per Share

Anti-dilutive securities 3,158,531 2,369,296

Restricted stock

Antidilutive Securities Excluded from Computation of Earnings Per Share

Anti-dilutive securities 7,500 144,972

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=zyne_EmployeeAndNonemployeeStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurements (Details) - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Carrying value

Fair value on a recurring basis

Cash equivalents (money market accounts) $ 62,316,686 $ 61,133,457

Certificate of deposit (included in prepaid expenses and other current assets) 20,171

Total 62,316,686 61,153,628

Recurring | Fair Value Measurement | Level 1

Fair value on a recurring basis

Cash equivalents (money market accounts) 62,316,686 61,133,457

Certificate of deposit (included in prepaid expenses and other current assets) 20,171

Total $ 62,316,686 $ 61,153,628

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of certificate of deposit, included in prepaid expenses and other current assets.
+ References
No definition available.
+ Details

Name: zyne_CertificateOfDepositsFairValueDisclosure

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1

Prepaid Expenses and Other Current Assets (Details) - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Prepaid Expenses and Other Current Assets

Prepaid development expenses $ 2,376,965 $ 907,028

Prepaid insurance 535,722 355,838

Deferred financing costs 195,754 240,439

Other current assets 304,588 230,396

Total prepaid expenses and other current assets $ 3,413,029 $ 1,733,701

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.A)
-URI http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735
+ Details

Name: us-gaap_DeferredOfferingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidInsurance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for preclinical trial expenses that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: zyne_PrepaidPreclinicalTrialExpenses

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1

Property and Equipment (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Property, Plant and Equipment

Total cost $ 485,024 $ 485,024 $ 327,615

Less accumulated depreciation (236,283) (236,283) (163,088)

Property and equipment, net 248,741 248,741 164,527

Depreciation expense 25,043 $ 24,773 73,195 $ 68,368

Equipment

Property, Plant and Equipment

Total cost 85,417 $ 85,417 85,417

Equipment | Minimum

Property, Plant and Equipment

Estimated useful life (in years) P2Y

Equipment | Maximum

Property, Plant and Equipment

Estimated useful life (in years) P5Y

Computer equipment

Property, Plant and Equipment

Total cost 30,319 $ 30,319 30,319

Computer equipment | Minimum

Property, Plant and Equipment

Estimated useful life (in years) P3Y

Computer equipment | Maximum

Property, Plant and Equipment

Estimated useful life (in years) P5Y

Furniture and fixtures

Property, Plant and Equipment

Total cost 300,407 $ 300,407 199,016

Furniture and fixtures | Minimum

Property, Plant and Equipment

Estimated useful life (in years) P3Y

Furniture and fixtures | Maximum

Property, Plant and Equipment

Estimated useful life (in years) P5Y

Leasehold improvements

Property, Plant and Equipment

Estimated useful life (in years) various

Total cost $ 68,881 $ 68,881 $ 12,863

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223
+ Details

Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1

Accrued Expenses (Details) - USD ($)

Sep. 30, 2018

Dec. 31, 2017

Accrued Expenses

Accrued compensation $ 1,786,098 $ 1,503,615

Accrued research and development 2,490,658 2,059,536

Grants payable 661,952

Other 477,034 352,340

Total accrued expenses $ 5,415,742 3,915,491

Deferred grant revenue, long-term $ 662,000

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedSalariesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from Accrued research and development expenses.
+ References
No definition available.
+ Details

Name: zyne_AccruedResearchAndDevelopmentExpensesCurrent

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from grants.
+ References
No definition available.
+ Details

Name: zyne_GrantsPayableCurrent

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1

Common Stock (Details) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended 16 Months Ended

Jul. 31, 2018

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Sep. 30, 2018

Jun. 30, 2017

Sales of Stock

Proceeds from the issuance of common stock, net of offering costs $ 30,014,017 $ 54,245,579

Follow On Public Offering

Sales of Stock

Shares issued 4,062,500

Offering price per share $ 8.00

Gross proceeds from issuance of common stock $ 32,500,000

Proceeds from the issuance of common stock, net of offering costs $ 29,900,000

Open Market Offering

Sales of Stock

Maximum aggregate value of common stock available for offering $ 50,000,000

Shares issued 0 296,594 296,594

Gross proceeds from issuance of common stock $ 3,200,000 $ 3,200,000

Proceeds from the issuance of common stock, net of offering costs $ 3,000,000 $ 3,000,000

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SubsidiarySaleOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the maximum aggregate price of common stock offering.
+ References
No definition available.
+ Details

Name: zyne_MaximumAggregateValueOfCommonStockOffering

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow (outflow) from the additional capital contribution to the entity, net of issuance costs.
+ References
No definition available.
+ Details

Name: zyne_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=zyne_FollowOnPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=zyne_OpenMarketOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stock-Based Compensation - Stock Based Compensation Narrative (Details) - 2014 Plan - USD ($)
1 Months Ended 9 Months Ended

Jan. 01, 2018

Jan. 01, 2017

Jan. 31, 2018

Sep. 30, 2018

Stock-Based Compensation

Threshold increase of authorized shares for issuance 1,500,000

Threshold increase of authorized shares for issuance (as a percent) 10.00%

Additional number of shares authorized for issuance 1,355,387

Shares reserved for issuance 4,804,869

Shares available for issuance 1,150,545

Stock options

Stock-Based Compensation

Granted (in shares) 837,930

Contractual life (in years) 10 years

Performance-based Stock options

Stock-Based Compensation

Granted (in shares) 83,280

Contractual life (in years) 10 years

Shares options vested based upon performance-based metrics 0

Aggregate fair value $ 663,484

Employees | Stock options

Stock-Based Compensation

Vesting percentage 25.00%

Vesting period 3 years

Board of Directors | Stock options

Stock-Based Compensation

Granted (in shares) 6,030

Board of Directors | Stock options | Maximum

Stock-Based Compensation

Vesting period 1 year

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of additional shares authorized for issuance under an established share-based compensation plan.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of vesting of share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the total fair value of options granted during the reporting period.
+ References
No definition available.
+ Details

Name: zyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue

Namespace Prefix: zyne_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the threshold amount of authorized share-base compensation shares to be increased under the 2014 Plan.
+ References
No definition available.
+ Details

Name: zyne_ThresholdIncreaseOfShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: zyne_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the threshold percentage of common stock outstanding for an increase in the number of authorized shares available for issuance under the 2014 Plan.
+ References
No definition available.
+ Details

Name: zyne_ThresholdPercentageOfCommonStockOutstandingForIncreaseOfNumberOfSharesAuthorizedForShareBasedCompensationArrangement

Namespace Prefix: zyne_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=zyne_AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=zyne_EmployeeAndNonemployeeStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=zyne_EmployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - 2014 Plan - USD ($)
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Stock-Based Compensation

Stock-based compensation $ 5,027,113 $ 4,266,716

Research and development

Stock-Based Compensation

Stock-based compensation 2,267,783 1,722,456

General and administrative

Stock-Based Compensation

Stock-based compensation 2,759,330 2,544,260

Stock options

Stock-Based Compensation

Stock-based compensation 4,809,227 4,086,836

Stock options | Research and development

Stock-Based Compensation

Stock-based compensation 2,096,710 1,604,346

Stock options | General and administrative

Stock-Based Compensation

Stock-based compensation 2,712,517 2,482,490

Restricted stock

Stock-Based Compensation

Stock-based compensation 217,886 179,880

Restricted stock | Research and development

Stock-Based Compensation

Stock-based compensation 171,073 118,110

Restricted stock | General and administrative

Stock-Based Compensation

Stock-based compensation $ 46,813 $ 61,770

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=zyne_AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=zyne_EmployeeAndNonemployeeStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stock-Based Compensation - Options Activity, Unrecognized Costs, Valuation (Details) - 2014 Plan - Stock options - USD ($)
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Options

Balance (in shares) 2,386,538

Granted (in shares) 837,930

Expired (in shares) (65,937)

Balance (in shares) 3,158,531

Options exercisable (in shares) 1,709,384

Options vested and expected to vest (in shares) 3,114,781

Weighted average exercise price per share

Balance (in dollars per shares) $ 12.53

Granted (in dollars per shares) 11.50

Expired (in dollars per shares) 13.76

Balance (in dollars per shares) 12.23

Options exercisable (in dollars per shares) 11.12

Options vested and expected to vest (in dollars per share) $ 12.22

Additional disclosures

Options Outstanding Weighted Average Contractual term 7 years 9 months 4 days

Options Vested and Expected to Vest Weighted Average Contractual Life 6 years 11 months 12 days

Options Outstanding Aggregate Intrinsic Value $ 2,290,510

Options Exercisable Aggregate Intrinsic Value 2,287,810

Expected stock based compensation expense $ 11,100,000

Recognition period for compensation costs 2 years 5 months 9 days

Weighted Average Grant Date Fair Value

Granted (in dollars per share) $ 7.94 $ 13.08

Assumptions and Methodology

Weighted average risk-free interest rate (as a percent) 2.51% 2.11%

Expected term of options (in years) 6 years 1 month 17 days 6 years 1 month 17 days

Expected stock price volatility (as a percent) 78.00% 77.00%

Expected dividend yield (as a percent) 0.00% 0.00%

Board of Directors

Options

Granted (in shares) 6,030

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=zyne_AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=zyne_EmployeeAndNonemployeeStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stock-Based Compensation - Restricted Stock Activity, Unrecognized Costs (Details) - 2014 Plan - Restricted stock
9 Months Ended

Sep. 30, 2018

USD ($)

$ / shares

shares

Restricted stock award activity

Unvested balance (in shares) 108,730

Granted (in shares) 7,500

Vested (in shares) (108,730)

Unvested balance (in shares) 7,500

Weighted Average Grant Date Fair Value

Unvested balance (in dollars per share) | $ / shares $ 1.65

Granted (in dollars per share) | $ / shares 12.99

Vested (in dollars per share) | $ / shares 1.65

Unvested balance (in dollars per share) | $ / shares $ 12.99

Unrecognized compensation expense related to unvested awards | $ $ 25,792

Recognition period for compensation costs 3 months

Unvested restricted stock awards expected to vest (in shares) 7,500

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
As of the balance sheet date, the number of shares into which expected to vest stock-based awards outstanding can be converted under the plan.
+ References
No definition available.
+ Details

Name: zyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber

Namespace Prefix: zyne_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_PlanNameAxis=zyne_AmendedAndRestated2014OmnibusIncentiveCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 81 160 1 false 27 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://zynerba.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://zynerba.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://zynerba.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://zynerba.com/role/StatementConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (DEFICIT) Sheet http://zynerba.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (DEFICIT) Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://zynerba.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Nature of Business and Liquidity Sheet http://zynerba.com/role/DisclosureNatureOfBusinessAndLiquidity Nature of Business and Liquidity Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://zynerba.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Fair Value Measurements Sheet http://zynerba.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 10401 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://zynerba.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 10501 - Disclosure - Property and Equipment Sheet http://zynerba.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 10601 - Disclosure - Accrued Expenses Sheet http://zynerba.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 10701 - Disclosure - Common Stock Sheet http://zynerba.com/role/DisclosureCommonStock Common Stock Notes 13 false false R14.htm 10801 - Disclosure - Stock-Based Compensation Sheet http://zynerba.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://zynerba.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://zynerba.com/role/DisclosureSummaryOfSignificantAccountingPolicies 15 false false R16.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://zynerba.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://zynerba.com/role/DisclosureSummaryOfSignificantAccountingPolicies 16 false false R17.htm 30303 - Disclosure - Fair Value Measurements (Tables) Sheet http://zynerba.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://zynerba.com/role/DisclosureFairValueMeasurements 17 false false R18.htm 30403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://zynerba.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://zynerba.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 18 false false R19.htm 30503 - Disclosure - Property and Equipment (Tables) Sheet http://zynerba.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://zynerba.com/role/DisclosurePropertyAndEquipment 19 false false R20.htm 30603 - Disclosure - Accrued Expenses (Tables) Sheet http://zynerba.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://zynerba.com/role/DisclosureAccruedExpenses 20 false false R21.htm 30803 - Disclosure - Stock-Based Compensation (Tables) Sheet http://zynerba.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://zynerba.com/role/DisclosureStockBasedCompensation 21 false false R22.htm 40101 - Disclosure - Nature of Business and Liquidity (Details) Sheet http://zynerba.com/role/DisclosureNatureOfBusinessAndLiquidityDetails Nature of Business and Liquidity (Details) Details http://zynerba.com/role/DisclosureNatureOfBusinessAndLiquidity 22 false false R23.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Other (Details) Sheet http://zynerba.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherDetails Summary of Significant Accounting Policies - Other (Details) Details http://zynerba.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive securities (Details) Sheet http://zynerba.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails Summary of Significant Accounting Policies - Anti-dilutive securities (Details) Details 24 false false R25.htm 40301 - Disclosure - Fair Value Measurements (Details) Sheet http://zynerba.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://zynerba.com/role/DisclosureFairValueMeasurementsTables 25 false false R26.htm 40401 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://zynerba.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://zynerba.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 26 false false R27.htm 40501 - Disclosure - Property and Equipment (Details) Sheet http://zynerba.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://zynerba.com/role/DisclosurePropertyAndEquipmentTables 27 false false R28.htm 40601 - Disclosure - Accrued Expenses (Details) Sheet http://zynerba.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://zynerba.com/role/DisclosureAccruedExpensesTables 28 false false R29.htm 40701 - Disclosure - Common Stock (Details) Sheet http://zynerba.com/role/DisclosureCommonStockDetails Common Stock (Details) Details http://zynerba.com/role/DisclosureCommonStock 29 false false R30.htm 40801 - Disclosure - Stock-Based Compensation - Stock Based Compensation Narrative (Details) Sheet http://zynerba.com/role/DisclosureStockBasedCompensationStockBasedCompensationNarrativeDetails Stock-Based Compensation - Stock Based Compensation Narrative (Details) Details 30 false false R31.htm 40803 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://zynerba.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 31 false false R32.htm 40804 - Disclosure - Stock-Based Compensation - Options Activity, Unrecognized Costs, Valuation (Details) Sheet http://zynerba.com/role/DisclosureStockBasedCompensationOptionsActivityUnrecognizedCostsValuationDetails Stock-Based Compensation - Options Activity, Unrecognized Costs, Valuation (Details) Details 32 false false R33.htm 40805 - Disclosure - Stock-Based Compensation - Restricted Stock Activity, Unrecognized Costs (Details) Sheet http://zynerba.com/role/DisclosureStockBasedCompensationRestrictedStockActivityUnrecognizedCostsDetails Stock-Based Compensation - Restricted Stock Activity, Unrecognized Costs (Details) Details 33 false false All Reports Book All Reports zyne-20180930.xml zyne-20180930.xsd zyne-20180930_cal.xml zyne-20180930_def.xml zyne-20180930_lab.xml zyne-20180930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 52 0001558370-18-008905-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-18-008905-xbrl.zip M4$L#!!0 ( "Q%:$W/^BWNM9( #+*# 1 >GEN92TR,#$X,#DS,"YX M;6SL?>MWVT:RY^>=<^9_Z-5D=IUS(!H//N7$>V39SGHWB;RV,WOO?M%I 4T1 M$Q#@H ')G+]^JQM\@!0E$A1 -!IUSE)]3[OK^V?]X^]>__/1?S\__X]V77XD7N>F4A0EQ M8T83YI$'/YF0WU@<^T% WL6^=\<(&7;LCMGI6^3\?/'R.\KAX2@DLA6[8ZU^ MN5HT%(47Q+)>#U_;IC4D@PNG=V$.R>5OV8/?;^. +DA__ELDB2SB]>O'QX> M.N+/G2B^@Y=,Y[4?\H2&+CO+GKP(_/#/9QX7/]\"7BU M_'7U*#3D^:MG\^WV7V<_+A_UV-9SG+F=N^C^-?P@QMH]-ZUSQ\JW[!<8(XCI MCM+9ZHTQY;?RZ<4/HHO!9A<^C[JV-7BND^R)Y0O_GH=L];3X$M_2CAM-I:C, MD6.NB.?^+OY!F];K__CMUZ_NA$WI^6H((%A"?A)\O>#RIR]L3"2?+Y+Y#+KD M_G06B*'*OTUB-O[Y3/1_ONRX\YU[9^1UUI!0IBA,V/>$?&5N DHM=0=^<1=_ M]KV?S]ZG,16_W5CPCV#.S;=H_7G!M9O/ 0U_IU-V^=WG-Z++FTM0>X]YEZ'W MA0']H+)">-?3T+]-^2<83ICX]^PJFLY8R&4/HHW?V/26Q=E(@1#Q4#)??(/O MOB?^,O993"0'V ;[EIIR]>E_G[TU@8E]V^IVG9]>KU];-\79G3#,U1_@3YDB M7K#OL\!W_22CA7@^/)>9_&*T%_G1GKT5P[UXR7!_>KVSYS6MKS>)_>GU!E]^ MFK'8C[S$9+!IEF M#(66C&X<,_NR5!-@1#1EW^CWRS291#&,8:4TRTWH;,'Z5 MQC'\=$5GXHULF.W!A*>XME"/8FS;IS3-!JN<"J\PZ#@5W@Y;T"&I(N-MAW1( M=/)"AW2@,J!_JM0_*2QX$;"+D7SX5PH#$%%Z%,)7O@$$\.=I%$KN-43PSPUK M;?Z/QJ6!X)^*8 Z3]!>64#]DW@<:AV .7"MQ[QZ*2Q9CIQ#&3 M,C"+$E3$! <+ 1X\7_T8!4'T^S%SDRA&]5=8_8N0ME/<:P>X*6]MG,MCBVR77V@. M'IT1#7>7#7;P:(6*3%.B]?-?J'AW:8!_4:_^]-TBM/G-D^? M5VJQ1HT-O<"I>N6[[10&C=U@L$%B0_:9(!0<:YX;K*IHXXU*>;0X@@:2N>!Q M C(1J^8S,91W\TIMWA7OVDHTZVQZ2U(X1S3A,4Z"_2),:HNV!WY M''2QJKC8JG8YHX]5P\>J(%^=,?ET6*R")-'+*BC9 Y-,Y2#R<]ED/UQG#;52 MB>.1^Z6)V#Q+-4BY**.J^00WJFHIJEIDS:"=JKKE45H)I06]*N*G0DJI+6B> M6"D1*8^<9[02,8^ M(#MXP<[HE0+TY,*37*>_"'UG98[*U4/!\A3; M'-F870S4XLC@,(X,RO2\];-@LY)%B7LR^RH-K5_-Q9P?J1__@P8I>S=???R? M0""-WF/UX;W/W2 2[Q[4^,>8_2MEH3O?36SN2?Z%N6G8?+)[7%X6D!E M.L0],LXM'Q80DU""+>5XU"XY;=078D?A"<&^,JB*X:PKN56U-1W1O"KJ?Z'(5(,?S@U1D M';X*[?83G_$/W]T@]9CW,8ZFV3Z$1<6N93[X,XOE'4[OYKL;*)Y%55V#*F14 MR5)-]:O+4S@5<*E4KYE9[106#(<5V0-1L MUAA0:6+8&-@UT[1QJ53?K!AZ9#1;],"Z&BYZW&::+BZ5-B?T194_H;=JM8KC M4JGJ*HUS(%PJ15/ ><6IC 'C^Z:80[N4%]5DGYJ\Z![R2\_S16,T^$Q][U-X M16=^0H-FZ,:S0UQ#V[-CU&#M?.LNOMI/6E=WR9Q*0ROGCBWKIJ>@T"S0VEXU M=T?5/M 3&>A_/3__(_03\I6Y@AGGY]F?4_$WP27QH]5;<6.:W2OVUN=1U[8& M%Y=_O/_I]?*/6?/BU5V-=!\U(A#-OYC!QT/;<%9M>/X]L'3-!?'<[^D48L,D MV@CTMBG^X^L6Q1F'=K\OFWW/P@A"S:<:SD;!Q<4:_*F6'S?QT^O<")X>L/TD MYQ^-X^E&GF#\+I+SC8!J?$MG =O6#?C[AT#ZL^U?/.9G48_X\6- [\A"U[ZP M\7Z#&]. @R8\:F3=]E4:Q^*//G=I\)\P*?Z0Z7FA;LZ7@/A;.VI#@5-Q;L3_[NKPU5KC[O+:#F&H7G@>;+%QQV* M+%^A?BSS_/]L]B":6#?\0>+I%?P=)HB?(/3^_K_9O% />S3[]_A/$.^G9_.-BD MY9G.'A&6Z79VR2/\+L+0@GKTGP(?]K6XW>]'/V#Q%T^O[ [F0H($S$)*]3I_X.Y6GQ+R6?@YY2Z+$U\L!1N$)BB=?($ M;/:Q -IE[.ZZX@I-_IG.Z6W %HS:)?YUD+@E?SNO .;96\?I]>P>A#?/]W$D M'6L&[".CUP-*S,)DQ"GS?O7IK1_(NZ5*XH](V>KC2#H.YH@U&/;-T; P&>DT#83)OV>S&-J3 MQ@J? R:S?Z&XG1;0YM]9AN2IVIXO8V#?,8>;A)="U,F&>K",;*=O#YW*1[H[ MD_$R&3G#D=4?F7DDVMW-L;044'1G.!ATNZ/"I/PSY8E@%_\6/?&&].JWE#,O MGQC\PH#1W$_85Q;?^R[+0JLOS(WN0MF*O+>YB-O;AVZF/;"LO*)43+NRG"HU M4:DXUX- K+D 8LM;(K>;7"RQ/,N[TZP%[&%CU^[W!U8_Q\:#!G8J9BB_3KC/ MA_2ZP&&SR>RM<4?"7M]BV]V>LKJKP ZFO0P<#8?**J>"FQ[W@:DY[ \=K12R MZ0#H/7IP" M"%]4U"NKX5I@^OG<_B.9Y;>Z=C^_*%X&??4.68'*IV1P,;>5YMJLZ9GZWD6STP(X.WO,SL$=.U^E:A_13QK;%_A FYKVAO=W?[GV" M>[HM,,K^L-??,+U]O7ZD?BRWR[SWN1M$XK#$LP-?&<+JQ7?SW[)#%B)BA7#0 MWX2/*QK'<]"D;&,U\S)%VM'MH>N#5D_L\]L>XHX&JQKNZN/_]&%:!4'[_%<1 MLF^,>O7,IQ!LBLL'K*TX_E .?N )C#]AU^/5&T^R;T_C'V/VKY2%[GPWL;DG M^1>!$3$(3B&Y/(;CNK30%F'%1B[SQ*-%)2Q3+'*\U^/%]G_H[W,4^.X\^]]O M()9W,.?]L]#1B_\6)&\\__Z_W25O2.[S7__R7_Z+^#HC/)D'[.>S*8WO_/#" MG"5OW"B(XHN_F?+_W@1^R,XGS+^;)!>6:?[]S1AZ/Q_3J1_,+[[Y4\;)[^R! M?(FF-#3D=X.SV!]GSW'_W^R"6*+9LV6_LF/QZ[)OS^>S@,XO_%!TECWXW^AT M]B:\Y;,WXNG7XO$\W:]GJH]BLW_Y&NT0*6$2CW M"2,4+&LZHZ' 8#!BFGJ^. CE@SW%_E08%@=;\^3IJ+$?TM#U:4#X,F8@]>9N3!3R;DC\[7#KG+LI_!7/S,9J(' MNK)S>-V'OF8!C/V59/#?OH/]7KWYY?+R\_K[^S<_DG$4K^A=D^B'\/>IU"9" M0R_K5U J#F['J3Q"RDD2D8_P&!''_.1CEW'BNP&#/XB1?6%WXIR":./K^7]T MR#?Y?M;5FEG[F;2#*]"DH(:+DV.WT@8HEW_9WQJ57!?4BJ&+=^:,QD2F&LE[ MYF9W0CB6042D! 1G4PDAB)RHUDP'D,@Q3Z"5SPX*X)5O^]V&=;,A(_F6C MQ0V)&3"L@.5$LI[VR%'!W&="PSM)Z=3GXEZ+S?:_?KC::+!#/F5#BV9^*)X& M]H"IT#O),$/^M*'HA=5ZP4,"ZDI"H5>!I#1>ND%"UYOFR:N'B>].9"<^3X0F M@ZV#*4NIB>-)\J0?6SCN;,R4\W0Z6RCEA";$AX[=1!*QB\ ?L^8])G0I!'%P M3N.YT.=9AJ-D#+X5^LR-XK_S7%.SB/N9<7\@D9!]'#NMWC M6NN0ZXQ$D,N2;M%B)LC,>K/+"0B8(L@S67%02,D//=^5ZS!BM-L-C--$1(5; M[<"/2YI%3C_.K"4#C!=#+)]$:> !?@ Q5)HQO///-)08MK:B X!#JJP\>"5& M#:IW$#8\-N=.LQS=00YZ$0N2U\LOK_-1XO++.H(]+#3=#&>O0,4O0T_\1QSH MN:>!/,N3+&=!C\\)%Y=;N#^BR'S(/S(7VQF]@9]"N@LH%Y$\?I M]O8*;.]4J3IVX)165;DIG'=1C1NHQ%6+;>N=]?+4HLW-/^2>? Z0^GOO9S!' M_=X@?T'#BVBI=EA/[H-X["#!C]O;@E%T5"^-3A0=U@NC&15&E1W _A2Z,''@ M#&;M\K^?9- /(+&<:'\!G/HP'C/W)5MY'M_A8@][W5&O)*X4'HJR;"QV*8+3 M[P_,T4@1+JYO@OI,X^M8[IWSI&=8KD<7P@?GT?U39L)FJ6%^ MY_$3W1Q+R^&\$3>ME4'*GIO?2N7-HXO?CJ2J5"X=0M3+$RN".]V=5.Q*3>SO MN<#%/\"!PSL6UP:ZR?_UD\E5RI-HRN+EY6#S,O;/6 -K-,C[] ,Z+(7$ ORJ ME,+?H] M8Q]2W]Z"Q8/ZW"3T/1LS^+-W%?&$+V[F$4#Z62PR^6+;^74R87&V MUKZ>NE6R;BY2IXL4[(/O)9,LOWNV3*8FXMH^XK(@F%%/F*K@@OS.9]1=?@?R M[\*?S\2^>#%Y7;1W&\4>B\_=* CHC+.+Y8/4U^^Z1 M^T7SMU$"_#W;)+<_ZCC#O[]9])5$LPMKEI P"AGYV_N1^([C>Y9+)9@+B:^Y[$PEW??)F1? MXGW]IK5\\XDT_.;2P2(EGWC%Q&?:';.+XBL@ODUAO)C_5L=&\ZF/_Y8E,1#Y M7Y?^(_X@_K28_X@_->N_V>G9R/\J^)]]CS>^-VYV<4O=/^_B* V]\VP?+OD; M39/H=(+*[> 9'CV56+VI]51"7UD]_^D820*#^(R"*.VS/0[*Z9BU F194A4) MFW,YTHLL3U*?G!^R/F^CP-LE^"?V:J+%JF>Q>R2))MQ2$UYN],]9L%6)!=<= MOC;>@DN)CS#4U4:4Z#A?>+#@J#EZK;Y,GOX@BP.6Z,P>69)8QT0;0AM"&WJ1 M#0TP_-,T9M U_+NZ^O#AXT=5 /& XN+#3S$6U\Y25AV?R-OAP=32V2:K54J MS^\#3.2'\NV@]C7,TN1"'/C7S/[-!Q>RXQJ%1FS#&?2-4;^'*(8HICN_$<4T M1;&1.3!,NXI<@H+S(+5LJEV[-A1A>H$9BQ_R-!87?6GHX!61AF9N7!&N'J#C M5:[$U.ZU=?'-/:=G#&P;X0?AITE<1?C1 WZ<7L\8.CI.#10QE'9- )2?CQU@ M$\M3RLL[*>6- #S!A0R5K:<9SKME_*[=2^N?VK-&,'WH=1&;FFXKB$V(39IA MD]TUC:XSTG!NH8^M:#'K4(3I!]B$O-^(+"]DHO*B(PU]MR("4=]#%]N^JPA; M-8#R MT[(#;.);E(AJ9XOM2EXOK:%QP+5(OC!]A- M W8FURD994, Q^A:CF':5:0)$%T1GF[.G:B MDWT5E_VOA+55*$#WNK O+H-\-96#:( YG.MGQ=C+JU+6'SK]89Z0=2]%^Q\2+V[RD_Z/* MBPT<*U^BK83Q%^O?[H$V'M3_RE*NQZ)*-4SCY5-?LGK64F-D/:!WE(.QT;FL MAUE)J9-="):A^,)YUX!G\L7\W2V;!,EV7@U_)+)PT+GD$R%;$8^L_OG_SHT$>)KX[(30(H@>^ MJF5_%U-9VIQ$8U$J?M$C%SI$HIGHD1LBLOE7"CYN[$-_6[]E7^DLAQTR)%K_ M]$!C;_5-8 5\F;$8*)B*8X39GW+I.OE@1OO0-D<020E5SIHA2438=!9$CF2BQ+,8Q%P1"YTP\>1N% M(,Y#FD(W+C J!-*$0LCJD1P^R8&&J;@J5.@*EX79Q"O+*H)"HWS.TX5, M881;3(VR-L9^S*&[F,K*<1Z=B^;^%X4.XSEA%%1TSFA,F&".H$J\$S"(I62_ M5J='P&@#H6<+&J!?R_R[^'$GB?#)E175EIJ;JUNW("F@CRE:WHNZ;%?H-Y,/ M"/(ZY)+GZ;8,,="A<1@)4A>FT,\MDRP#[NUBV /E:YF WA3'$5Q MAH-%-\;R9T'D073 WUA\?XCL0 Y=8VC"O_W1HK4E"YZX UJR8_TGR[!ZIM'K M]E:: Z9 [ZD?R+)A^PCHE.&]CL3]46$O+=\;=7K+%U_LS&IR7]<9R#^GHQ,* M0$=E["6*VPF;!4ACTE3-];B%S608OU![P-/8];D4/H"+2_E$&#)HO'0"#SX' M&&<)BZ= C51WT>]M!%@JVEXA/ !BSL=.X'WIT>"5A8?:\!B2 G 5.8Q][#0Z M60BU:F#9X$9#]^"SB=W[.TEG&[@&R G0'W,!"@ODD.\#K"1,=B_'00.IZ?!$ M&HJFT"L()#Q+A$5,(#CR21F[%Q"Y4R6_'V*[ S+ ^F9 M=GO);#"+84"#@;^&O2A<=/+LP RR""?D*!<_+X2RCD)&;S@)(4)?NA<)0A,( M9:'9_%-DREB2@1C@9.2ZJ="=<<+BK6XWA+_5SZZ1;KA2,HL"WP67$PHEY#EV MY%SX1K CA *\2<4 U\*1JCM;S$8 %$$-L^?SBB-YL^H@UXY\>X.LE?S':1 L MI;+DJVRR3C"L(Y17('A?BG+H&/;0S(=KYUF0MJDH('$(2T6TGX,,^+(,%X1S ME,H+*)HWF(ND#Q)&\2,'IN)N4Q[^&U,P(.+"+"G0/- M9'?+F.!,L@#E\\>1_'*CPG(FQCL>R.2) 0Q(-L,:$0 M=-QO2RW7#K#L5OK8C( %FHCI9LJ?U9'GA4"G^0D;R)3="RT:TP5C/R[<00C\ M(A!O)A-.LMGJ<]$B6?]-YM*C1WQ>\!$8"\K/,P7P&'#&6XTT0^"LR/UBVL)9 MCFT/,'D0HX-)H?@90I=TFH)."K2GWC]3GLAA+B8\F6L5WS*5DQYRT9;@;]:/ M![/;:#'#6[&5A5*#Z**-;&J0ZVRG,@BYWX6K^138NYP^"O>:&:JT]RR%0*=1 M&B99MP]1&G@BKLHU$(G1<0C+!'">"UP36@!$TY4*+W?&K-DSH5ZFO##9E4EM MPD5:((M:&"!RN%8U(F8/ H26 8BP)WH'-GHGV+-LU,M'0)L0M=14,=8U@P5/ MN- EP9E%5QEN>.?/&5T8)1GM6RH!@EIKU@_]OF-TA]VV.=&Z\V$[4A%'H83$ M'9%W-_+@M09,O@]O%YHD7)#(.^4==Z:H&;0!1 B025:^?9G'HD)=91+MHJ&B M**Y0-9;^AIXZJ\Z.WFAIVYTN%@]M;NUOJ]/'VJ.UUM[%VL=U\K_N?>)MY[_= M,?O(_SKQQS*1_X@_;>5_K]-%_ULK_MA8>[U&_@\Z0]3_>OTOQC^(/ZWE/^)/ MW?&/C?B#^--:_N/\JV[]=Q#_:^4_YO\1?W3D?_;]9=?(U+ZZ659QY?)7QNLK MM=P,8%-7^+[NWOE5B@/6F== 5]ZO;#F@ 1YO@/)&PT+F MAK,(G$5H(#D]S#MU;J%31A&;(OG \H^NBRI%U M"$X"O\\+?<H+%/-[J(HC_LUA3B%;:R"^CJU[R@^ M474=-05*;,,<]8V!9;9C?4IE="PLO)-'KG5?OH& BX#;=,"UC+[9-9QN%96; M%5PC5!EP-3L:B^BHPP'_EJ/CP#+,@=..]5W$Q@9R'[%1 RDV$QNMH6%5,E%7 M<"4>L;&!W&\S-N*LNMXTIMT?&(-A-9&C^J.LDRDAIN+M!2=FIOX>AV&:P MAG@Q]:\QJY3MC70[MC&P;*-7R>&!NO<6*(E-Q46DPQ8"+?'N)9M!&A&^(UP^ MALON$/X=59/AK7=G@))PJ7X>%Z&MA2"N M(:Z="-?ZEC$8Z+@BC[BFGH4@KN%4]'29N][(<)PJH*WNY?1V0%O-EPT@M"&T M*2E @+9>MVO8_6+0IL5:>,,V$CTOV^K-L>[E;ZW$=6HL+7E=W8;?O2B]#=A+ M;EG!C6-U^\0ZY=A(=]DUAN;(L&T=U_ ;!K#E5_(N$1(1LJ4(:0[[QM#! M _WZ(62I"6)$2#V.K2)"%DVY6 -C.*P"'^M>_D=\U,2N$!_UD&,C\=$:C ? M==Q&@/BHB5VU&A]QAETO/O8,TQX85D4;2/%POS;[%! A$2%;B9!B0X.XQ?E% M!_RSKQ2XOGK9\^_SO]8".R_8![ :U6S?*#;I[O1FR8DH_S9A9!P%0?0 .DHD M]PE/IT :M,A) C_S)'+_)-$L\:.04#?Q[_UD#B_%\M<0FB)3Z&7""0L]YI&O M;):PZ2V+UUQQ3(.(*D,7M;)G5(0[Z_=6KQ62,JCN)DA)=3Q;JG;&:9<%P0(? M?CXSS^1W/J/N\OL"]#(\7X'> HI \P,ZX^QB^>%-UA$9F9U57T?O%NI9G5ZM MEVTOQ0UC 0$4]89' T%TS^(QF,,%F?B>Q\*<(A1%RO6;UAX5*BN:J?=ZQ"9( MK-P 4F 1LORD+$4V:OFI66XA MRS$N;RS+M_)TS4PGJ%MM_:B"LT]6$]8OK:"9Y!I2)KIV"&U2O?!3K%2B$6II MA- [GU&0NWVV1P6&ZFTV5=8@JU>*_RL?9MXY>ES-)5VC#ZX[/X**<#J3KSD,\,$D7HS'$P0*2 YQ$^5\!.S-,VV!$R5-#.J MN+QG,;VKID*8'O:F!?IAMJ(U5H>Y"@6\'-A;7[7[/-ML;W=W,;NC23&+PZDS M3IU1MSG)3CI!RE<3JSNX(_Q=1- M4AK@Q%Q75X<3<%BRZN@.>WL5_^$9]C%*#6; %:__'6_P\:I+B&K_I%T,]+?<<=M==IPA,: MBI$0RDDT)N^9NWU-J26O*:VBUJ"" 9=6XFW;50C'7BXM[LYMW/72MN$,^T;/ M&:)AUFV8FMTLV3#N%S:=*B[;K_MJRK:CH65W>M64(D$D;&R(HN VCY?7,3FA M&6IVRV;#;$G_"QW:PWU]9DN*<5^+-%/1$&WYKV4KZ]=_B6F8,$_#B*S9]M(, MM&K'G&7H#(R14T6)6;01_;,T2O(8W9CG;P MN-Z<1@MXW+2Y@&(\UB(_4=[B4@,R%Q^^S_Q8R\R%KCG YAZ@:=1J4/$IPJM^ MSQ@Y@VHV"Z,M:97[J,N6U#2=AJ1%:A):4S,F3F?01RRLVQ@URZ6TFONU9UG: MSGW<4Z+5C :YKTO.1DD1%(Z9'A]0^LIFR?8))5.>4-+Q((0>4FS2.20;?O>B M]#9@!\]KVC%[<0RK-S1ZCH5FIIB_JB5G4[V=*&H(#4C-((8]?4K(UO&4D!Z6 MU:2S0&AB3YC8H*H<)^ZF:5@V!R,$G.4T#KYLPQZ91L\JMK-5BXQ1P])Y1VSL MD;?[4Z'T;27%8AL]B>L?(G;CEF'@T861,_5C80,I$3B2:)7X4\NP! MYA$OC<41M@0:":%),H7>)IRPT(,?GTF@R+R+K+ZU^NF!2-!U%4TG=%P+AO\VW?H>?2&KUN_C6CLB4<] M/X;!13$W"+0-+P*O62#&&X4&D$4"GZ7BP7^E-$Y8',R)2_F$S.A\RH#R#FF6 MLC792-:&(*6\J1M+C9#JX=+ 30,JOJ=\J:;O NK^>?[5G42!:"#3OUGLN^*! M:>2Q@#SXR40^.XZ"('H0/SRR3,IY.LTZO6@6#PO)'F!_V]$"H6=+MR!]!-A> M$"S\W\]GYIG\SF?477Y?..ZL/.7*<2\<*CC"@,XXNUA^>)-U1(9F9]77T4GZ M_JACEUWGLU!_'%CD<)(K=H ME4U&*A#-\!B[RZ:7%[=1X#UI=*N&?X?7UN+.,B[K[S+ULO[Z1 [FY+NE$*I+ MAFH$8B5DU\09F"K@VPRXK6B?8=TSNR;YU)-86=GS/+2R@E8VP*!$MS,7_W=[ MV23V^9_GXY@QX@OE%)N\8YJP=L0L6HFVTAW>=:>=GQ;>+B0KQ'PKE\A;]._L MVD]Y!B0]Q'3V\UGVW]6:6VY);AQ$-+D0+%C]NMRH87=ZUM\UBT]4MA_UXY'6 M&8#UE %H$3HH:06%O^2&9,QKS'S6,#?20G=810%-@KM^Q MG":[>25-03-GWGQ=UL)C-RRB/=Z79ULRQ9Y*1NZC@"9^X"=S#?VX[A+5VL,W M?XHS&(H=LDWV_@TS(,WB @TL8/"T!6@1,RAI!L='!B VWV.A1^8^"ZHH@5YW M1*"'O+3V^TW!MF9[=B4-03/_W71-WO+0V5<\=;P?A>'=\5AR1F+QU$,A+GL_);R549@XP#OA-XS4*N$W#(6$H^Q*3PWBZ-; MH0"&.'X9,R+/(HMKB F,.Q G-8&>-(R9&]V%,,9%RXM>W&@Z8R&G\DBGN$PN MY(S$+#L!FD2;5!CD8>*[$^+SC7OG;L4;J];%R0="'Y_^A!'ZD3PY;'>ZW6RA MHJ0SP(J(_MO&\=?LG"=/IT VM,_EZ5BQ>R/VL-IY]*R2QTF^QL=!(3GO"%K7\Y"RW:KZKJ84L'W9&;3Q'7C.PH):K=%J\ M]A!4W6-L1YWOV#S H74HJJ[D3G&S8KTQ:8MYCWI_FAL0[#TW((B,D:V#'/2X M &%YJJP:1Z/:IB0-# ZC-XS>4'(8O;6+]ZCW&+UA]/;(U5QF:^@8O#7$WC!X MP^ -)8?!6[MXCWJ/P1L&;X]PPC,8P MNE;1J'S?QO-FM^/4VA_A/>/B0!J5)Q??,W?[2)EED,)733?6[ZHL6_U3I<=Q MGSCPKYG]^_@DMIIF!XT,C8%CHE7I956UG]1I&/<+&\X/%5A,W4=]6HZ$G7ZO M'3&]RH;8KJB^J%TM_^TKBXN_9&7<-8PGFFTNS8C%V^!G!D;/U#'>;H%]U!Y5 M*\GCPB90Z:IIW4%T&R#,@KAII&&LK*1YM2LB+F\.JGZL_ ^9\=8P%-!USMG< M[1I'LK\I#NG5(HW](QJ37L941<1=ES&I:3M-"\9KDEXSXW1,:2M@DNT*X)44 MP4NWHSQSQ;&&$8>2(E0[2+?A=R]*Q57.A[JF-C@@S'4WUD+*CKRKMQ!%C: ! M.T40O3#-7;==M2M*;M@4YGG;:>512)7%I7:LC-Q'W6\,]^O>\=%N[M>]F:/= MW*\[3M65^UL1;/;U1=43K4=C?/F07A#TK495K+I;#:/8,>T[H'1BKL2AW3,& M(_M%Q0W39:YY=UF^LNH=FAV[MZQW*&H$7@%9-)POVN2$!D&6K]M+D.A=//%L MW43Q292^>[VMU"3_Y:?7*3^_HW1V\=[G;A#Q-&;7XZL,+ES0OO M!%,_T_F4A0G_QKXG[P(@[>U?_T+(3\O&/M X!'S@GUF\?,=W+T/OO1^DB11) M*)(07]CXY[/W:2P[NK'@'W'"].9;=#.Z<4SYY0RXX6,>,SUIS3@ MXO#^VW.K,QRL1[&GXQ*H'!Q%I=GI.Z>D+G2(M M/KLAXG>6D%\CS@F(BTAYE>'E3L+IBQA M\11>]$C*9?%;<'-+CTB6'C%,A5L7'E&^*+T]N.@I..=%F>$TX0D-94%D+XW% M?Q@%_YNYT@Y90HH@P@_A598G(Q2UE!=U=MEX#*[5(/Z8@*^,!&PE/H'\*-QPXYW"K1O P6'J(T MD X\#025LE>?\U24=A:M YTQ$RX4:-C-AP[)>"VZ\,20_7LF8YDTH5DU:'AA MAR#$OZ(W3J>"'0NV+%-;CT+3W=P5"T\; SP[:-\M2KPP@F*_%OM;X#1O5;3'+1F97,YU17M>0LK?H0/2VM84V L%-2/UYH9[E+]98WLI'"#0.LM'FV64CW8Z_5JO@:VIFN)FMZO:BHVK)6U)'4#Q'2R^DA=? MK,X S:<^_J/^H_ZWF?^FV1FUL1CR"?A?RD:6NJ,K=:^,5/UZ[[H=2Y/N=2VU M<$5WSY6[=J_C*'=J25G1G."^[=TS_T(FB5B+6*N!Y)J"M2FE?PJK9M5=^JX MW9>/.(;5&QH]QT*S1+-$LU1$LL0VG/[(L$?]=H2F:)::1+)Z2/"/IXY6:.@D M]9!8TUQAL1Q-&SQ>59<0H7VA?:%]O2%6MVN,!K:&\62K+4R+J%&K&4$KU\F; M*ZZ&.[LC+H5K=V;%,:Q^WS QX8F&B8:ID&R);?2LKF'WJ]CS4G>(BH9Y2/": M?7W1%3N*'=L7GXI^R];7KN0O9OD]6N0R+^6E M,-^BA ;YW\6-+;]'R7^RY,OJFIK/\F#LQRA>_$D\9Q6X]>)F0>&-[//;?,8N MO_M\]=^7?\Y#=7$Y9Z,$ 0D^\*:Z9@4ZZ MU]/0OTWYIU!L2_'O67Y0HHVLV;.WGYW?VKW!R#Z!*/>Q\U12S9G)$1)4P@"?D^AY[^RM95DR#CB%5'.#WI3@1^K' M_Z!!RBXY9PEPA(H;RKSK\(NXJT+<#2,N2>&5W.#4])L?NE;'QJ.[S;WYP>[T M:KU\M7'BT^SZU9;SWQIU!GCS0ZWZC_A3[\TG-O*_1OQQ$/]KQA^SUL(+;>>_ MU7%P^E C_WL=$_$'\:>U_$?\0?QI,__-3@_U7]F;WVK/KN)M1$U-;+3E!H=F MI%E1&BHE75$:B%2J2J/NA"Q*0Z7T+$I#I60)2D.EU E*0Z5$"DH#D4I5:2!2 MJ20-1"J5I%%W KA)TBB:<]Q[>VR-I_8QM8RIY1:8+*:66R4-3"VK) U$JKK* M'PWWE#]RP/OC!%69*@+B!-I:VO(LVOKKXCR:J.-=03"!\3_&_XT6?/UBQOA? M79,MU:O:^XH*6ITAS@64\:I7-([G,.RUQ.D4>%.%%T63;%&@JTJ%K";:).5K M84=C\D39SXIJUV&LB[%NHP5?OY@QUM7'9(NC=T[4SW\Z1A%J#;/1IY?ET]>? M3^O<$2E4T@DUD,+J=KJZUL=MHE;\RNY9L!9^%9=HX\X[E02N!@R8_8Z#20!U MM&(+!JJH*H,PH)+ $090*_;"@(,9OT8)'#-^Q02O5<72P_O,DZ(D.SL^KK^,4' MN^:;P1I79_-Y#5J_:9WH&A*SUC1=)]5P-X#D-;2Y5.146H:@P-PQM]0TU5*BRJ:FF;U=?)>^9NUURW9,WU 0:;&D@; MHT^,/C'Z5-PR:ZQQ7$6HBQZXB =>?SZI*\8HN)T&;W4[7>5*Q&@N^:W"Y1:: MLP9"5<.9LHSEK(%0TY[9*?LN<'>MOB)B5Y1/ M"/M7Z@.K0=,X>36%,>6';I!ZS"-^2&8QFU'?(^S[C(4<:*&A M1Z)DPF+BIG$,>D,HYTS/Y';S+:JV%':Q=5Q%;$;]8_J5LE5A]VZ;AC70<2M: M6R"F@E0R0DPEF6"$F)9#3",TOXID!P)*);F*M@)*:Q*OF%Y5TC0:PE9$G.8A M3MU)T.;/FK1(=>JPX-.V@^IJ"4CM1*8-OWM1>ANPEYQ(48OC-6U9*SD76J=D M% X Q*:UGF/T[:&&TPSE34OME"F"66E@5G+6%<$,P0PWJS77AO1"M[(3,HAN M[R$H7EW*SZZ+*A7<=?F%B&RS(]AWE/O\&9O&/!/V GPYMO MTC;A)&K:#JCX9Q,,UEPXK(XH7ZXV.XM]X$'/KWU S_QQ;[P MA(R%!.^E!,5SK@MP24.7D0<_F9#+[!84,!7R-8&W:>QQTF3I7D5>MGL>[)6\ M6ONVJS>77Z_67]^_^9$,;=/8'.LA1B-_NO 3<'INUN43-B*%D<.6(CW)=CL$ M2!94$H^-X:\\+TO*20(*,8M]$&4R 4$_1&G@D5M&8N8R_YYY)(D(9T$ A&3Z M0:*8R',#\$,2TY"/64SH2F'FY)5HDGWWDZS='Z7&A$0ZV&">O4-=R=I;ECPP M%BYOTYG1./%='Y0SD5HG&IJNF4$\FK .$2I\E_J9_D';R_%%:1+( 5(YNDQX MXYA.V4,4_RD9Z<8,FA!/Y)@P\5E,8W>-26,*%Z..1KG6YQN"U T$+, ^O:(MQ9FAWP*02P)BZ=^**QGW88AWUE9 M*OWN3T&9,W&E7![J^%<:B?8DDQ>'-VX%\<*9 ^VS-($.KK?_1&B\^BC'NXOW MF1:(?N0Y$?@[$">Z7FG 6MRWP"'H>B5$$!(%2@2@P-_'<32%1CPV8_ _0E6C M-';%T(48=TK!Y^0VCOX$M?"BAQ!>%HHVB1DC@;@AC:][%!1E[0E^+,<'&AX% M0?10R%9V>*Z+)B/8B_U3W:/8(1!Y01ZQ2'ZN(2%3FGI.+]*0>O],N;".32.1 MOBL!6%LHJU"5F/A",0'M@Z4#S.DW^+].0SFHN1[8^_7@$1Y*E#Q$)3C ;4#C M)R(BU @E-<(Y!!EVZ\0T\H1GD0Y1.$B>SF91+-3D=@Z23Q)X'-0BC-87_X'. M@/M#5:A]%#*0D!Y_,X3*!W9"WER<>.4B!O%#L/%I%B#26X@;":/N!$3[3Y"Q M.#-[%\593.>'$&7Z:\^PB.R\K3F1:$=$S%F^0*B;+P,1:.(KFR7;U11,64UA MF,7VAQ=;*#]\$7F2S?5O(;:S98>2;3 [#()%ENOG,_-,?N[+ M5>)ND5 #P@(ZX^QB^>%-UA$9FIU57\=OD[0Z=JUYP:6VPUA ;T^6"]SL-KIG M\1C4_V+B>Q#*Y,RI:%9W_::U?+/B392]6C=1-DY\I6^JK/>VN9;SWQIU!K5> M,-MR_B/^U,S_NF\A;3G_:[]MM.7\KWT#3]OY7_>U>FWG?]W7Y[6=_X@_B#]M MYC_B3[W\KWM;G[[\S[Z_\!!ZW=G5LLJ%E;],H7X9]7H3&]45>JM\R:F2,$NY MHA[ME4;M25>4!B*5JM*H.R&+TE I/8O24"E9@M)0*76"TE ID8+20*1251J( M5"I) Y%*)6G4G0!NDC2*YAPW*2@O XFI94PM:R Y/0 44\L*20-3RRI) Y'J MQ-( JOB,@CB&9\]+Q@'OCQ/4*N.!IR]EV1$NB*LGUM*6=U"LO^8NHZ@@F,#X M'^/_1@N^?C%C_*^NR9;J5>T]7M6VU*L9HJQDJO>J5S2.YS#LM<3I5-R2A2:I MCTG6$>@6JX#5)-%4;Y.4KX7]_-T,&.LV2A4PUL58%QUKHTRV.'IOW3;]]*=C M%*'6,!M]>ED^??WYM,X=D4(EG5 #*:QNIUMO66'4BKQ6R%L"U\*W*H$!W'FG MCL#5@ &SWW$P":".5FS!@(TPH+G $090*_;"@(,9OT8)'#-^Q01_9+FJDRS M%)'T8FV-3PC[5^J#&&21C5=3&/]\?3FWK$?#?VS'1/_E-1>57FT[^0;8%WM5 MK6RMBBK;%>R3K4EHQ)D]4YI138F2OFTX5M_H#_L(D-H#9 57.B! 5@V0%=S\ M@ "I#$ JEQQ2V1[5/XV-<%@Q'%9Q:!OA\' XW$J65E?F6Q]HK$>TB)6(E8B5 M[$/K7+X>QE4C/I:<_$=\5#?'C_C8OE0^9J6:8#>*FD8#DD^(:>W. MQR.^-<&&%#43Q#?$-\5SZ$H:VK%Y\>PK!65>"E!O""MO!K' M+/\-AK$U=Q.$GBV'*<=,7!8$"WG^?&:>R>]\1MWE]X4B9BL<*T5<* @(-J S MSBZ6']YD'9&AV5GU=?SB@UWSS6"-J[/YO :MW[1.= V)66L:KG'B*[^>2JW7 M.K><_]:H8R-\89GXUO*_[JJ,+>=_[7486\Y_Q)_:\:?>"F9MYW_=-_M>=IM:7_ULI[&9F5\NZYJ<=-SK7FTJM[DJFNE>#FI%*;3G_ M:T^EMIS_M4\EU.;_BV_]>]Z=-'SW=:,#@^JAK>XL;:NXK0V0-8/;=6= VL7M MNO,=[>(V(@DBB:[<1B0Y);?KSI-J.+E2YTYMS+*J($K,LC8!"#'+BEG6%O-? MFRF%NOROM02V1K*H(N/]D?JYHI?_H$'*UE]_8Y2G,9NR2BK18P2N9MB&$3A& MX(V450,\X $%HS$:/*T'O*)Q/(>AK:5*IZ(B5#6&AN&-OJ&F*A465;6TS>KK MY#USMVNN6[+F^@"#30VDC=$G1I\8?2INF376.*XBU$4/7,0#KS^?U!5C%-Q. M@[>ZG:YR)6(TE_Q6X7(+S5D#H:IASF:_X^ ,NE9SMM&<-1 JFG-;);]ES@[F MO300*N:]RJCS5E\1L2O*)X3]*_6!U:!IG+R:PACG!(C[DR6$NJY8'>(_MB,5 M5EJ9/E56B!JW&;)Q!E1-?3#EEL6/K5/:ZN66]/K&1OF58CF-T>RU)^K4, MVA0\8([0IN91=(2V=D);4X!,N5.I:O&['B!3\?RJ=D"VE1?4MYI7)?%:I>)# ME$.4:Y)<$.64S(YK,RO5(J'='*R[8G'BCWV7)HQ$8^*Q6<3]A+SR0S=(/>81 M/R2SF,VH[Q'V?<9"#K30T"-1,F$Q<=,X!KTAE'.F9W*[^1956PJ[V#JN(C:C M_C']2MFJL'NW3<,:Z+@5K2T04T$J&2&FDDPP0DS+(:81FE]%L@,!I9)<15L! MI36)5TRO*FD:#6$K(D[S$*?N)&CS9TU:I#IU6/!IVT%UM02D=B+3AM^]*+T- MV$M.I*C%\9JVK)6<"ZU3,@H' &+36L\Q^O90PVF&\J:E=LH4P:PT,"LYZXI@ MAF"&F]6::T-ZH5O9"1E$MW9GAQ'I$.D0Z1#I],]**V]FQV:GLZ\4%'LE+,^_ MS_^Z:Q 9#Q:64,Z0-D:T1_G6[ZU>>R+7NQKB;#D\&!UYO3U6DO_RT^N4G]]1 M.KL0Y3!D$8SW/G>#2%2_X-_ _-X%D?OGV[_^A9"?5H]&,3 @O)(;9]WYMYB& MG+J)'X6_4#_\->+\'1O#,]_H=^("<=#*%S;^^>Q]&E/QU(T%_X@K%F^^13>C M&\>47\Y(&OK9@W_ !\L^(QYS_2D-^,]GYME;IV]U>V:.X,.I*)G\P3'D#_K= M_E %ZA?,'^:I'^ZC_KQKCDQ+)>X7I'\T&HX&)9#_"PM93(/+T+OTIG[H\T20 M=<\^9!O+2]1W4!BS.QRM:=[3=0ET'J78]F#4&SHGI?,H%08-L ==IP9^%J/3 ML>S>8&@>2>>GT(T9Y>P]R_[[*;Q<7-OSFZ9I]ZQR*?Z< M'=IYS\8,8-I;Z#O8P;4XN',IS^N4R/01Q!>][G-#.(2@R@=54# P<,L>ECVJ MA$%XF$!;T72)0[]'831C@M;P[G>6E!KY.4X^\CND^[((/LHE6GUKY-1$\%%: MTG=& ].NE) ICZ\P__2OUD_J)Q]T=FK^ODO?^^[EY,W,$L M&M@CI^MT=PNE&&U7B].A+V'5H-NUGU*11?M']%^*PNSL_G>:P.S_>GR=&4\4 M%G)(;Q>9AU6NH9XK[ M=?=J=KWF./:=GR.%Y)I7%ND.*_V\.DZE;2CY/ M:#RE+DL3WP5#,0AXCHY!DNB.R5/A#WXR(3Z$8CR]Y2!;&L\-\L3+Y#/ U:^) M1U[!JV2=';YZ2+JT70[#35";:$DKS^33'^$-_5($/'E%1,ANY.Y&K :/B'C( *]&8.& MDFCM6\&1N$R\S6;B#_(]T1X-Q97+Z30-I$9Z;.R[OK3L'RS+[%AKGL*P _FF M5,JOT,YV32-3UC0:=DB>:!J"NODS:'U)O+ FL<8CZ !37PPDA>< B5)W0A+@ M)4#4F #4Q "7$YJ 0@M,('9GD"+?\'Q/ M=KVX@".8"X7/8=@&L?]=O HQ#=@CC]+8E187+/VNY-85DP MR1GT(B.>#FFH!I9C1S71_0G@- V9+*QE2"$ME5">8Y&7M >BA\@Z@S);]F5 MXU]I 1=WL5,EF)_[&"W'MAPI9D/_U]L/(8!P%.__GIED%?YMU>_;;XW2V.A M0(E Z(>)+]0^1_"4"G4* B-3:F$1XL',,M*9^/Q#S^R89&F5H(6^S.E,I_"- MB[E'AT 0+8SM,3\XA)\2 H06 U_L4=_HC;J$@XM@?%=CPFQ$"Y%@W/*N=OA_ MD@6TT 8%8Q5AA"!;] J6E%G'#X C@RX!+,K:-Z0?OXO![H6ENHQYLLL?G(Z] M'$^'B*G\ZE2& M3947X6S I**"_@7@),]!MV?I;0 !XU)_C)7V=@VS;QL]TWS.)H0!A&OE6VO\ ML ,OYA0>&D@#J;E@1KLTW^[TGE#]F+D,?+OWR :DQCX(?P-?@#/9PD(6!1YH M'O:H,UK;1]%(OH$:TVBZ?Z,AX*O$I%L6^!##\"PV6EXN)L,_*?_M&AMBPL#3 ML8CM6.9RQJG0BW5\F+TV\Q.(R&+Q:BQ[XFN7.?9CF"1,:# 6*FN;MMDA7V'> MFH@(#][*A71C/X30"!0.% VT"\B%&)4)O+R=;QCEDA!A66MBQ QY9:_K6>K6 MS%-0G#TW9;'KB[GD\I$G@D 9Z\4B="-A)*YB2V,9P4DFRLAS1?B*;GI/_4 N M$SY,P/,MA@'^*Y*!,\"__!%,<\K;AOAU!ZM[IDN^S*O\D[E2X9-)Q!F)??XG M%Z*/0&.$,Y#AF_0/!R5#I*J(>0#/:;Y$55!^L9LIRU$PSFCL9L:X/=F(F9S) M")MXI(3)QESDJ6:$:HMAK:T+E-=EG(_38#%=6B@_7[XF1PK/1K<)]84:B\?% M/"=F=V+J)_(7= 9O 6(80KUE*W+^)O\*[R_M:=GGAN'=^$,.@3\[Q('-MUO M9MUR#BA$@OO_3@*E[8L\CM@SW.[*03. C6C.V-(3AL+S@J">M)Z^WDMLL$76./@/G?,"+=_,_ M./,^A1^7\'()+OR^[/7\7K=G]NQ>;K'D<#(J(;_@EA33M+HPS,K(_Q2"QTRJ MXO[YR#('YE[B=Q!1"?$%=ZY9O4'7W*\YQU)_O5PAK8;UULBRA_U1=R_].^BH MA/Z"W+?[UG#4.X#_A]"?K4Z+W85EDNC8EFV.''N#Q'57Y5!QLVC@1J:[A7/( M%DZ%$XE"$8Y>?O?YZJDO3#@SYGV@<2B"S=_D3+S"H5PN@\%OT96-]1 M#C/)$K7:=H8C9V#VGJ!S/S$5C.2HG2KG0\<"EBLUD$JLH$Z1%!S)8&@.G'YY M(GE8[&P$.P30"N&CFTT@/T>![\ZS_UUM]==]J7_'S&3<(5^8N%")K#E%-EG5 MT&E84Y,JN].'']EM+%=D0?GZQ=:/91-B3K*(4&$2DY,U^+30H[''R;L(_K.Y M2/#Q\NN[S?6!169^9P-_S$0^8[.%RZ]_;#;P>]218S@W[6+#R!@J?KH0Z2#? MS0;VJ]C(R0OSPUBL;BR22HN452 :(S2.Q1PO2S0%$7R4$\^06/8RS9YE3E>S MQD2LL\7,C>Y"_]]R(3',[M27L[U@L>=HGJWJS?+6)2:18B7&E2NE8I;NBT4A M?RK?I&&8@K@@O/(C3ZSR@5J&LGV9=7T/EBMB"V+ULN1^EC> V3E,2:D796NJ M\/;43Q+F=8KS>Z'H?C@!$I)U,F/5N-P( &.X2WU/)@QD%BN1R0=79#*2B$PH M#(V2*14#@^'X,/=V5S/E1_M$1F]D<"9O !3)D)<2O3 HZV-W-'B_]\:P8S@R M7AD67T:(?'.Y668G)-.R%1N #*%K0I1\93^I_ Z,BCQ_[#.QBR.)(SY;*(?< MB.)GR^0B^T'%XEPDLX&S6>!GO)8:#"H% :FT3KDL+E,G&XN-4G^,U38/NK#O\"(1+MR 0)0V/,]"8(9\(5% 8_LQ)-F MZ7@#;?-)> =[_3VZSS3F$(L='F&Q6_T^8<5?&!<["86."",MQ7D]BH2R#+=, MB-M_RR_H9>X(?'\@,R"K9/A2BX6%Y':#W8IM3\N=C$7[6EC@RK;/ MH_%Y9O#R519ZN;\D42*W;SZU$LDGT4.XA]P3H%!AL"T&6\.Z8>M8':WDU'_1 M[,!6;B%WP&;CY$V9QZ#M[M#,)^^?ZO-%I!UW\MD9.J-AU:0=E0ZS';,_LD_$ MM8(G$@=#9V,IZ3#25OGU#\N-,N7IF-WM6\->/@OZJ+>CB#E*JX:][JAO.F73 M5IJG5BP.INC(7/Z3FO-B M@H[-R3^I/F6QJ&AN_4D=>I(@>0CZT=GU,LX%.CW;Z>9/B0D7@24!GG%TL/[S) M.B)#<ZS?W7:RXJ4LON,"XUBI'C1.?VG4HD/_%^&]9$@.1_W7I/^(/XD^+^8_X M4[/^UWVMN;[\S[Z_K AG[;.+';?.TS2):KES?GCT5&+UIM93"7UE]?RG8R0) M#.(S"J*TS_:68S-5J_MPE%2KJ5)\E)SS>=0=@G\B?X86JY[%[I$DFG!+37AW M9KL""ZX[?&V\!9<2'V&HJXTHT7'64>.O5E\FM\F^I*BI)9-M6O7 MAB),+S!C\$JP?H>)4K,;5[;5U\<\_I&0/;1OA!^&D2 M5Q%^]( ?I]ZQI ;\1W7/C;?12LO M+LV<=\OX7;N7UC^U9XU@^M#K(C8UW580FQ";-,,FNVL:76>DX=Q"'UO18M:A M"-,/L(GK'1<[:>B[%1&(^AZZV/9=1=BJ8>ZO4CDHZZ =LVOTACJ>,5#$4A" M$( 4D(.R &0[IN&,^AK.$!2QE';- Y2?EAU@$]]D69;9H;?":NB[E9>BVE[= MAM^]*!77U[[@6*!:'#_ ;AJP,[E.R2@; CA&UW(,TZXB38A(ADBF&,<1R;1% M,LL8.(XQ,"T-IS/*V]6Q$YWLJ[CL?R6L>FJ;;(QHC[ZMWUN]5DDYP&>JQVR6 MF5E6QKT>?TW@QT^\&R?+U!UQR50'R\V$TG)?29 MQM?Q5U$)T_L'#5+VF<5?)S1FARMV3'-O%HMN&U.L[D^GDI4:7QZ$":I&62[]R_"/W@Y[,D3ME9T9)N MKTOHX#D8?]R^R"0NZH(!4)=P!6O[.BR#PL/K]G4MQ[1'+R?PT_*H MZ NK//:&SO 1-:O&"W=],"-Z3F]@VX?W'+F,>?QC'$V7@=7U^"J:3J-0JNK^ M0&G-E)M%JS=?TUON>SZ-YU]IP!9QV^5WG]_\>QZRFVL0R6\T_I,EUV.P"K#& MW^1UKL\.[;PG*M,^\A![R"]EM/T=8>%0U\'F2ZP.%I(]>+ ?9:VZZ_!S>AOX M;N$!]\H;L?SY6I:'YQ^^L]CU^9;_?5G4WW6Z_9&UF]2=?3\B=>PGI5!EF+?H[JOW#I7\LV1XY]4/^[YQ7O?>X&$6 5:TT)4_GBON*?/5'\,^.9 M7"5<,>R91,!S@VY"\485A;6SMF=.+BP_2S^ZD"?95[]SQRWW1&--J+>,YZJO MH_=,]$:=OHEUD)IMCKVZ4CF*R/+I MO/+SHBZ_H*;:,WQ4A+PB?.")/Q6;E-#D-9=TC29?=U*C28I0_45)=:FJ0(IP!)Y6Z3:Z\T:L_*-$D:)P7)(C"("2!, &D@.3T0%;,P*B%J MRMDX#=8R#OQQ106LT 1/:(*'5Y*W-7%K>ICC$_MUT2);99$62D89B]R]0[X" M@\29IDIBQYDFSC31J:KN5$\^TRQVN6Z3Q%$]I+[RP[6$YXS&_$A=U7 M8&CK-[627=OVDA\IO)K"GL+BM,][:(1U&Z%F9\X;QOW"-E/%!? *;N*NXOIW M-05*ACVC6\F< H&PP=&(@CNXM1)>-3BJW#YOQ%$MH@7V53$^UINS:('\JL/'NC,32N)CN_(/#4L.%3:>CVD< M^DD:,UG<8NQ_%Y^YAK&&[H+4.F_1OKT;>F8T&F:$FN4Z6KU^I746I-62A?C? M-+HF;O&H'2^5,LK:4R>M-DJMDRJMEBRQ1B/#M/H:YEL:!K?MRL0H*8+"UO,K MHYQ-HL C_G061_=,; ;1,=^BA[BTSJKHFCNYI[$?I6A4JKFAVK(DQ8Y@MR"& M:UHR! 6X'83WA\9P:"'$*2J?IB4VT, :GK] 3Y*4]C&L.]HF*50$B';E8LH M+P&X_->RE?5EWZ*$!L2-N(Z'5G1-^34C ]%N[J/N:Y9GP$4D1<)KE&Q]<7=W MV#-,NXNQ0MUXJ911XFX,726+NS'JW?QF#XR^5<5FX;KS' V#VW9E0)04P1&[ M,3@GU'73:1K0A'G$8[.8N3Y-_"C4,()14FJ:Y33:P&/4XT;F)W"1J.%IB$H% MV!2AD5>VTS?LH?,C>FA%1=2T3 ("8\,3!@B,$ABMOF.8PV$5P%AW-D!)8&S7 MG+]5NQX^Q]&,Q@\_S[_ZZXA53"(/^LEC!7,C:W'@&-:HEWWN#PVG M/URU'@*I3S2^EL">7CID_2@Y2&[B$Z@>>;VMB"3_Y:?7*3^_HW1VL;*#=_-O\QF[_.[S MU;.K6T4^Y2X5^4TR^^SMXCJ$ P:]BW2%1[VLJK-Z)AOQZO! M36G ?SXSS]XZ]J!O M]0Z@4G95&EEEHOO>(9J.-6K&" N.;-CK6H-FC.QI<]HW2<,JU^,T;Y7"RZ M;YCVL.^<:)0K9-Q'5'?8,^WNJ:G2%1Q*C5M4PH:J/.U^X9E=LQF#? $R](?# MH57R(']GR8O"!JO?[=F'A%)!T.5W1T.NH>PZ7"*5MF/ K'FV=M%&F:5 M>-G*!HH,S58*WOS[(CLGTKHBDTA<%@2++*D8G/S.9]1=?E\D?K.;*%>)WT5" MUHV"@,XXNUA^>)-U1(9F9]57%LD/2_JYS^5KPAUS_!1$?**L%I=1Y/77-(UFGS=28TF M*4+EQ_IJ3W&@-! D$225R[PT21%. 9+*W5S;7FG4GI5IDC1."I)%8! 30)@ MTD!R>B J9F%40M14'FU8RSCPQPQ-L/$F"%3Q&05QV&=[PDU;$[>FASD^<1P9 M+;)5%FFA9)2QR/?,W39(JQ*#Q)FF2F+'F2;.--&IJNY43S[3+':E=Y/$43VD MOO+#M83GC,;\1S3!QIM@K3--5PN*TSZNH)XU&J%&= M#]VY7]AF&E#EHSZ9-?):^F'/Z%8RIT @;' THN .;JV$UX "'XBC:N"H@KD9 ME4VQ78?XE11!8>-9WNBZKD"J83RBAZBTSH'HFNEPM,QT*&E0FN4S6A"Y58EH MM>/=6%&S1,-80W=!:IVW:-_>#3TS&@TS0LUR':U>O](Z"])JR4+\ M;QI=$[=XU(Z72AEE[:F35ANEUDF55DN66*.185I]#?,M#8/;=F5BE!1!8>M9 M%4\E?JYZJH:ABQ[BTCJKHFONY)[&?I2B4:GFAFK+DA0[@MV"&*YIR1 4X'80 MWA\:PZ&%$*>H?)J6V$ #:WC^ @7X*$UA&\.^HV&60DF$;%77C Q$N[F/NJ]9G@$7D10)KU&R]<7=W6'/,.TNQ@IU MXZ521HF[,725+.[&J'?SFSTP^E85FX7KSG,T#&[;E0%14@1'[,;@G%#73:=I M0!/F$8_-8N;Z-/&C4,,(1DFI:9;3: ./48\;F9_ 1:*&IR$J%6!3A$9>V4[? ML(?.C^BA%151TS()"(P-3Q@@,$I@M/J.80Z'50!CW=D )8&Q77/^5NUZ^!Q' M,Q8G[6V*34!(+IB<"TU'P$@FG1DQK]KM&SL;1( M[=9X;#HC^TI!XU>B\_S[_*^[AE3!(/8HWW,.8#6.V7(,, 3R>GM )/_EI]W;/ M@D@^_.'[C(6<$1=H@O>^L/'/9^_36.Y&N+'@'U$=^>9;=#.Z<4SYY8RDH9\] M^ =\L.PSXC'7G]* _WQFGKVU^J/!T+3Z:TJ?[?G%1 Z.(;(WZ#F#?O=4-"X8 M.%P:)V8D<6([ Y[HY%IET_CYRCPW7D1=KY=6-#*9M0%!*]# MEH.7R;[<\)]!" 4']-??EF3-.:,P(R_30(Y03/W33.!:?X7'Q MXRP&$XB!1GAA"E_$<]$8WDE8'-* Q$^UOV@UUR1X:A9#HS$-[[*K>;JRS5? M?W__YD=C_3XP-!W#AS2&H.#91GZ[7G\=O=G1($^#A K"9>)Z.@NB.6/G,(9<)C!HX'V;,I#"XF,TBX "\ \[.CSQ# M/B&*6]$P8SZ(@\L_SN@\8]^4>HPD4=8 :,N][PJ)1?>^X#3\(#OA"8A0T >_ MW,5B5UX2/=#8X[+5@ E."#+$P\NAP*/_9&[2(1^!<5$L^J7)%D4A%]V(T<+C M#,@3Q,,C?-WGDA5,OAJFTUN@"[J: ?OE"%@81T$ '4(C/ &>"0T DX &(-@3 M^P5>@*/ ZL$.??4#T0LU@$D V%+&!3\,5\V9IS%.PNZ6H(V&0V_D.*HKP4W*P4V(,?$ $L1UR)!0H\3[0. 2UY)?KC;CO 81< M/]F(."[YS?7XQK)O'.N@L/)\,!@-S6%_(_C=UV,)%!XNL'OO!3WP0*K"8@949O0BVVW:5V&KFOIA1@[4'=,;9Q?+#FZPC,C0[J[Z.7DKO#SN] M6K.LRR +Q@+A4M%DP-%QVF:WT3V+QT'T<#'Q/8^%N2BN:%9G_::U?+/2/&O= M2?+&B:_T1<->K0OF+>>_976&J/\UZC_B#^)/B_F/^%.S_M>]KJ4O_\O8J%O[ M[&+'LB--DTB!1!MD?2\J)__=(PB M0.]\1D$3[+,]WL[I=%7;=]]BI?C*9@D32?JU_!W3( @&FLL=P0"5XI%2O&?N M-A98E6!!W1$WBKV$&!"#>PSN-9!<375X"N:9@"J6/5%BT.+ M0XL[H<6UY,2#LA:'<2J>?3G^V-)BOY7YNSTFGBZ:#-_2K8(_MV@2D MI B.GF4]=89*PQA#2<%I%DFTPO=4>HEOW7%%*R1(;*,[,HU^3\>Y%.*<*'?MU M3]UTA5 M)G5*BJ"P,5V+"R,UC#Z4E([Z,4;%E2B;Z&Z:%DJ@"!]'#-W!P#"= M+N(*%EGZ#.+OTYH7$VYH*9);?FMZ66.!DZGC_?$-[?,D25U ,57 M7YF+ 9I/K65>4/]1_UO+?YAVC+#,D;)E7FJ/KO FZ*8ZEB;=DEGJO;3=/??2 MVKV.,]3T7EI%S.SDQ580:Q%K-9!<4[#VY"&]*OC:#$2MZ*9]M#*T,K2RZF_7 MKW="WA8KTS5D5'G1MO"*^]=$+!-&,[$P6,7&3 5=FE;RJ_B\0;VIXQ)WPS1R M+XS5&QH]IXJ],&B6:);U"Z^19FD;3G]DV*-J;KE3+C1%L]0DDM5#@G^$]XPG MV5WB2>R[XB,7,:R&3E(/B37-%59\(K:!'F]@],PJ3L.B?:%]H7V](5:W:XP& M51P"JSN>;+6%:1$U:C4C:.4Z>7/%U7!G5^_QOP;Z0<>P^GW#Q(0G&B8:ID*R M);;1L[J&W:]BSTO=(2H:YB'!:_85#_66>3CWJ<._5[E:]%<13SY&V8OO*&?> M9SH7%1,OXYB&=TQ\Y) M-$?\:2W_>YTN^M]:\OMN];.+G^K MDBH7PBAB5,6NM9-75US+JRO(+S$-DRHNL*@[JX[&EVTF&G5LO%-2'>/[LG7\ MEM '&GO5&&"]:1TTP)7WJ[?X+!I@W@!E:*55 O1EZ4-%-LG7O141C5]/8=9U"-4,/*KK0%E,4)YDA M[;,O!,Z][8UB1GBA;7-HNKQJ-ASD\!^X*(L8_30RT]6KU;E=KF MT4Z>F5/%RG"V7O<6*E4TH1FR+QS/Z+JHHM4=.%\89S1V)VO;I:%'/';/@F@F M[E!IQW*+RC+5["Z*\KA?4XA3V,9^:(8[K$>*#;WUS1SUC8%5Q=7?"JY/J8R. MA85W\LBU[LLW$' 1<)L.N);1-[N&TZVBLI"":X0J ZYF1V,1'74XX-]R=!Q8 MACEPVK&^B]C80.XC-FH@Q69BHS4TK$HFZ@JNQ",V-I#[;<9&G%77F\:T^P-C M,*PF)*.ARSS3O#6['-@:6J"I7Q>&! MNO<6*(E-Q46DPQ8"+?'N)9M!&A&^(UP^ALON$/X=59/AK7=G@))PJ7X>%Z&M MA2"N(:Z="-?ZEC$8Z+@BC[BFGH4@KN%4 M]'29N][(<)PJH*WNY?1V0%O-EPT@M"&T*2E @+9>MVO8_6+0IL5:>,,V$CTO MV^K-L>[E;ZW$=6HL+7E=W8;?O2B]#=A+;EG!C6-U^\0ZY=A(=]DUAN;(L&T= MU_ ;!K#E5_(N$1(1LJ4(:0[[QM#! _WZ(62I"6)$2#V.K2)"%DVY6 -C M.*P"'^M>_D=\U,2N$!_UD&,C\=$:C ?==Q&@/BHB5VU&A]QAETO/O8,TQX8 M5D4;2/%POS;[%! A$2%;B9!B0X.XQ?E%!_RSKQ2XOGK9\^_SO^Y2^PIX\(*5 M_]4X9LLQP!#(Z^T!D?R7GUZG_/R.TMG%5W?"O#1@U^.K:#IC(:>)'X57$4\^ M1O'7"8W9.\J9]YG.13V!RSBFX1T3'_EE$$2N?/IZO'YPNQ7^;OXYH.$WP>-O MH%KOX*4_W_[U+X3\])B$W[M@UXI!6](7G-PP>RGN MLR5OI>80EP7!PN)^/C//Y'<^H^[R^P)&,H1\O8O]#K<<3:T=0'((@"-(]XPBV9'D]KVUI);G[ M]7YQ@$!1Q#0(<'#(9O_ZEUF%DX=(4"!Q53O^'"UHSA-U9Y;S_1V9FX9![93DY=4]R9-2].1)3W'T2\[OU8%BQ;ID M4J_D&N_M0[G@\O.C7.HJI89]+43YJ#LN]?1K"U$.BD5P>5$H7XN6ZNF"5K?G M[5%M_W;V=&R>*UI=RIT\35BZ3]IBW N^KTR7;J5J5<);W#[X-_9C:IS&T%1M M1ZH! B>\-^&]":D<:X;S5 ME7+">6LP[@7?"^=-.&\;IN:CJ\%H5YHO_+>ZB)SPWX3_U@#*-4-_[FGY"$-">P$^:>$/B&D_FD E^J%RV$_WBNN-9,E_RJ68%PHX4;72YI MJGSA]7FQVW(7[ZO]1#V?&D3SB#,C5U2GBREU$RK+4H?T>R=JBE@YNUMEVC8_ M5=JB*[!2;]113]*P0$A5N24"RKVI4S/LYQ:<4Y0#*/NJ3\LU87>HM,.GK[(@ MMLNKSRM7T=]A9?4BVV8ZU0%OT=NMX;YX&^R,VE%Z3?2W6R ?I7O5E<1Q;A$X MZ:YIV4YT&U28!'[3N(&^<7$Q:/5]Y5]9QKN!KD!38\[Z'M=X>7'. M2AND-V$:^ZT0IF8)TRD\[K*$J9JR4S=GO"3JU=-/%RGM"HADNQSX2I+@I<=1 M[NG27S^/TF/G448-]#@J2<)J.^E'E%YO@P$2N>[:2DC1GO?I):2B0E"#DR)" M>XDT=]ERU2XON68AS/.RT\JKD%4F5[5]98%]P?NUP7[9)S[:C?VR#W.T&_ME M^ZE-Q?Z:!\O?B@9RA75OR]<:C@UYL\27WNF[P>TG95=9^E4BYNDA'^5]P>7G1KGH\RG\\OJBO(B=\-+3"=6M.5?U M^L!E^T4-HUQUBH-66X76J1[H.?:'A1 V4@@/KM#;&U7O@$9E!?)\+68OA,5M M.*5+M,%EYT<$(YQ/Y,M-RU37OI_#MZK<^:.VX%Y$&972<$<:,Y$@JEZ$(Q)$ M%:"6N$]A/9BM9(G\?:]%Z"Q"9T$Y$3JW7GU^"5C=.R%B]1(Q$9/74]P^_*"N;GHB M*!=!N:#&^<3N$CYR-=T/-$L$YDTU=2(PKY3,?0*1,VW/U$5@7AV!%(%Y72E7 MR\#\Q=T<6JP_G5E"8%;:R!/R5C-Y*S5*%[)WO.S=NJ8N8G01HPNA.Z/0_6+. M*'ECVN1WJKG>6Q&H5STN"*>X!)Q/7;/X*S[',$"IV0(A_<=+_Z^:%8@]_*H7 MP7V>ZENZ;-P$ON=K-JXD;+9U1?7U7EL2Z[6EML/A:A1YVU8*X=CNDE@[MW8- M33L*/(IFN )P2SWPD2YE25KAOW.R\UIM #'=8L%*H;C1N0GBMMDV,G/1U!Q@?2_0 MU&HW*'^(\&:H=,:R>IK#PD*6&I7[*$N6JBDZ-4F+E$2TNF9,Y*XZ%+JP;&%L M6"ZEU=@O/!&B M&52LTSVD/GQO.,'4H@?'->V(7N2.I(PZBBP),:N8O2HE9W-Z.:FH(-0@-2-T MV.Y;0OTFWA)JAF35Z2Z0$+$=(J:>*L$0=[6'5_#9F^C;FDIM.WX5FFUN^>=]3>N"./!D(TRQ;-QF6F M:H;_*GBD%JY)8KH+G6('L5CMT&)[(:F(.JY*2U;";;RW M<>E9GW;@6%01:OI=M7KC>"T?PM_B09;88!KF4_K;;4O*+@*]A6.6,<;+6D9+@A61OZVOCZ3?_/UO@7?QJ&G+=_?ZG!J!16]FK!?OSYI' MC4MGL:2VI_FF8]_[CO['S1)?>A/=-Y],?_6 ^'L -^EG"[Y\_Q__AY"_/S?> MK;9:4-N??-=<(ST>MD9CDTP\+UCPS[)C$QT6"6_NZ.P?KZX"E_WZFP1_,$?R M[<'Y-OXF]]B;5^_#I<>+S4W80KAS#UT/IV3=X48N7--D .BKB"^9$!*=6E:H M8/[QJO>*O?>6FAZ]#S4C[_\7:\908X&FL;2E1]]%+W[B$Y%1KQO/=706=#CN M]HMNI)A+\4;TA;4 I?*JX:-9)#NM\T3=F>5\?SV9)T MC&5?:YJ=!2ME^]MA_"M,W0(4GQXU(Y?W-".7P1$7SLJH4BK@3MZAB!547YUD/=GN@@5]F179ULZEFD MK.@X3TA93BE3A5/2M$/MOS$0J'&A/5%7>Z3$-;T_+F8NI<1$YL13M*[FTW;X M+(TB[4F/T):==MY-O&V:+!?RI50B+YQ?WG9@[16 ]-W5EO]XQ?^-]]Q26W(S MR]'\=XB"^-MH<[C?5:2_-LP_J;+\5-\?:9T 2+L$H!&N0R6E(+<5^1#?J:'N M F_3./P$"7ECVF1%-==[VT#?H!FT:[0'4!03/HU6B[7Q?=5F_+ M7DE!:)C]KCLGKUEH_E97_MX/^L.A*@U3J]DZXXNA6KM N@GDA^E]^W-ETV\?%DO+ M65$ZL8TOH!/"=VF&^,Q._<9CW%J:_45;I(:8+-A181CA#B#4P#V#20F"-^^X,5VE\]%UNG_DZ7,CWZ&=\&!\1!@> M2&H6@7.(XYJB'*059?_5^UZWKZQ1M6C<%R2V'_X=F/[JD^WY;H ?>C?^G+H/ M<\T.4?\1AO !A9RK7D[Q6)I@6:Z)<2TC]$DIO$ZN-+4^?;E^]5Y5>KT"I# G M,LLA872J<,(/%;(OKP"?UYKIHA]4@%17@<;RFDA*_>YX?'X:[\7VN9@ -.L3 MJ\;Z)4!T98@\\;[=S+Y)_6]RZ*I6EZP;HBOU1JI\%N%=PV!U"%<'<2Q-Y99- MM7SJMD:2N*%@N\-UGZ=DS-:"UG40WM)L:?5HS2N:-]P=/I]-S:*S'"*VU2$^ MD[[.B>R"TA8??BQ-3JA#)54*;>X^&L)X,\==:(!]-O5IDQ.8(.JM9XB*0$AI M>*Y#2NB<6#]&Z&)I2>U71,<$KL)3 G>PY!P[$E6FQG/9M@%FVW 'KP!==BA: MJT3%^LA4#:AXC(@_-]T#=1?/;X/41PC?WPY_ESY+ZE4!:G$OSBI!F_J(5MFT M*5I,?XW/O;?)BJGJR?5?%K'5HF1]Q&T_)4?-H>2=Z?UQ[5+Z*2PYT2:)[/4E MZ41TW(;6*E&Q0=+8ZRLUI"+?K[B930S#Q$CWF T+"(1OVO1I\'IDV9:>+CRVG%9 M_N^@79%SJJC= MUX^D]OLC=22M.ULGP6!!PK YS]$;^U4DT*8DJ;VQ/!H4($F[,'!#]BQ\9YP M-J1L2 RQ&9./>\I&3'X*!)Z,3L=?DJ@B@38L8%\>#16Y0/VY@;KS4Z:.DK-! M&%E21HIV7L=OG!L5H6$=92X+13L5X*"+TA9[Y[T MCBXTTX;/+X%XKJ;[$#GA&9Y^0WS(][?J[^//@R*./1V/RV*)R8_+ SKB,U<. M?K0[D;H+KD:=;9,^2_T"J5PAF.3Z&SLQO]Q5T:J]@^1H%[[=OPEE,2O?Q;6 ?+7GUMYO[DJ;JWMMCID%PP MB9_-[;61NE)7R9-\*PZ_6PCK??*\ (;%KV$ ]MD6 Z=N[.G>!U//-$S-7=UK MK(@?HC=!X+5C6<[W&_LVF%JF?C.; 7#VXV$(PL+?:_C9!N:VU:3,RV$YC7LD M+F*4WY-%$@#+ #XS*AX^7CAVZD[PH2(JC7EJ';X/"TK&)20/*)=Y\CJK+^L,RL9YTW]+ M[H,%0+W"EE IQ)$$H9@$MA88)A9?9QU7S05J&-:;&&TVF9DVN.6F M9A$O4I2,$#7-D=?0PL M/L;]Q?_KDHAR80^'G)]2B9::8+:JBEXYE<.-AB[U$ MD:2),I-[C+8C8L*:8-# XGAQEC0,?V+6\.?8IAG788-V(> >^7,OY)7G1L8G M&+/@"UWSYF0&?FXR[G&C=N$Q& MT9U:H#?%O07/HZ$&L$QMBE>I(W,+R](MQPMP7O@E!I6@J7#J70_Q:5#11'8R M7N5&$Y@7QG?/M)?)1YH--;B)(_H#$T:P0"-@-CW!)7-(F:;O0EB)VV&Q7="9 M;C9,S,F0F>LLB!> \8^IU39561+<.OJ 82*1$?A!^P'&2J?F$VYPMDTWEAA1 M;G4AO#B_V2'_NX*X;ZJ1V[D&CK1. XBXP",FMZ *?_$-\@;E+N/NQP^OA1$F MKX)[NV@HF&'3$+G,=]0>'UWZB AW 0P[8""" M;#(+9I/7_5ZW1X!#+1;P)4M]FU7(YF(:N.S80JR3=_)=I(8C9'!MS\Q<>BD^ M0X/N>VD21)XR?+2&^GSL$;)I[&>G63NKL_!Q-Z6S4MP>.>B[P]BI9K$$BS>G M8+3!3NV+ZSJ[/?Z7H T Q5$8/[*P+&8,#SF-!.I*M&(@68)#73&Z.%2_- M-_\&MC=G)KQ)<4_L9L"C"+^19N_GDBPU>2CXQC< M?[RG[A-H78_Y&=D$Y?U#-C\)3.1%OP;^QI)\3-NF6 *TH>&X7&BSE@AYRU]M MM1KXC<7Y3(M$,I17@ $DS#R#9L298CZNK*(SGYL]@?EUKSN(!1_U%\<",S6X M4&>;\#(CMTG+M% _IXPVP>V2Y#-25T^PKG"#R-REU?U5HN[KM9"Z$N#N>7<5 M$[:A##(?(!9#EA1Q:2K;COK#-?%W++;WJ6OSN'W[^)N2#:(/UE=+G1V)DJVF M:_ A;-XWV-'X'#P[+)%([["([PGV&R/&,E+N]NO+5H)GX>$!K,\-0M4R#/ M#?+Y)J/4-P?$'(46Y3RBLSL7D?Y.+QDT(,[F@7)UH\S0E-IT9C(=ZX>Y;8Y, M39]O9$:RSA13WIA1P@^7_)@-IK4,'BO@ *%1C&RB&SG:D64RN#?(X@,'3^AX M;%2+1JDU'@Y8T4__!6:J2ZXUO!L=)L6R$/']$I9]XTFZ4#][Z>1:M-/#MA_X M\6.8"L)$DZV VJYC6=R^>3[@##D 1 (&<&Q$FSXWZ5/(CPX6AR>Z:V*F7UL/ M*.@,3 S//.$.2^P#/*Q!]!T,$B;_(8;^%TOQ.23<'T,?.*X0EMGQG(*;C!(: M1VC@'-/(_0ZW'F%\]FZ6T >&CLP78YB8$AL.3);:#$3NFA.;^AR])ML681M> M:5[+8L&C7+!![;XPP;=7KE$[Q.$#0AFF_%BW\&5/Y,Q6"*O88ON7 MX"P&&D_>OBQVQ%]E?*S#OJS4+*@%V&( G5'@1F!@4C! H? M_1HO"DR^A\=;P4ZP\ZTIB^?Q<_UL0PC/.P(4>.3021VI#",<9LRC3-R5:05^ MJ%\Q-[N@:3"X;?4B\P>J%V(S/,H"$6Z^+DU/=P_@R6CSD;O)/!#1PT>V$((_!L?^T$_A*&-N20<-"UYBOXP/3\^ M%A3/PO'FA6<3]JPX7.H4 U_?O(@&.5+3$_PK;0BMI/SUQ>WE7\[\M5$_._:- M9^R,-_.G(P& ("8F>\+Q&1GQOK1^=C(I8/SRGA+%MY]-T!!#7,IPC)WTW#GW,*QNS@L\R- M3BUKB7ZR_8@%.]A[;ZGIT7NPE8_V/UZAYX5GNO1=].(G M/A$980>/OZY1W7?CM_R]09["X:>.[SN+5UEP5;D[[/_UIW NWUF^DT#";(@D MR%^NQOB'1%]:=.;O_I:/OOM[E_/WQM<1X\-:@(5#++W+LO,)9"<[K0/,A>>^ MWLU-PZ!V2K+6 3GHQ#A[4HJ>?.8 0<)+(6_Y1C[R]23& X)\!Y,O2XR7XE^2 MNJH0G_+P+_A?\'^;\=_K=<<#@?]3X)^_=^OM74TU_8]'UPELXX([_>0O6N [ MN0E5?*IA=+1C-6J%8U44Y?!ZY@5;Z3L>7YP^;724F@.H("2RL87,\Y3I*UUY M5#!EV-8^"5'2*-(<)6:[3T1OD<(=D7\ND12Z5NC:!E"N+KKV["Y]5?1K/30J M)DV%E DI$U)V8BE33R!E90?D;9&RIKJ,EY?^FIX\*(1^3P8,*:WF035Y2R1.Y(RJBCR)(02R&60BPK0EG2[\C# M<:<_'K;#-15BV1!/MAD4_&H_L1+)&^<:&V@DFT&QNIG"?#F:-E@\M:/T>D*^ M*DH>(5]UER]I,.B,U7X#_O+[EJ;NSZ\+WA!'B]Y 4[ M?BW*K,@=:3CL]$3"4PBF$,P*T9;T.XHTZ/2'ISCS4K:+*@3S$.>5O\6KDO'# M!S2'$=?V"[O].TM7_,*:M6O-:US'AM28JS!#7/V?5FRP< M+%M_RW+@I4LDAKIC(*OT\VN:?[)*\S2N$9BJ9KWAQQ&5:NEA= M17:+':_8W5/XOEAU=) 40Y!B_AZE+?=;QER!P^<&74064)3(1%4 "[6,5@N;1,CFO& MP6$EC[A:0P?+F;!#?;P+B,/YIT/^J=E,J?!RK^.:U4^MH7*/U/DD> P\/U3F M3#>#IHV5Z_W71$VB:!>@)B\MT$>L3UTDMI?4]3508)=8?)75K5^&5?O8)V&C MRN,U:U@JS,,BS#K.G.B(5$$VAORD$0_1LW RC'BGUIMJV#8GH]1H2J?9ZS2) M:OC,3!?(^&\0(I\7,6):V#!9MYM0\=EY%=[6#AY"-D\-]T[U#O+ZQ7GB''.( MQ(Z.D-BU>7=(\5UR3 &%M!#CM>$)\5*/7EB'/)J/B2CO8Y+]#!^#H#RJYCAE MU5(MC=7]BEK.15P<%WOF3;>FJU0=T+QSA1(8R_:%,[N(>FQA)4D(P9-/? C)71* 74Q@0O B!G MH^%)7-OU5C.-3_:EMD3UL[WI\/IB)'DTEH;C3._G4E>SMVWRY@H495 5Z.^H MSY3H!\U%I>$=MH0+51V/>J/AL.!E)'V=][&TK([EOEHT&H]MG?TRCE;ED:H. M!N.*+"8_0V,;\(H ?R0_2U(/_@!3OV097QR?7L5-YT0[\U1N\8WZEG"^(O<; M)U]%MO=<"8%_!C9E3F"VS'DF:<,ZLFC8/V3RZ%+N@+*$WS_1!V4U]--EP+E; MGQYMH:V(1RTK*GT+"V#UPN'?#@F6^/JUDFZ)%1:*S]:A/:#[B1XL6!?KI[A^ M)WB)<'#;[G/;5 #&W&S!B]1IV>>]' 8"K&X<%2]G0$ (_92 M(SK1>MB7;%&[5Y#JQY*KK; (]<\G==9J2U^NL.D#5J$-B^1>8!X]F$)L$#-* MAXD2$GC0Z0W[>*HY5;IY76RPA:EF)URV=$U>^?GUJ L/QD5K#V#Q?E?9P>-Q M/[%U9F<\^AV+^6(1;3"$O ,I"X4/E(/^N#M.IFV\E<@=3![J<_Z*2KZ*=NBC+AW%^JEFQF;BGED?ZYL^NT&J/N9Z>"; MD.+;';*T/_;IR_6K]Z"202.OK7SO$HI;]C"U["V^:$-7O=4I+3I\V%CU !2; MLA'05V?9)R)VB0M64PM60YD^>,'7S%;=V+?,4N5<].EIG62O.=S88>DC,W 5 M8GGU3[$S>(:GD/;DC*; M=LE7CP5O,1;J%?DV\4@KWYO%'HOQ"9=M^Y$85 /'8M]"3&^S]-G'R>0VV?X& M(#5^^ _S80OMCW1G1+:M"]*S")L=L5.#&ML!#IM#8HM*C, 7/,0&,-A!0"]S M$C!J=VG$\6'8[XGM0<;]Q;<\Q*;^ILX MBI,-J9S9>KO/+IGH?L ;J@86RZ]@%Q_#1#^79S198ZZ86L_ET?+&]UFEEU6( MOX4]BR:\9=$7UM$,G'-T$F^2OD6L?]?$-J*&97N#^DAQ;FPCK^_R]-6!+,LI M\W\<1*=;E7K,JN3>>#26!M5=U4'>^?JJ!HH,]*H^K?*M:JB,5%F1BUD5QK+O M)KR+ZR^)\A,;>-LW\(9O28@L\B%4H\(=*=L=F:PW(6;-H%FMHB&\XZBI#T(%^IC> 4T0BKU$9P M(\'_)?*_T#]"_[08_T+_E,S_O:XB&H%6MA%EZ=&%:(Y65\->IX8RI^\:E"+U M\Z^.882X!V9_3P],2>X.JE9PK,5,440+3*$,ZD=WH0P$4VPPQ?:\_ ET0=D> MMR![ 3Z@<.Z%<]\ RE6]6V0EC*KHSUJ!+LA"XH3$"8D[;T=DX:=6A\C"3VUN M->[HD!G>5Z>VQTX_ML.$5IF,#=MHKAGV6S7(:!*DN#H*,NE'M5< MG5>0-N@3M9PEWFIMH(]12<(US)-HA>TY<2._1APV,DNJMYQH1"]4L4,TM/Q]=#6OY++45Z^O: M/%^A9@1LF!?1\AQ>H_V+EM.6#(=29ZSTAQ0T) M!Z(I+.T1_I7YEXZ(' MQ]FH [%Q5;I$"HTH-*+0B&43E@3 M]5SR)EY5Y9L ;;M[Q5HC12462=3QJ(,=E%Q*OFL>>=WKJ@2 LK#KHVGK5F! MM&;:Q* SZKKP^A&/)A*7/E$[H!UB.?;CA4_=!;O(Y>!(4;O%F>/R)I+F[NM> MK.>8J^GP;06+DR9LA[H!FZ3HPXP)7X.@F XSD"(V5)UZOH:8.J )7N^UR4/*0B_ \;)E$9],QD27.H'KAU."^O% MCI7P<0R*XW83)IUDNU[M0 0 ;L'2S)G)$9$\GZ'[=EHSPF3#=P[FS.(-.TT@ M>0 P4SRW&K7\S(!;&4G*(TC)<_%C!RD'?'5(4\S#&_1M-O2["WD,F_XE'!8U MKKL,@(JAC$5]_2;>MYO9-ZG_39:V]HW<:/_=4\:*/,R">="TQ4%[>+/VP;@W M5$8O!/;QT:6/(/MWG.\_:S_,1;"X=MSM(UVB.%]JWOR.ZX(C.E5_LG5G01^T M'Y/ GSNNZ:^^: N:[> =>* G+5.SX6=LS)O9S-3I]I[52AHQ%PJ2D?\7H>9E M:TQAZQ*T'N@3'<:ZF5W1I>.9OG>MF2YK@ITP\;-,&*\R?O#GU6>JX7,X._:U M7&O:K;GN"BS"7=C]=L*:WVZ9]L >]P"#%*+FT 6= P?QR_\VP1H"55:_($TR MJ(A_\\E>!K['?B#Q9>=&:]22]V86/[$3IWL&OT931FU]M1W8U"^].ZJ#$ (U MST.LN68_ K(NM:7I:Q;3 X:)9LL#,41M8/P<^%\<_W?JWZ(=/[ZS\*9ZZH\B M39H7C-0*KD+S?,U[5=N/3#I/#?QH/.Q':,\!P0G@?KZ9[CK)8P.H]XQ5Q,CJ,A2 8K*[)F.NK M6U&W!0LI9/$;8+?\ E@!KM%P*(V52 ZV#9Z:>R.7/]W'#R>?7OWTMD,@A#5!'[C@5;+@ M'\+Y6/AYQ)X\BC^FEOEHHOJ"2'>I@2^BFTMX$)_34H_:NY,!/G"5&?-9F']( M!?:9$!^GX!VO8>[PMSS"WPU6F*P@&M%!5\<)"]=9L =3,$;*C7#MQI(:&EE2 M%Z'3'FG4:_OYQ ;/#6!:9KK: &T#G6F8 '#M23,M+80\7H7.& #S'RP9HR%R M[0!/$T1A3)RC !!!-CV8&'[UNM_K]N*LQIMDJ6^)D2247&HNIH'KL6EAM:9C M9)(S6;ZCH?J.D*&QR /?99;B,S1@6BM%@E2&:PWU^=@C9-,X-Y=F[:S.PL?= ME,Y*<3L^R!:@<_1B.,7ZJN,I, ;FE)M;XJ&]];IDLJ^S>B;95!S: % ,X;'G&;>]#TC&YLH8\G-?BK)A>C!#V$6S-4;. ;(2&AI60KSI7G'.$_X M6NX.4UG50\G-L9+)C/X;V)ZG[U+<$QVFP4>9)YMF[Q7,%,*[D?D]-B-7DC&H M&;C@/Q#85XS8X/(;V9^QINT2'^\?\B8*0),Y$6_!OY^,D-M MFV()T(:&XW*AS5HBY"U_M=5JX#=6E($/13*45X"!8%;[])H19XKYN+**SGQN M]@3FU[WN(!9\U%\<"\S4X$*=;<++C-PF+=-"_9PRV@3W.;G)E:7.%QAD(PJ7 M:AX%#<3^W3E0@0F+04^2$[@/F[YPD//E*BY&H]&@-RX4ZLMP@^TWX*I+8"H( M=MUHFV%5).S#83^)TK=4(C7PN%A MQ!QQ[)ZHN'O-@G'8"$G2X :$[[/F_D']:-0#@WHEFU _'.K44F_Y3N$M;LN9 M-L8L#ZX9Y@)1([QDWV;<4WO]:"=DST0O NGPS1E9'8Z'RA$@.3JEAG<-(NL7K>7>--)A^F,7'H6E++OY]K+OT9[+]QF>JJ,W%=W/QB>Y"K MY">W_-3(Y+OF&C_Q1/4G^Y:E9=@5$O;1%9C8>)MOORQ(&PS$)GE8+;/H M@FG 25_P308 RUO;*[B%."'&,>.TR8)YWX 2P(Z/T026SKA9V.8T\&*\I!>/ M8QRVT3D6YE+3(P,3@P.3,P+GAS9.U8G=VG+6$+4*TML;*9'].&J=7'5:J'V74QX!XK- M:2:E9RV)BQ&8QKR;RE+*U56]_O3T5'MJU;A8 %.C6?_M;CC1=)6 \.IY)ARZ M0Z[N1 RM.F6>Q,PB$;U#V9\&7=?VT@B06"R+OL4N\ M%;9(3/[WFA$QPS6+N]KDQF5+(>40!42?"[=+YMAWY$WE+Q\[VD<5A*44=.9+ MLD/@LRV20#7&&?/=9%ML*>IRO2)U(*H"%1'4VO:8+6.^;?LOZL'#N(EL^;NR ME<5F\P%IA*XQ8UQB">&KK]6=U8JR.0\OX89R[97@#IE".TC]^/HP2)2MGM4G M($[[M<.9QQUJJ]B\Q8["?K(D1'H51.V;2@ZZ6(=("YO,*:-:6XC!1@-542P& M?G=&]Y/1<-!M3WM==-L>MN\[/33YTNM-)]?UEP)>RO:A>XW8)_U[)8@'(K5? MAG CY Y)3)P6=BS?.8!QHUDZ7W@WPN)U(8IO>J/Y:$6$ML&$50J#&;0S,VB3 M*?R[Z]U/)VC41Z-Q[Z$]'0!!"5\1^#K86_8=_I07O0V]&;SS(N!UVI,OJ#\< M?2O!VP:O2SW+X9XO2!]3\2MV?')'L+K68'2)Q-0)@A1+_72*6B-A8D!6F=N]Y19A'O#:S1W))1,<7 NQO>QY)!; ( MJQG/\WT\0^$HDHXPLY&6C\(&4-!"B7 FPAQF,KD&?'I_^72E^D4JHNFD9@0O MDA ,A&GD8G$E7!EPM2U+^"3N52E(I5"907J_#U(H9]/-2G@2X0D+W.B_ZB!, M4KD>0%DA7*U]"%$>2G-*TKA4*4DD8/NG[DE:&MH25R)5J%0;8S5[+(FD8%#> MNFV7*:N(N\A?Q*%W.Z++;I>_*AC-)Y);?RZY8Q/AJ1E&KKN@G45EGB+!Q&X& MN)6S9E EPV0ZZOSR933L]AXFJ/>?KX/I[S#&]OJ#SF!:@IT\!=YC"7]'\UO? MHXQX*K,<4L#'!H1>3H1&6A.,3>BG>]-A( WQ.8KDZ3$WEE@"E@C8Q'==+-;0 MH^B"4>A"&"8^R^(^S%5L,8:N9U&RE\/DY#*#>+8/8BA7H;@E&6U$HTAV"6?^ M*CY7^9X!5OZZO43FX&K]D#(] [=CZO,2R=Q5>9YR/ .IW'5X"4N>ZCNC[,X M(T>]7<*0"$.'NRYG.C]_"<'V([/[/^R[/V!&FKMT?7(NIWRC-^;!62I(MQ4THMP#EUC$H!VV4&!>HLY(A-9&:$6SM(YBZ5UK"=6SQE8Q> 4XSF.?[ M8!;8*"WA+5J1I<&92FF&[R()ON1=TA*K F5:,DS)1&:$WN\CM+]%6F)3O(!( MR51,M&:D/B9D)BG%1(G8X?LM*>\?Y&$QOXQPP.Y+^7+"JQ0-.CE(P?4 "6:8 MC]J? >(@DRF!?PW@VW#5I8XOZ2.9$,L7H&?J&T:O(3(K-(Y908")&>Y4[;!Q MY,6ME]&2?W4U!?P$"C.6&6NM)20')4W)=^^Q4 <3'DE:SSU&EAGF BNXT2.4 M\"ANM8R+5XR+L$!YA:AX(2DK)O(GXH9'89ME1!P4$:.5^NNU+>A5D"E_98)8 M'";0OQ69)SVUVJ<)"T5'8:E9D7)>(%+"QE'4^D]HNWVD%?@)Q2J4@7-0X#P0 M3PIJZ1T77MVG8A$R3<<<]9QMZMNV&PD MK M3\;>T>?Z*E@:A8R^'JD>"9!4*O9NW A2KY\0,'W0(/A@PI!;6I"!15U5([ZJNE5MGE5;S=JS9T'(\0.5V$EDK\8D3,4(@;5ZL51_C_,]P]4%QBL531_R1& B8YTXTHON5#>B=G0)OQ.BLSDU#/YA.J_6GD%* MA2W 0>F^.>.604L=1VV[W%2D\*$[!^.P_J3*E4K1V&(@B:OR%##2!S8J?27A ML^#^*B*D0%)!.!0:B0J>P;!)N3W58FU?A.^II1G8@_&?KPD!I>\Y(^&53A'# M2N..N#,B(B,+T"<:&GQ!Y4V\Q"S/@O,U$&\M=(C?+4ALB+EF2$"7>X[M66:BS7UFP[=L9%C(E0L MX 68N;7'-/*EZG+J$W-]+C:>2#,(B#*=M.?@[]MVU1Z\2NDFPD^\E$!^I,<>J?X.1YD'HA%Z&-"CI!%=)*6'3P6Z/&KV5,MBD[YKS!";P5]$.>1D[YC>V\Y),7>3O5KYIOQL4?R4!Y?ZMCR M:KE68X,_(X-7F\F,R@\ITTUYN4S=ICZMRB[NU9!^0"??].V7=6L>PO\1TS0J MZ^#O7DU7F.O'%W?1O-LEP?]4$[9LS,WPMB/[QKB"Y= =?J:N[[87"Z$7R_1D MNYN;S.=$Q5QD="&.DYS/OA&Z6,*TT'XD C*Q(+D:>![4MF-!+0))FKX765R MWI1Q:9HW#> 13)9W6/Q)9 3!;H5D>'YBU4^?.PY_&K&Q/X-Q(MF:#)H3LZ@' M#;BJ*$W(_^(RW4QSDITI=4]E[\3.<8TKJT/X#O1J<( 75"_% 4\F>O$WW!737F M*U_MS';W:C2-GN@7.C9KB(>P_B#TLQ86HZ%)?=/X@R"-A/@DSGSX7R4O@&L&-M?&ZY-%B3C,D#B_3@^H\ MV"\9L'&@"X?14=_J@JOB=9_CUP2*-7::KNX22&Y@>.Y3!O20Y>@8,_.MZ M\%;!I_\"4$L#!!0 ( "Q%:$T%18%83 D $!W 5 >GEN92TR,#$X M,#DS,%]C86PN>&ULY5U;<^HX$G[?JOT/6N9E]X%;R+V2F7* G*&*A%1@=N;M ME"*+H!HCL9(@,+]^)6/ @"^R@;'->2*85KN__EJMEBPK#[_,QPZ882X(HX^E M>J56 I@B9A/Z^5B:BC(4B)#2+S__\Q\/_RJ7_WAZ[P*;H>D84PD0QU!B&WP1 M.0(OF'/B..")$_L3 W!;N:C4*M=U4"Y[C9^@4,*, E?+1:6^_J7I*6+T'M3K MU=OJ1:U^"V[N&U?WC0:P7M:"+\JP(8F5= C]\T/=#2AP5#R61E).[JO5KZ^O MROR#.Q7&/U7#6J.Z$BPM)>_G@FQ)?S56LO7J'R_=/AKA,2P3*B2D:--*JPEJ M5[^[NZNZORI10>Z%V[[+$)2NNV/M J$2^EMY)5;6E\KUBW*C7ID+NZ1\ , # M9PY^QT/@&G O%Q/\6!)D/'&TX>ZU$8*.!MT?82Q%"6CMO[UWUB"T%OX!*XB-J_JWJHF2ZDDL75\4O6%O M@KGK[=0FAVD[O>U-*$;/#OLZBND^90=;WB(".4Q,.7Z&A/\7.E/\@J'^[MZL MA24DCHG5IHJ.:/$;QQ-([/9\@JG PJ)V3XXP;TXY5[>TA,#I "32>U0\3 6E M7*@;MO\W)1/MN'3V1^@YHKT60GR*UWY*8VJ8"L]*!!TT==QNVE4V>99I'88VMA>7R52JU?C1*T&RF"M3OW=[+WV>]U.RQJT6^#)ZEJOS3;H_]IN M#_K+1*U,=AC:4N_H(8+Q;:]ZMKOCP!"*#W5+$CQ>J*]O]- MN5;WQH2?O,O?EY&XTNS #^RX _W6C]4,#'.[R]* 5T;1LM^$V!DH^_VZ<7US MU]07'Q)?5%A\&Q3D:'4?]>=6H.P/O)Y$54S'8U=;F2BJ5^V' MG(WWW>G=C*4!P+B-N:K,2F JE%ULHN\)G1+XPN1S)-U?)IPP3N3BL721#7>K MY/&F.HST9Y!7'$9A5)-M1]SFFLG$.#Q"+W)-Z!)O,[(3;LD4B;)XPSV.&KGF M:+OB6!4<)LP9M,PKGU'F!77.=$!/G'3WZR-]Y?L SCNJWJ"2S%29A3"9P0\' M!U,9WZ#8#*;$5XCDJJ=B*A;UAQXM9M#1DQU+-B'G"T(_W7E02-RV)<,_3EBCC)<:+1R$1( \0A64V;\ MP6J(JR#5/!YBU5.7T*.R48!D_N@TI":P>C!"5PA2W_4J"<5V&W*JDJ>P$)J. M-178;N$A022L6(QO>$:4IP1;B++#LFVRM.M-U<0=VH03(K61P;.[8.EM^'=% MYCH)PD)4%$TV'C,:F[1WQ7N>;25X/$%X+Y8S!-"14'J!!)MLFH MY!#)WXD<-:="LC'F*V"+V'5MP]:YYCO0N*"NFAYJ(0HNGTNB5^/V!<^!7T-4 MR3KU54:5$T)L2J5X@XOP%;EHX5Q3&F5C0-UD#K 0'=5[G&S<7T/ESXOC!!B+ M/S)',V[2](S(3PTWY2SIH;JS9>/(^SC"=G 9;>BXB-[0T1^HCY?VZZ />L^@ M]]9^MP8=)9#%UHY7+#M4N0)WF1#6#!)'Y^AX),5?!FEC-ZVAS2JL.V$^Y(YY/SP<<$49R$FY6LPJWW <>2NY/)' MK2DO$8Q&@HM-Z>4\Y/1O6!7ST+&H;=EC0HF0&MHLIK*+:95CLB,IVZ1C&;@ETEFX$VK M_RMX[O9^SV0&KJ'M[%=3%$I.D/*!MY]M^X)/\@TK7FPU!' ,!6[AY:?Z[DQM M-W30"-)/_*[\T!X.,0I=K?J;CJ'&LX&<+YY 62'Q62-SYC?(S@B=F]<.0]=>A_CSIZ$T"W..#@.\X$7%U=99X3(1]-F>2%2Q1D'P-'^=CL!W M0HWSAHFR,XZE$SC&BZJ; HX\.SNED@P^.TU_R) Q=(,7(+>Y3CLA[NK0&1:' MK$L%*,A?K.1V7\GFLUFM2\&%NY ^8!92[MN:,8CQ9#?':,Z&0H@.R4H""_(5,;K.2J?>2K<9DG)5Z0W(J3X[ MK&9QQC^J7--R"1<(488V^)9N6-E9&_HVW6D/-,;1A&> M5LT9!\%175*(UR_\8%UP/==,T9YCCHC8//???\H6W>Z,H^0P'V3_-H;I\:X& MVT N:XU:'93!1J7ZHK4"5RWPZP7_]C3_)[L#-M> -P:'!'B$?'X.IS*'8]P^ M?_TVEKGXTZE,<69SP%Q336S(D*@&:IQIX0D3Q(3:1&T+2NOA&).-PI) M#J,VRKZ7^]G7NPE8W05 :@/W/L"[$5C>*=M\?-)C,H]68[MW4A](":L = :< M0"=D9[M)D^T0K>>@&R;@P5 MLWK2U1NJ3U7<1ZUX!,J>#:?FZ IQFI;Q,!%]IG"A*36$EO)$K1.5/A'_Q\*H MU+D**G662MT29ZTVZ[KFJ&?N9W;VRN9\QFC MKF.ISV.'CF=_YT"7TWFB&$_!0C%]XY&;_",:%3\N4N#+_A6S^'\%9)3HK_<3 MO:=O,Z?-=BGQ6"=3'6F:ZNF/?"LQQ,3$[?/7M6+96$];#\:9S?+@-S45BSGD M+E2NR'09XRG$A'19LR?,'-&-"DKN > *,4/U(/6A [GIV+ C7'!F$X ZXASU M8?W_67_^/U!+ P04 " L16A-CKBRYJ47 "5N0$ %0 'IY;F4M,C Q M.# Y,S!?9&5F+GAM;.U=W7/;NK%_[\S]'WC=EW:FCBP[B9-,TH[\E6IJ6[ZR MJ I#_.7W\!DJ)("0!!BB"7$E\26<+'[OX6P *+77S]Q^O" MUIX1]BS7^7;4?W=RI"''<$W+F7T["KQCW3,LZ^@??_^?/WW]W^/C?U^,;S73 M-8(%Z2P MZVAA*Z?O^LDOEW%#KO-%Z_=[GWJG)_U/VOF7LP]?SLZTP5U2$X0-K5R2]J6 M\W-">M,(G/56!8^BDE]>/2M3^N5L M5;;?^_?=[:,Q1PO]V'(\7W>,=2W:#*M>__/GS[WPUZ0HZ=[TD[)I:C[THA]) M4<_ZXH5=W;J&[H?(Y+*@<4O0OXY7Q8[I5\?]T^.S_KM7SSPBXM*TK]BUT1A- MM9#6+_[;$GT[\JS%TJ8\AM_-,9I^._KCS:$M]#^=?#X[H?7__.@3Y*@V7+J. MY]J628%,OAQ-'WW7^#EW;9.HV/7O@>6_7:&I95B$3=KIC_$PX8TVCB?Z.\-= M].AOO1W:[NW*UY7E&;;K!1C=ZS[Y=S2]"#S+09XW<,Q;B_1FAOWYNF5[$KP4 M;*]"^A^#Q4+';T1VH#,'"=BJD]])=+%PGG&O*D,FJ7J7^TX;#E95TM$2.%ZX7 M[&_O=8QUJI*E%'^GCAKB^/J5?E3.[V8WRKD=+>F_WL @0B;+Q@\'(\,E\]$? MM)CG>W0@AP6KX[QXE\JE,$:>CRTC- K([US2JA-"X1YC&>C8D!4#QXQ;68?4 M?OL02F=.FL!&,$''ID7F/FK 'VEQ1VDFDU8LQ^^1HKVX3(_9@$*"DUZ.37>A M6P6IW:Y=#ZEHJ@>V7YK65765Q(;R.%Z@Q03A@H1FJRHD4K?M8J2%%6*"B!0M MQZ(#$9T'1- 2RG9.Z1Y1J\^_ M1CLPPJ3M&IFN;;KW+/WY_CKWQ*RG_3)&E%;GR [W/0S"_6:)#2"B$[%KD,-T\&KY>71S:Z3L+%6 MJ@'.,D14<-5VK(TE)U,7$_7Z=M1?M3;%[H(OX)@$5YJ5P".$N>&ZK-O- +1! MV%4\-3.!X915!,CV>B&)ADC5TN!PV-D'4'[[>/;Q_/STP^>SL]./[T]/R!]U MX+1:*^L BLDB .Q2V\6[>%5FXL8HIPJ@K(T@!D>H>FE0&/0#D/[ -*VH_P?= M,H?.I;ZT?-T6(I%3IU943G=$)8<7 B-Z<[*0>:UCAW+F7E":'B%:\7D;$=, M>$P ".9BHE9CH;D8ZY-EBJH"(1PWR"Y@FR1S32^8O-L0][1!N>+X3H^V21< MVV%1LDE",_IA_;OM>LC\=N3CH"$;>NA0/QT]G8K^'SK;>Y^Q:]LW+G[1L@E_X2]S M4G4AF!]5#;E\;EL"<*2:)1'>J@QA5BVDR1+ ;C'9$F1#AC<]-U2IOV/7*S.4 M!6W5BOO[1H:V@/N6*$2DR!5I1&YCT*>"7#E(3PTMTHR!^=_ \\,[+D\NY]0C M9&JR[0(F \BS?/2(\+-EH$@ X\C_2PN$0N6>%:GNME9M^Z!L E(O*&@:>8]\ M(C=W@6[Y4]!&F5JQ_J@,ZPVN\H'YVLLZA$L[B0M>RI1P#+\_Z9_TM6-MW3+Y M(VI<-LNO"HF="57VD4CED1"5(I6D1.:7QZ0 UH!\AEC@2\$ !-NBJ9[?4$^ M/F&=K"%&>(=-Y#*5J0C%J9VGMAFX)/C:;]RR3N%S8'[O:K%D\KH3O-L7..DW MO]V0U=]]&3D/P<2VC-%TBNB^@>FWDR@/8COP'AA$L M IO>8-VXI)ISWX%5$<0@+JP8,IPIGT7O]%=K$2P&LQE&,])U>)(PFJ:N,JTF M&-:\6J0V! ^1/$B%V0,W[^Z=2XCC&B@Q([?5%Q02&!'^@*-SP/ [H<^=61[" MD6H)X/@,*9\H?T76;$ZFYL$SPOH,R6)1L"Z$X\^"DZ0\<]#&TP-V#81,[X:P M3PFF^0\RLSMG7$G4JQ7'\ZK&EP1CRL=9+@WW=,^S^B6,3&0-N5+-U(K:ITI& M7RD^&W%'E$FJ(.6=.-WV3L1]4?=$JC=MW9VVZH\4#KLLZZ_@:+&01Y9;0;I6 M$Q/EA6Y3[7F<(^2OTK<(' 7\XLW["0JBDYX=^6P!6,M8Q E/CD45@)STYZE= M'CB #O@KA"=[R/T)UH%^-9 Q651A; Q)_PY-ZC%PS"?]=8P,9#W3\>]=ZF%/ M_"-EZ:H03O?SU2\Q**3Y4FX)"B@),*9A\#M@Q&RA2:C*Z*,,:$Q&H>W$HKLR MA/)!X,]#RJ@C1&!BB"HT8&2<5F9DB!@#"Y1P)1-7 6)JY"M@/DB S(V*80)M MP//Q[IMZ0ZA.TI<-243"Q*'<.=4@F"6R*AIY@9M#D\ L%IE M\'NPZ;R?2N-W\?9$^A8L:5(U&UC;SBI;VZ0XA(PAI5(XB4K5!++D%=!4*1#3 M+.X[B* 71'7 0ET@::Q$X".J6?Q(EF1!4@W.4IB8V(+16G6$)3:W\<;H&3D! MBB_IW;AXC#Q$1#$GQ%V1WVQW&25+]7SO4O?F8S0-G,U<0-4T"??@>%-1$RAW MYEDYT&PZ"'<)LWQ$Y>LV/A2+0R?/G'*,KCW?6M ;RZFN5_2SF=]=UZ2QOG&L.%E37VF(N1 -B=I-7O7=%1L)]J!YQ+C6;<+4#X]P M9-\2@10^462WT?CH*VZ4E.04\/VWG%=VTF (+L2=[G0ACM)P;,9$:%Y"1<,Q M_<8M":8_-WQE4JX$9!Y=*00)8U=CDY?JF\ZL!\:G4,/3RU078701%F&=\ M$1].8+E@@.D!4U9*MB.+I>V^(6JBW[L.BO^*(B6CM[;XE_7DZT+PT\AJ]7HS M(LT>M*W(1@J\G.STS+(0?#E%$,MA!P H.\XP/,=#]$MA=H/1[P%RC#?!X8-433B'")7K0>9R@XPL %@OK'&?4"G<%DK5!'(:4$"G MF2"*6-QW$$%O[]4!6_U.71W67C)'B>^1256%L*,W,D6-T9(P@\QHUUY4!PJW F%5+J'ZF+UFV;"<4! M"?;T;F&;Z,+[9T$;\,PT"87/W6'Q^3U$E+.&2Q^LS:82>:8,("G#T%D&OA=DK[B/YCSM2H3%U);=C8>V>MII# -A MB_Y';[<_ZW9FR*U-7.[>3[H^A-V MRZK1\&7-I%DH43C\_ M2\35YU4$%W;4V>5=N)(LYJJHKM(H3I4GJ4*"-;?L>L5!C>N M!'J_60[-F#-H\&6>EU]B9%C1,V!H::-0[ Z]&XM]ZX_P>RY[/(]49("\'3):/ M1MS J7>7BWE_S[>]OU%;6MA8PS[?Y$GJ47@ [K_=(7_NFD.'V"D^0JF'JB_> MM@NOB@G]PI5VT<1 8[[;+3A$%)0'Y"=6@'QF@\07 H"Y,T4331,UFCYAW?%T M(US310YDF8I CBUSU38#EP1?*N['W;BV[;Z,G(=@8EO&:#I%W*ASB?(0SL_D M52NYW"9F2H781TODW.GX)_+S1'<.)5 C@^0]"P>L"N@9#IT6R(E&#=,;(S!_\,*Z\>A(.LXMA),*8\ZB67 MAGMJ>ZU^"=^?8JUZI9J!<,I55G8_G'8@9;N8?63QO@IZ1U*4$64_GU32 -"I3.+[LD1\&+SHVY:(N=FZ_D=G;UAVZ;1/%7V2* #I JQK9S"2>81K",AL3)(ZN MV"@$Y"",I60L80,*CB@A[NPUN/>P[O(5@X#)BI('1Q?A&C1P3/H< '7NDC+O M1PO'F@1>\BI=>E130OE'9;NU!^'TDJUXZZ=%=V(0P,"*IEUQQ-]&&8@7P14L M.1M< \"J/)-K7AQ3:BI5TQ60]8^I\UO;_E M"(+P*SQ@/#4Q0MZUA(=A(JS[_)*@_##* 8W5P@ X'RB)TNCZ= QK6?+ M#'11\DU.63BY-I6:@!SN(6+XJ^7/Q\@.>?;FUO+)O29;#U^<=K%P*T ,.*$& M"P',8_!0H05M6:F"NW;C2<)& F4*E53%+2L'['N?5Q9&!FE;:-!L%H)@Q^R M#(\M '# SD; NTV@T@+ITA4<6+H"Z,';)8/DP05OYXY5WE"]S;MZ6D'##5Y/ MK4PL[.#PG:=(,/=7G\BO7IC9QS$PS?(CP1R/M_N CHNX 6\0^'-B)?VQO@N2 M-A3KZ1>"C5.M+M8H/.77R1(V'HBQ0NC19QN7@P/?\W5B&SJS&Q>O>>613 KE MBD&HB[72 >+NKT+=K%68T'9D.P_'@6E:$0,YLVDM/8*X[JQF35'@MUW8&XA Y:"[=EMC?*&'NT0[:\ MH1,%/8DR*2GIJ585/&^%"HK$!5+[)OE,3C:9O'Y=6CBZ>AGR)]*Y:MJO5=,^ MU:YIU0AI;_0K_.<7Y/GTY5UK-O>]]0:N:ET3]U6KWGUNA=Z)!092!\L(+\UF M-,#Z52^MS"[J=3VC6O7F^)$H$I M/Y2NU@I]?%0W. M9OT4]]V%9G>AV5UH=A>:75-H=A<$W 4!\T/7NB#@+@A815= 9MHV!@%WL9D* ME;^=L9ETQ<&60=:V6]D1% MP%^1A34.)$)3* .XJ J7W9PZ0-9/"7V5 I0W&7E4&7#"\]AQ516"1^340"( MDLD>$0'-R(#P M3KI4[S E-/8_1=%K0I_>^ M@$\O)D);4?$W+4V'%A+R-RTAI7/Q=2Z^SL77N?@Z%U_GXNMT;%],?J];!G,[V]UA;E<1 !O15PV<4.:9> U?]0%@+U8YB10JY$N"^Z>(A M)0JI>C*L71_;DSQD!R;7Z2L23A5I)+.G5F<\K%TCF2+Z+,W)FJT/8J*=BS4P>5&E^EV/=.ZQF[WR94OS 9K39;8.E_ M8=FW;A#([[D;,'*D>]^S@Y0&C1QID>^;IN?OT1L8 +L2M6?'- V.BUV1V+?A MLGYS9AW>Y0TF-(C6J/Q1#+D^6[T(*#VNR1$<2-V/WB/ SVZ3!!CN+6U/<^')04UN&:9'LPZAPY"&Y<'']%R_$FY+J):/6SH> 4G"-D M:)J^ZR*5B&9C4[#]*HW,R5_-A+1Z2L\_#JQ9FB!5>X>Y1'BS(?>UK,:H ',V MV,BLHB[:1D+T>S,"UN+UO& 1+ZV.>8?\N6NZMCM[4^7'*=)SJPT6-=Z<(N+; M:VT=6][/&XSHSAD1$] ?DY%:AZZR^P4S)]I5OO MTJUWZ=:[=.M=NO4NW7J7;GUS\6;]>E6V][NO7#?(2WH=3K.2( &1U MKI,N>7"^1ZE+'EQ:L->_!V3'.W3(0 I" 8W\.<)/<]W9=%'''*\Z\FDUSQ_ENQ7BN9/6I6^+W+,9?+>O:.3^VJOME]JZ?K%FCZ MIKP/1]&CL+[&%'VS^U8[9%N@Z)OR/AQ%E[\["L):+T9EJX=-T^9\,5%W(T;] M'?=*23N074*9:0W:0#NDT=5P&$GU]!W('@7N.#ONVN&8U2\19?>Y1<&G;W]_\'4$L#!!0 ( M "Q%:$VT4:=5/D $W' P 5 >GEN92TR,#$X,#DS,%]L86(N>&ULY7UK M<^2XD>#WB[C_@)N]N)V)J'Y->]4/]JBES$1F,C.1 !*)/_S'RSI!SS@OXBS]XS?O M7K_]!N$TS*(X??SC-]OB55"$5Q](@1^N'U]Z_?OO[7=^C5*X%\%A0$.$L1H_+] MZW?U7\X%H2S]";U[]^:'-]^_??<#^OU/[__EI_?OT?)3#?B),+:*>R&3./W; M QD-$>'2XH_?/)7EYJ!Z_BM"B#-&RP*!D5WKL??_SQ#?LK 2WBGPJ&_S$+@Y*I MNY;A#+.?O>4XY6:BR3/WU#\-RE^I)^&CO C'>'=O](1_DG\^F/P@)-O$(7\ MY?9**]"/+5H"Z8TS+N^)>>-1K,J8@M^$_NLCX:O%,7XI<1KAJ.*9$C%\7S8& MLPM&E)+-PA;!A!I)EK=U\-LNI=_ZW0]O?WS_EDE(?_/7#\(AEVETD99QN;M* M5UF^9D:V?"C*/ C+BA!CGU.RQ'M3LTA1EWF;SR /*]+DQQZQ!<2;,"/>LRE? M)5RS''V59^M!C DVL@%(?TT>DGV)6N+DN,BV>8B'?,GKWZY^^;?/[]9_N$-HS4MSRW-3\1KA8H(+N+(2,)&%?J^0#:6+Z1ADJR" MXH&)0Z:GQR#8T#G@]V]P4A;5;ZB/_/[5VW*"ABL <;18'#UX_9\YL(Q]0>?D=_H&;P.\D,R*_^RF/2 M+7Z,:2!*R\_!>C\(Z,']:'EOSG]OMV!]8D?A7']+6]P'F'-S753*\_YE; M0"#?6\&!_L-S8)+T1XB"N[*!)1D\H@Q<)L&C0I:]O[O_YDH&JV_=^J/3;ZP8 MN?-M:QA$@5Q]T?-MGE.^XB(,DK_@(-<[MA[4_7?N8[OZY#HXIU_?S$3'$ 0X MXO"((CAW=)%D<$YN\2;+RSA]I*N)[?XRKA\<+)4SLK^7T2EA(1([ R/:_$Y8 M3(V$.)9;:[F,$YR?$R-]S')]HK\'!64;2F;;)M$" ; $Q?@Z V"@J()U'"2R M]3I+[\HL_-O=4T#4<+TMZ7$-/='26[D1"2Q@6(BR%S8,&!#!HY<=;0AAF(BA M+A!'1A*VZU5&,UE>DM^HYAPM)-Q*0\/T_EIC#PQDM:'D0;_>D',1A@!C#WS9 M8V<1+5AHFU PKK8*"1#0+CI<]%J&6)!.8AL3G#ECA &]GN68OI3J3P[E$-HDQ:K0 MRC([L) &JF&\:Z=[@$#FJN1"NZL3,)R?(*UW$H;=6?-Y4#PMTXC^Y^+OV_@Y M2 A;Q;(\#_)\1Y8F?PZ2K:ZVQ!(7QMH'"29;OQ6B!^\7!&+(ZOY9WR+0TR&>$BP<.(] MF6P0 *H0K42HRP^-T#!UAQ8L=6SC%F\(+]084/F$45SA,WLI@Q>4UX0*%&TQ M*_Z.4Q2@U;;E;PLVG-SG>!'%T\;+!:8%)3+LFQI*W4@-- M#+3"A)E+!P@ESZ06:,[G46N>.@8G,)% 96;'D!''7L XT'2"88Y:,,DR)EG8 M2E/G$2PK@V0>P>XI:;09*Q[0DM)F=>'%$K)WZ0B[9#1N'\SLK'TV;6^]OICH M34XSG7)W0WADURE(GKVA^=IGK)_03"A0,UF_&.TI3 \/,'?U,:.([1QE@1@2 MBWTUV@(11*B@/EH4)@-N9$AGDN$9YP]9WYP[IQ3NG%N:43\3'S+.0QI8&'Y3%::P>&M)K[(XY)81ZQ8V^5$B=J[+.W6/886W2( *>V"[#,-NF97$3 M[/2'4'W 0&F/D?56&J2$=)\6&=CHIDD"& EHX WA<;QO.#2H>>=;''6=5"^F M#A[,R,T"[-FY&AC"U$VA!S5\0#4^GJL_G5\.RPA MRE(V>_X:ET_GVZ+,UCBOQ-B9G=<.%:B :(!8K?HA"SSWY4/63'6S'X&**"ZJ MD&N_W\WK]1:>4P9K; _G!O-)A"6J7S-$[XY_/4E\E2>)A3Q+S'R$ MT5]C>I" ZIEB@9(L?7Q%QEY[,6GTQQ$/IHF>^0%R8NB?$< G N,,X$7D'WP" MXM^9Q[!3#H_.-09O]JLV]]&R+//X85NRLN RH\<;/FS<'B@<9BB .[[6^^V 0M;UJ'E0EKV(Z%ST9&/ "717%%D=@!;R#N2\X M]__[[>NW;]^A39"C9XKW;^C=V\7;M^Q_J.#M)H)M^93E\6\X^C>49M5O8R8P MO=.03=>.XI!%0]UBPWCQK ,&M0Q0L]O.]]LP (F]B@%%!B_W*/' 'X;QK?6$ M[]\:7>'=[Q?_^OW[Q0^_?[_G$JQ*O/$)>E/NCI@#7C_@'+U_NT#LK08*]>[] MXE_^Q9+$!QP*"N\8A=\#'K1$$6L+$"0W01Q=I:)D0;<]K8,&.F0Q,]\Z8E&# MNC]@,?'1W=ZOH1$%?W65PM:4C.:>WKUX%:')$5&&B;R5<))"_ MF]9GE _ 3"N7+$3$(6'\?DX)(+8_FQ!V&T]>+#E* M,Z2&V[O:;4Q[&XN$\^N<-:6+V"+^!N>L_:G5 M'I@>V8>MT#[1]+NC.DS@#5,S6_U[J#>\.0JGP'>0:.=*WN_6ASW5T0**S:5Z M5\D7[^*=A)?U=I:5%KI(/GB33A2]%^UC 'N/FIU^KQ'=H!M$'SQEL##"0SH; MK'YY"M_.'J"!"L$?#VF+T.<='-H+SY!9L?8*?\[C!@G1]H98*02L)^B?$;#& M\L M:0_,Z=NGW!ZN6 X6S9^U2N>]E-Z%BA$#W&MLEB@&<$@OL_40*],1HOA MWYJD(XIQ0:*%]L03]$L1#2B\!QCS=Y7U>U,"9<^_7XN/ 0^8V:%X8OP]:PXO MGBZS9\;2%\#7&N,E\7"5<96&V1K7+_;T7)+00L,X1 _SLB]H0)V[@9$/\W-( M=_?D/Y\N/M_?H>M+='US<;N\OR( @"T;J[[SHB]RWQM)!GB@UHU] K3:-^J MW;=P-'/2;858OP]0(8!?HQDO0M5K O .S2TN,+$R^EK(!_R,DXSU3Q62: 3N MP8&JW;00I%VV:4 J-CLY491K,EQ6-6"A%6Y!E2%XX&21 T6G%_\C%/BI0D1 M8AFMXS2F'DU?QS![1B\6C&]8"B-[1P^*<_^PXJ=C5P*+F54;#]9'#IY$E6^1%\7F2=#\%4X-GRRTONLDX*Y($%\_7,QZSHM6$9$MB*NTPK M[;@!@[/D?1X,MLQ!T;<4>.++)H,-NI=M^B=$/T]EUED*:!9"Q:[<1!+Z#7QH?+F L9!(3Q7> M:^6KE B,B[(EA"R=_NT>.U2HK4=[L=K[D/UX )N2MDPI7D#DJ)4;50_3M5QL MMA=^^EQI"L&X+\$YT&66X_@QY;WWPMU]'J0%\7\R8?X_<: MPU_'5@F5]MX#JDG1R_1R%8>@MD",'I K3B8TG9G@G+%JAE%5Y#)NZ?E1G&Q+ M;3U?+Q:,LUD*(SM7#XIS9[+BIV-'=43X6#Y3";C1_QY2_N@7:^8?%(9EYTOC24&XV*'B2Y[ MWCA*SAWR$#8[9ET10X(:XN10ME+<@?+&A2=5P=F^&Z.OE5("H12?*AOK&CLB M[_!FT%:X4$V9!@C6[M-D@0C0NLF:JR'UD>1/?[ZXO;\Z^WB!;FXO+B]N;QG, M]?E_HN5G\=.?KC]^N+B]JU_,O/B_OUS=_P5]^^'B\NK\ZAYPJ452U!P'!?Z M^7^OTJYR;K,DNJBB%TK M/TNF17<\]"TQ;)Y%S;-3:=O5;SJV'3?8Y+?3/FQSPO0-$Y;=6_Z,O[*_Z,J4 M+'$!VW#:"M;IS-F'"-.LTXXK=?].<1\2<6S$T>M^\80$!P![1O,0 >D?F4N1 ME678NC:6XI+^,JX PJPHH5_8Z0K)(\=(=^L@>^5O&M$L'&X/TQ>/4[(UR.6J MN79FG[-[E6>T@*9;RL QPTZ"@4'#_^GZ%I-U?QR6HJ'/DJX.?L[U5<8C:7D5 M7NP$MYW>M81\"3XV7(Z9_AN2?(6(&-$%8F2]BDZC-""[>MZ(RMS=.U_FT6LB M9^XEYI4W6XING3QX[\]6;(Y*+H['H\?IP.32?DS5R^B_MT5)-^F+^TSS"@^3 M_2$H<'2>K6FE$KO4<4M;@1=QB>]P_AR'F.OI%H?98\JHF)Y8FW]8J(>CW*BS M_0+5O&,"/&7E0B#%JU+UL+2Z:>^)++HO+<86\>L5&Q[)X].()CA @@41\Y#$ M!-036R!:98%2J"J4B%97'3VI>;0I*?.B7K&W&A&VUM"^DM#=RSR]KF$K 6Q9 MH'2 MB%U326[R[#F.<'2V^X5$ZJNTON^[#,OXF3\E8[:U,83 XNE(D?>"[D J$)%Y M%(O*X$MBA;RDUDA9]AYJ;Z@U%\,NVDPG/!%]13V]=:ZB5WQZZ/V]9T'\F6_;@\DV6LTQV/Y7Y3#22 MI249/>'WE/A]4ZC^^18BPB8VK94)75:D89S@5E)VGTTS27%TPLV9;O]_L!P@RX)L!!TMZSGJ6%'N96E'@DK^2++V:/"IK^VV7 M8NIB/[S]\?U;YF#T-PJ^0Y)7QL]XF4;WP0M)9''\3->=>W(/17;K6.-$HTXU M#',6AXJR<$N3>]5\/H8]1?=GDL<4?/GPA&F3$.%CD>QC<465F5\9O-"%AB!< MO)[%RU2A9!*)ZS!2$4 U!41(T*Y'J"$RK6P_8:WH>3!;&_/INW,+RC6 MS0*IL?/639R::]^=1?9*R*I9,Y.2=W0*E%).F@"7&?;E)?^JS.#["&)'_DN2)FA MDG;J(S:.'K,LHL^1%J(NB?PM%$.B%?G]UZ3T@>I A*CFP=JD)& MN7M;^=4#7W M&S7WP.Z2;TG*T^PZ#!&^@^J1TVC$ZO6;/3P_7$?)U #OH?A((N"1 ]F)5LD M_ZZ)?3G0P?5$_M>U'5;/YG$=VW3U:V M3 ^7M+>NP#LOO$J?<3%%M:F1D%=> M:2&RA7<:J/CBI;TL#O76FN 15)L.%WZ_VC2NI?6B+HBDS-45HO#OVSC'1&(2 M8EF1Z]RV6&2MG)9U5SHG1=>QFF0AA/DLD9"7GFEA<@6WFF@XHN7]K(XU%MK M@D>0RPX7?C^77=72'IC+:@Y+"<T89;J MS&44&8!#TP/$K0].1]" .3P=S6CW!:8GS*>5.*6VB;[-MB7]X3MNI+3F*FAZ M/X2B@I'=Z**WO*IS50)&*WIHYJMLQ>;X9'0Z_524$"6%ZA8VUZO6@S_TZ4?Z MN_KOYZJFE0Y.2&<0O+:#N.CIOI>M5IAU-@)NV5FM=T2G?5.(LT.!77J;Q% M MME7P8,MK/3/Z!35];*3NES67.[67S_>]-T='RT/%:>9Z:->0X@,3Y'K#WB2_ M>,%Y&!?:-X L\,!N4]L)M'?)VHP$*,V]1J"B&A?LKO4$(K',0F!0 M3^+=XC).ZAB6NP9;DB)62"$$^Y3[7@\4VBWFI/R_Y(CW_V?]="$+T>%05=3A[>CBM:S1M\X![" MFDLIRAB @A)A>MUJA3ASD&]I.9?\ 3_&*7VZ62^_PPXGV\TF8D;!Y\*'X2"( ?FXYH8!1 M7(1)5FQS7@ 45@>9],RHHC?ER65U0:M>I[)=5I)+;>EOS[;EYZS\"RYILV[5 M&<@@=("3RA'BU2>4 W!A3B8',]@QOGB9CEV[P^)MB[L<0 @KTK&([/)0_73GUYL=EE8C101001*HB0080.Z]4/ M< HYH9C[GWOP%YXP+O&V-_7[ .R6?!13:[4/3L-I $2HL8+686HH 9A8-8Y+ M33-*E\(OGL4_",41;R@1T'IFE5<56_#H)D2E[% MJ,D_OKHNFL0C5G(=H0..9C3+PE4G27<'BTRSB[7HEKAD1NW>F: A#HJ%;+OY3HC'S[OT$5 P_GWS?S%HTU2 M62(#[7L.$JVU[6F%Z7[7$:U\4/P;CD2;TW9+U$;0GB!\,%6H!V4F M44;[#9J#2 (\6S,!O]JFN1=RTUS>&OB<;CW2O&-T\]R)-@DI-X(9SDO?!&'$ M -K0ZQ>BM4VG!W>_^=;'2\>H5/;CP;0P7) C\ YM!Y6>B< "#^P>E9U >_>H MS$@0]ZAL.%)=.FH.;[0->SRPKV:*Z0O'PTAX9G4&,:T,4('OCRUJF=.:I>@G MU;9.*?WW(,Q/**TO3MAM[%I-8[T[YGUX8!OG=@+M[9^;D2"VT6TXTO;?O9B^ M-*C+4G^@'H((4 0T2*2Z\L<*"Z;<9P!KRC8IM,$)";5--2PKZJGJS:0WSVAQ M.N^(PDKSZ8\DHZ7O8Z>/HE#=<7G/(:(K.F_[,?-,)MDA\6"B,S1ZJ_TI2R(B M*YWXRMWGK.S;5.I# CHSLQ*E=59FQ'!_1F;!3K<,3&H&Y)L9V2\9!N#[9%R6 MBP5K9$],SCZ0R?C_C#@%6E^)G09JF^=]#Q34#S=K^&6MM>IWAV]Q0GL)L:UB M]I Q>YJXZAS4=T1P(%&@$X))5-$Z(#B(HOOS@0G8U3QL?=;[*K>')G\FB]DW MWQQ,U7.C-RMCE-6K2?IK]B9^N[=^FMDJ6[4L'PG"_++3 LGOUM=]X^ WP>91 MBW_A@/ 2%]>KO2*K'?__/J^W189Q[F&BR3YLA^G<58>PU3$]ADR=L4%?\#JX M'?HB_@ON==-(*-]H@/.L7PH2.BZ*,EZ3@*&[>; /!.,I:E9ECVA#.+=\U?"= M[_\+[RM8@_EGWJ/$F/;59?7K[C9!?Q0%F#>71P@I/[D\ !WLQ>7!//:D:*P] M>%,@O>$>0[?%:3 ENN?=6R+\C).,'UJ6P0N]Q,TYH9+!A_LA1&]J4>%.=^9,5/QZXJ+-JXDV^P^."1R!W2FSNAF^RDBYM@R39H5J7 M1:-+W-(EW2 )V_ID2.3O7W'\^$1_")YQ'CP2(I23@C8.*TJ2VA/^/+@@S"_: MB+N9T75Z2R6ECWRQ?7/K.\/69("O$0\45WFSV)(&W&7C00P:KNPNJDMF%2G$ M#FH%,<1/5GR)%1-)+T6"5=7TJNKBMZ[4$)1H1;7TS"XV$Z4$=&-3J.6!#G-T M%YQ[2SD.)GM45YS-Q1P'TCR62\Z]9P55$U=1M"%17B!!>R%=[A31I%6SZ$?P MF$E!L7SI-6-Z"<6EU\#72Z^CKR*"N[^]2%;7#CV\;'C8%4-?''"T M>&T74W5H]6)_H7.+A>E]P+Y!+P'P_0!+$37K_!YLR/6[%6OF=;GBBI4OGC>I MH%,T9Y_:]YIZ3+FVJ[6#ZT)X[D8+4CGT@ M<4"_GX1SH[?(1<2VF,(:VX00FQZCQEP)!X M6J"&*V,DXF_/D!!$F?,P9_'K8[#'RX4:0UF-(A_R(4RKI98?O1N\&QMSQ MA*$#Z*$J&9+Y]%/U+N6Q97E4KK/@EWV1H+^HWE3?>1ALIE9/<]3 @?*&)'J MU77 -P14(LL)KBPR/7/AF7%1;-?\=Z,CQR&#^!-%#E=57T09/X(7T>50]JTC M36NQU DU]7!(&L_KN#.KXJJ"A5=5P4(@:65;\(L:89"$6WK953H!+?9#F,?[ M/LT+Q4Q_OZ0Q20JI.B?->@:/XD_PFD!90_*A@4-X$;X.YG]DIB0]B,XC&1M- M[ 0=7=XTD>::)"IOU,.#D0>)U/:AB*.8,'B=\WXXGW#YE$57Z3-A%N.[@.F' M>BV](JM K>@ZWIFCU)11_C%%^5>*V[>M^'!.T@)E'4)J_" #1B/3L& ML]PWOB\4%3%L$)+MCJZK M#8K5"M/RQ#UQ!F,#7-T?+EQ];=\>%>;*_E#^%)=K-KRM2<%*T=><'@HJ@FA# M,B+F."%OK2>6:8*JXZOV!XLK"*":@GA;Z)H=A-2M U%%!N!^_60R-M]0E!GO M?NVW&'OM5S.E_BIVPY9\ M,\S6N@?B DRG0P6K)U-;1)BI=!AW?1-IY_+6GJ&A8$UOL]*@C/FZ1[HB%K-1 M'<^M!\I?H2.!CUIA C9*3"I??1L/)\E$$62RZOL0XZB@EQFI7 %QXU;>H"^= M[L,#J[VW$VBO]-Z,!%%Y;\.1JO">X?&+HA6FJ-G1=KF>1!R+3MUCI?HY9WTV M6K+%DFQRBCKA;&Q^^5FQ/6J-!3 #VPM3S[W]*#"SKBU?QA./."4KF#4_B:47 M.(*87MZFIXW[O><(4U]3'[T].L9'=/N>@S!]\Q7E#N@ - ]]IF\+ M<2]/3>@^:$SAV2X _54A&9[G_M.[7]KG0V#;P+/+YJ*_J^;%"ELDG[JXJEZ< ML,/PK%=KS\L1GS,4X169'WFE8+4%Z$O+U![NC5U2OU3(7G5%M9:HVPAURN<' MJ[W@6_R,TRT6>\276:YN,RGNL1=/MWBU32.5Q >3A'BR$@&63'GV'E50_4Y#D_9UE4D!AVA_/G.*2[ MP"\W0:S,&89@0\8%:^&Z4:(7%3AF6/+7%T%P;7"M-0T]_F)TV:144:83+J91 M)(Z\C!5C==)XG;10$?(O]^1'E YD,#E+IH?V)K?J,C;-(-#73*=4U3P/!@ W'9N.?8\3I0 M7[JJB.G)PWC>U.J1?6XJVLZ];5K&N_O=4_D66''#<2GJ:(//DFU*S:/[BO91 MAIVV8B:,.9SPL04NYG&B!^"A'&6AZ%?1*\9"/-V_OD)61U')9\6X) ?B< MI7G[&1/#HF%"^EZ\UG.X@@S/^(PG#OV^SZ&<&Q[^J1[\$;U"FR=_Z&Z#3!-^ M 3"%4OI6 1./<;Q.95P/3#K 43I77\*K>%F+.I3\*H#ZI:V.VXFGM\!7",ZT MYN-+6_2 @0A$_T.W-@F+-%S6*FF>"=(H;P ^3,@8+* <#JR1G;OZ0,XZ!LG. MOJA+LA\D$@LD3:$-&1C7G$1*W&"B;]=9BG=H'>1_P_7-DG$[\)JS]G.FP+[)\FIM&C9$V6NJG.R" MUGGP!6VH,K5XS9>EAWDCOBS@R1_/=>SG>0,\ MT/9]9DO^$!)BX M8G*?QT%R(;Q-Y?2]* #SJ:48]33: P\S>UHQU37JNI*5Q4&R&DH"4<1*M%;$ M$<[%17H:1DE$#:)G5G5&K]]LFK%020=KXFSY%)2TP/694$"8D,K6<8@><(I7 M= KZ&I=/E!A:;4OZ<.L&YW$6439(4LAJ,9"X?IS2J_P)HJ4? ;O1&N["A"QX MXQ5*LO01YX[GY'%J%EA(0D,,#UUHGK9S,/\>)HI<,0__/I_@ZBHET8_:I[:& M:!\,JC)-S6Z[^*P- U!?IF) :Q U'%1YV"!N8QVW[I]6K[K/L?MO&NDTL+"/ MH"L95[ULW@($>ZY76*H@/U0APO$ MMF=9T@YX&A&&VS5[D2_Z0*^LAC';_R,_)YB]")A&RS4]7ON-_5XKIV['>C+R M0&<=$ZNG=30R$6WW)RF3,M[=HV[((YG^ M4C,-^7QZ /$;2BP\(\[1RFHQ^Y MCE+6ER@RGMC,JZJ/N"AH+46MKT@:!#2HY%LX9S- !PSF\ ;6]]Q7 M 0GAC%HV5*Y%@5$%#;Q!,(KW4'H$B9R\NLE0=4:BMN01^!#=#T<(V+0Z M'( ,U-=P,(>*FK4\W]%]5%Y59&J]P8XN'Y+X,>#O&\;1^?^($H M@Z3ST";8L2:EQ,P+.@"[55,9M+:G6'7,YKJQX>&:K$33]BNLR,#$GZG%U'W! M"&,*2& P@W)H;KL*("@@D?>DZ@P\0CX\QQ#!B@#@Z*!"R@ M0P_G6>@;^L2,1Q'IZH/-Z9D>"?(DK4^4[JF:#@/HA,W,CNZT3^4Y I" .^*3F)2CJ/3QY$%>:5 MR@E85C]G^>J!HB&9-))HL\?*)3A!'[$!/#BIF4\Y]!FN5V<=Y4R8U]Z3OQ9/ M64*;=^:8C'2]&BW.Y^WZ >>"0+'[5&B=Q[L8%&9= MX$ZROA:B9<6)U(XXJ&GPYR=9@&KMD/'?%Z)+<2R$B- VC3"ON"8^^3NV9^YX MB0&HV7IH5(U-+TSQODG=:->:"LYV+;CV5,#9J&D5J.$$8#WDA8(KBU-9*W]T MK'K^<8Y)Y0;GM+US\+CWA/JV+$JRX"9K[,LL;]2CDY( ]6K.^ 6<\@$YZ0 H MO#L).60">%)R+JG])+6I6=M_UQ5E#7LL @1I$R;BE%\#XI%4&33J9\M:X<.G M&0W^LS0!^*;U'>2W@Y'$#WM=2)X,#5,9@[69+"'G/)\^@?TR1P2#I68TY&?'(=F_LE3C)MD[_<,>SWV,KR_0;08LJ9M(&R?7H MT"L!.(5*.FAF\VH*;Z+@H4L 3^*=JRAW,K'-240[_C@&$;U.)60-T5W!BCCR MYY.+2-5BB62R[-1[9F5WASON^*13WQQA:G^LHXU6:D'-G$O$D6E]BD MUFGH T:A*174B3U3$(>).--Q/D><:482\04PL,RHJ?,L+?,@++>!3^_ZC16: M_=^?Z3NQZ>-M_/A4%LT1QM0*-H]U9.'&1G&3A![30,<3AOJEF",D\?H8,2SB MXRZDL\DCBU CE%C)OM'*? 2K,EEN'IO?39U5*H&\?;.H(;ASJR#(@"[5-D@ 9QCF>_*=7 MB%EW?OBPW7WK(\M_1BJQ0!E'1,\,$W%E;3>TX3C.5[3W-W$3H<,U+O,X'-4( M4E,7/.U6%VO?Q'[U(2AQW95?59;F:&" RE^G*JU+?9V,"E/;ZU"TWF)>UI]L M)3V@MJH=^%'LY49;UC69@N>8O<-3)R".JV\A%<<('W1U1#!1'0U<55MWB#>) M8[]&E!7I/1* ^EI()2\?'W/6<4LR2< >5PDCCB.U2D0#$QB68@QZT)2OKOSA0Z-Q-C'UH-@C"(%SDF$ M*+YZGE^KU3A''YC:"ILI)O%!CCD M#*5,$PI]5P9Y>21B'T\0;LI,Z@7I3.I5CG2<@=B@M"E#L6*8HPO&6AEF#U98>)#;.P[B@=?RSIH>*<8XU*FD4-FU,VAOD"".24H*9 MXU$]YJSIX>PK5%OE53OYN($_C:C$3WOIJQ0O&QR2'^\S^BM7:UG[X8\SA@U5 M[Y2AS7;LHXMXPP1S4/K!GZ41S-"N?/37[A;1LT?) Q5>!<_G1EE84A;]]6D$ M4TDAOV):04R4]HSSX!&+>0;?Y'&(Z5[HRM4!AC4CQQE@QZM\IDU&2RZ.+NB. M%='=-F7%%A)\55DJ1HPS]&7Y4+"[1<=_FG+8%Z@5%0A%X4I1&Z:H#S*'1_(KQ:#XI!M4X MSC&G3,F!I_/*]$H>-+=,-[Q_\\O4LHV:8XKQO5(@9IK#,_;9M2YW5SFM@*HX M!82(JH/9.-+0.E+=D\;7@3P<7Y =)>"\D599.7"JX78:_3BF7NWJ'XXR=L^I:5QYQ4N&S_Q04(*H>RM1Q!MMI M/H7;8HN3"LU3B.M)8<9)AO-9OH]M'4//D0%V&2%5O:OUL<),_T M\7K&/,Z0;:7(*2.R<<"C"[@6TLP:3Z6'?R0&CKZF8HQ:)55$#=+Q=F;33PJW M>!W$*?F]U)7W'N?K[TU?PS4GQ]G7[0"E3]GV;00;1]<5;K2,@'46-6=(;HA- M>3O.IG+3?8,J"95[)734)RNM5"CM>(*S)I'7;]?H]&GLZ>L)@\<9RJ?_1-,W M]IR"NZ,+_%.+#K=A8=Y_/K7)8O;O5LTA!IV;YY2/\>HTBJ.OB$QQ6L2AJLNI M@_&.2=REV_7H$"TWH;2I2IR;[IL]*CF>A%F:)=IJ MF2L!-@UXG EMOPJG3%#UHQU=PMDGBKL:!1<1SJ*)J7.%5D%.0O0QR%VL-TFV MP_@.Y\]QB-53P>NF3BQ MJ&E4M9/PJ>3@=.*H0;P9 RKE1!E5Q?,6])EZB:$3"Z]#="Z!B =4F'):D38D M8QQQ^4"MPKU-V>X3(#9E4XX9.#6BFFZ+8KD4E<1I]PN531@3,'G=SW1 8,O*11=7A2ITD MDMH/>SS1 MDKG"Q6=0CWL"X="DT-F"H6K0XPZ%>HG@ -=YK1 MY@3WU8KJ):[TDM-<^MN Q$F:-X9D9.BL<V?ZGM0HG MV>?L'>UX]C,M17$9_^HCZ",L5!^KSJ;*G "A;(4RD0#2I?$.DX4Q=&";:@:H M)/USEA R25SN7&5_NI%/(/\S*W6V#% ][''G@":90*)@P\A\::#;U? @%>\5 M)/&'")X;G7B5_4VMH0_QA]=CS*R M!?I"&46"TV,[F9GR<]P2.)**-HEI0(%1$)8D'I?'>%!CKYUY'GX=/O[)AML9 MGGX=.O@I!MFY'W\=&U^/\+6LB93^2W6;X$%Z'XI5_QSI8UD >CF%J:5=3N;\ MH^P/?VH3BUJ];N:5]M@G-*VH! .<5?;K3X^N7& :A-MIH#Y(]=TROJ+ .7@5@H7:CCQ>&E_45A7)Y:]#WH8SG>+1G"X@G%\@/D]V/GY9@NR'K_!4_V]NR$6O3X _\CSR"^ M3AO_D'/%\4T0)[UU/_9[*7>O^^_WGM@&OV/MG<)L"MRE8GK^3FU>A>QL,35S M)S3#>M,-8^19Q8GVRG#TW4ZNB\; C4W_YHG!_)W:/#'R T$M]E.,D*/F3=-OJ2[#[!Z.Z1?^V2S$- MSC^\_?']6Q::Z6\.:!&X)V;[L3[IE2GE/0+'8[L-N2"*I>'5Z<"SA-(H"UER MQ'B&M!EMUS9Z38J0JO=MBR=,@F!$/'7!?I_6EZEXH0UM8Y2AKT]Q^,0\NWIE MDCHTOU0DXB5W;91)[[.%)&@^8!(=B/OG%&^;1BR88H0V9/C7LX12U73F@^XG M6)'PR>A>FHP4KZVVW@J<\>Z&=LKR0=GU^42NO )7=&W9C]HR$CF8=OAJBZHN M2^EB:_D2ZY8"/3A NS8V@K1V4DP([GU8I M2&Z".+I*SX--3!;K1B/NP8$Q:"M!9.,V(C@W= MNNHNH&@=1)'25(H$&[ (' M"K,A2*]"C@/G&;>X)',*CBZ"/"59?F%T"1TPC"^869>=0 WIW/I-;"B:B7!@ M5$$#6_L@YI=AN%UO^89DA%=Q&)> J[SM0Q%'<9#O[H($7Z_8I&5:X>GA@59W M?0*T5G8Z8/>K.C,GW1T; L7:"O'T!G@U)_'\.5B3'^_S("UH+Y\L-2[M;!"! M[,A:I)9!]6*YMRQ+EM0F=EV9&,6E_Y*P@=>'APG6^,X!*T7-R<]EEB39U^OT M9ON0Q.'U:H5S,@LHLP4+>( 3%AL!ZE,1$S#,248_1QV;N$I76;[FF]X;G-/I MFQX3E!DJA+70HP$R:%SN_KD0^[5QB@*T8H.]HGAL. ++QW-\A#!":(Z"KE/$ MD5"%!90^32['A#Y]O<'IIR#_&R[[_5D/"^#+?8S7?JP#A/%A,S>3^2_];4:& M0FLVEF.?'2@D!4<BAO; @8[*OLR'0I3 M(PUBKF-3-WE,DIX=6L4IL:TX2$A6)$H+4,CQ2<)$ZR>#HJ"91EP-QU[5+(,7 ME#$%7/#>Q8IOGY$^'A PE!;\BAT%( MFP"B0/TWT1!6V M?,IRLORGF\6&A9X) 299[Q=!3M;UT,Z3]3Y65+9$$)@1U2@+?O0 O>A3RV)< M]IE1?+(E_=+/!.^)/1D73BJ+$@8%N@*<2)2%61:'16-;VN8OB8.4\,<2C>O5 M*@ZQN6JL!PFH;,Q*E%;=F!'#?>&8!3O=*I0:"558B*-!5XY-*PVZ"ISN&2 M&?T*//6AETZV1 LU9WW7/=308)<^3,SO7?U0@4)< -'SH;I3P: EGP"_##*& M?5R!P][9ZS=P3PS;PJ"A#=G. GRQVX'?A%D.]9#.S?I/E:ZI7L5 LM;*A1@4S] "IJBK 0*X&Y,6L91G&SIMOP= M#K=Y7,:XN'@)DVV$HTMB:WQ>$@YI:EN^$C(: & WS9K1:D]^B@'\TGGS ?(?3A>&*=O?OO.A/SX#1A M6HDF.%30%(Q4G>+(O/HY2W'5-XX68XN6.OI2$7M<@"*1H8+5Y2&VB#"%(<.X M4]@7"J0&4E^?<(X?=B1'0A4IE.4H;2BCN. U^@GO?L0+07!5J+_:TKQJ@8KM MPW_CL*SZ(]%B$IIW9:P%5=55B7? #51=PZ2[ "@H"4RQP6&\BLF@&X)*1@@* M=A4WY&1:D5 M)M .C[U0K:V>?C3W>SZV/'5L3 )'-3SXDJV61R6-<=5FA0EL;_U"*>U-CP9G M;WT\=;?IFG=)-:8'NHJ;0K#%0,E@W:JXI8M.[67J8:C^.)9.K#[/VL?SPK74 M3%GZ5H%J;.@]_?&BU5 >.$]KCCT+BMBT*=^+Y5/NTQ&F/^^I43S)>?;X,>8[ M#!8\U[G)S1W5>-#>6M6V/% M*:!E*3_;+OW8T &.X-/)&K1DE;U2)Z'#:K(@SW=DKKG%FXP^3+!<9]NT'.J5 M@ZD 59^-$[95E3:,A/MJM3'\=..K'(SZH7Z1Q6O15EO Y* M?+T:/4<.(P%4+S="S%8QW0!\]Y5V@YGK'F,($K0'HN<3Y032JJ='+]8_]8]_ MBG%.#/QI]Q$_$S^Q6@89D<%70Q:B:19%!DS(M5$O6\:=K!H)?)FDW#SH"C=X M<]A PZ/=K#Y!>[>U= 3\V-\R]T27]7C)<[S:4#Q"W7RP C[Q*-]NR8&'E MG=TFL@H#V-OT0BA]JPL.YTDZ7DR&Q'$01_)E7]A:$ :"WL'9_D?BS?@I2Z*K M]2;/GKE;&VW?B %C^Q9"R+9O '=N^[V\*$Q&8" 9!=CR#Q$CEE 2YYH::$A M\9?^#E3:M,]@JYRI^J/[$J;VR-T#+_IW\*2;<6$N8Y,A +^PH62M^3/,5S8? M;/+O#%N39LLE>,KY*4[C]79MM,@]&!B;5#(J6V4+P+E=*D;OGI1R&&#;', I MH%D&+_UFV88!,DL5HRVSE '6J /*1*8WUVOT_AA6]3]:>F58YP6[+(;94=_U? P M>@#7#Z=00'TE\1!B,-<4#^=84?.Y(:RR79I8^[00O1B?%1 MTR!9YH"UM$+?4A+?,'#Z[V^^&>]K;Y'IUE4;Q*$30_%4[RYSRY8 QMC M;C:8BB>V92>LT>K,).#MT88_C:5>MRR5$D(R)72?(4X+.+>91N:6:&6O:!-T M)[-H0N9#K[&^EF)>= XS3]-6NVP73:\M1@NH_95=ERLO&EE9L@HWNWT0_=", M*?\^$,S 0$G\5:\GF5T@4K2L0H:T%#YFUMWU4.6 M%N_$&S$@WWPS"M%]\DT)#O3BFX$7W2MI-8H_S\9K9+%X0E"+XY4]]3TBJ$'P MQ:9LWMY3694'SPC.+8O3)I:87C%:IM$'>LTB8V])7+S0G=&>6F ;3+ &E[9" M[;6[[$.#:'YIQY.JGR3#9+OO$BX2R-!ER(<+1BL H@87SHE^QBG.@X2(LHS6 M9!E%GT*D9]"J8W4"EWE3&]L3AYI".-X?6\:6 M91$_?R2#DW^3?Y$?Z%[_O_]_4$L#!!0 ( "Q%:$U^5@Q?HBH $9! P 5 M >GEN92TR,#$X,#DS,%]P&UL[7U;<^,XDN[[B3C_05O[,A.QKO+] MTM&]&_*MQ[$NR\=V3^\\3= D).,T17IX<=G]ZQ< 24F4B!L)$""LZ.BR+>&6 MF5\F@$0B\?-_O<_#T1M(4AA'OWS9^[K[900B/PY@-/OE2Y[N>*D/X9?_^L__ M^W]^_K>=G?\Y?[@=!;&?ST&4C?P$>!D(1C]@]C+Z#I($AN'H/('!#(Q&IU_W MO^Y^/=X;[>R4E<^]%!6.HQ%I9?_KWN*;B[*A./IIM+?W[?3;_N[>Z>CDIX.C MGPX.1N/OBX+?T<"FD%LRA-$?SZBW$2(N2G_Y\I)EKS]]^_;CQX^O[\])^#5. M9JCB[L&WJN"7HN1/[RFLE?YQ4)7=^_8_WV\?_1Y"]KX6::ZNV= MG9U](]^BHBG\*27U;V/?RPB[N>,:44O@OW:J8COXHYV]_9V#O:_O:? %\6 T M^CF)0_ IB,R@)^RCU?PRY<4SE]#/'#RV4L"IK]\^?,CPBWLG>Z>'>SB^O]^ M64JX^CF.@JLH@]G'332-DSD9_9<1;O^WAYL%&;B=Y-G[ZL?S;_B[;V+-?.LZ MVL<,@0>W?Q%':1S" &/IW NQB!Y? ,A2@;&*--+#2.^]!'W] C+H>Z&28:^U MJ(>&Q8?I9#IY!0D1;6NVTUK3//;)]#&+_3]>XC! ]O#J7SE"ZB680A]FG2EA MMJU?)A=>^G(=QC^4B&2EL0HCD*;(6-Q"Q*< M<4K$U@@VI'#$C_E\[B4?2+1P%J%IR?>0B?/].$S#YNQ?FX#OP\-]$R%*#IK2@<(SW"7CU8'#U_@JB%&")3I!%2R[R!-NV<9J* MV7C9!I52$"-#EGW@*1!A\17S2'+$30TH'"&"69*#!4ND!K=15^&X+N+Y/(Z( M]90:4ZV>2JW'+9*E+.H!TRN\&N(VT;MMTFBCM-@JL:Z?O.=0"TU5P[JM;PL" MF.WT;(E;#%^F6@LR#H=S A=KK MW282=6I#3IOF>Z=NC/ZZA&&>P3?P"/P\@1GZ5!^YG/YTSP]M"&,WU/,,T88 MJ78USQ'MQL]H1]\LT6:HM";TK.K;C+"INO99K/G3.R_!#JHWT,K<=.K($,4E M+G33N]Z-=FHGK\3/./81D]%D_5N4 #]&L\"?N%B:I=A\DH+J*)?O4CL7'D": M)= G/C_T/75HZI@@W6/)@]<$I,B(DC9N$_HHW\6G3^ &<1]1MF=-P=KXZ45^^?QP?')R?[1V<'!_O'IV2[Z8V7$JV@8 M)_71>XE?]8%^K0%D\V2M+/'ME1R<[/@O,%S(?IK$T; MD%%%V!-JMD$TJU\/7R)<:DI!'!@4Q#U(8(Q("BZ]C"616CEW1,,GJY31H0$9 MC=$( SS*Z]";-S.*$O MX&JE7!$3GZA2.J?FU&KIP7I\07Q()WF&HPIQX"5=N1B57)&=-(VE*,\,+O^6 MIOP:?=)D'"DEAR\T&<*J7>VN<5$5"U8Q8:V4=4UWX[N+J]'CWZZNGA[EG'*K MR)MZZ3.169[NS#SO%@9%73212S0IT/!L]XNDB^)9G4 P45XCXT8RKJ43M5T$Z-J11# M(5#3";!TI9=Z^C%@U(C@PUTD",M\\S1%4N9QYH6VR+R*C[L/O6)+6P7)W0&Z MB:!7L101DNM,:0H5S2%O:&L>VV,/5DSA71SY3+O06-8--(B3IFA2L P&U;T\ MQGS@AJ 9M+AH^F^A]PQ#$D./;-SF16F.GT&TNG78:.MNZD2PAEV&8:/H M%:S#12?Y,N$B0KE6K\.!H9FCN,*3WGL?=.\$N[#-*!$1:\,L(TZGHYC MUPV MV4B'17-Y)Y$A0:J;>XZ+."(L^QUF+Q=YFL5SD%0,^6 C1:2J>Z!I3;6;FQ5A MN_(9#(J<)7%J<\-4"ZXW0["V>XCI0C@UP'G +O$5AO+MB'MPX!%'#9,>L.60 M=H0,R/6A>(MKW@=B'"WWU= )+U@A& TEK<-'9T2($JEU9VMLR;$(H6:&XJP5 M)*-M1 B_HGM@:4FSJCVL3;C9Y*7P"K3&H[U=!W A M2*.J36CCCN38^":T<=7>\H#6.HSH.X 3IU_5_,/>T?9\@V8[$ MK_.,_E+KXJ_;ZSU:MI>(R9.$##8@"^M[D)#+FD([3EIEZ\Q V_B,#N0Z),E*Q7 $&PEM.8X-&I8=MIV'4IN<80J.D,0-K2JN%@U#!(!)<6C!HN@D)F4='Y MR-0V,#!7%)32[H* OY;8S% U< #P%Q+".8:<@H+@$F(S)U97/.AW,M%>#!1R M,.VS\\4\/J$?WZ_NGAY'D^O1Y/[J8?QT@PJ8<"W=1(@/8#%4CC>)6MK(';Y" M+-%L\8(#>_#4\M8I*$R%BPCB8PXCD2,?9,]A(X=1R#BMMZ'4QWFV# MCZ+SB'.($*-0ZWFBH?/H!>7%%'P;IUP4+$M:AX,VZP@..:H4?T7HQO(_W,51 M7">[RI7#64@*51XT&MI3Z,AYPDV$1@#2K$;X*D?H261$JEH'C@X2WX1/:PZX MN B]CA, 9U%Q2\7_>$J\*$6L1(3]ZL$(&]IS,$5EGKQW"J D6G ;5UT9H775 M>F8&7E3>4L!$+>\V=.3([B=4KF>@@&RYMAN_>3#$.1J>XA6O;AE#>.ZET*?! M1ZX5ZT EL0A20:J&^\,W9$YGX"Z?/X-D,B5L6#D0$H-(N\:&C!R%%&L[;^_Q> U1OA&]OG9S MB'/8=B!XV(;/VAZ?)A?__;?)[>75P^/HZO_]=O/TC]%?+J^N;RYNGDQ'=K>X MG"U0%P'GZ.3HZ.SX^.3X^!3]NK]OZL9/.=HG/(OR2"*%ZJ#?,Z_F[3F^:0<$ M2&7LAJNUI&EA%J3CMY?C"!^6C]\AS6'*K&.OJ.GB88F;AH+NPD("1( M=>209(U9E_$<,8#F#&@JZR0.Q"EUY(K%@FEH3PANT*_<)>"BH+T :+7N8]-% MM?]F#CC]!'@IN 3%SYMH4< MH>.CQTRWJTE(+KSTY3J,?XCF(#F4R4%R,7[\V^CZ=O*[D1PD*V%U"RK%8Q\; MJAB:\/%([I/X#2)YG'_\AA9(-]'B7NW8S^!;D;&939I\0W5%V#>_=! 1Z-JB M0 7)CH1?(39,8<98-RX+6"=Y19+/4FM[,;R1BGP8@MH"^BE68W-T M=/5YL-D;]QAG?H:CA2\!$J@/B3@I&%LM8ATV>A/A)GJX?''QJ>SJTES=A\3: M\FP4WF*H%8?1G-A1L8(L[95RSZT4TO"?'^#K=/3O8)>C" MGS30Z"-6PSJXC@LRZ'6Q)*;Z VD M*@[Y& U]6KS)\D3#(S3&W>MH55#%Y/G_RF$"$),0L[./^]"+,K1WP4$5),4_ M[42D#T"07B.6XEL9^&GXR70E7Q-BQF1:?7,1IQLN MU+;-U'EV8!Y'BL2^YOY2Q1D7C[&K)429#Y"%,I$J[B.J-1?4.M^?&D%DZ%[R MJH(1;DP(<>G5.TA\F#+>,N?4^T1P:L4*NXZ?^UY7=5Y/?1YX=>2)AB3PQO>) MF!_X?[Q'?O-";,N7=U_Q%VC_7/]@I61Q-[ A)B#, _+JF/_B13/P@$SUU70* MJ&O_?@=A'=Z5[QLLX&>I*V+YZVM([I-Y876?["::QLF\@ #GJJ!8;?=M8A=&5-BR MY,%?BB^PBNE;+,R)/P$Q$C\8%YSGV5V<_0-D.)M%DP]0HKIU:.DBW#6'7U#PYF7D1_),P:IFN ,F"NY7F#B9EB;$"Y>9#'AO*ZMIVXCKK01 M.4VCP=-<;!L%K;,,2D5<T*" M.D>=_T';8 A5MD[%^4*K;1[:$SDT7;[V8$*2U7U'VR[T]WS5S<%1W8--U<7- MC4A[HUJ#)IXBKRA;#I"GJ>PJ1MY3;Q@13T69=>J@/32OF2)BJCV++DW=T%2R MO+-7WM5+J\MZQ4/P6?UB)$=##S M[J[@GR H!UV_M[@DBZ/6G5LUH?F;,N?I/:.&=5JO2-"KAD&6_.&9A2)@NRD MGF,&CIK,0-$:4?]E>V8B@IH#T3E:+5#/4(!3\["6[.'V_J<=G08CHWM"->NX-9F6'NQIA73XG[>[,?OBZ*5[1. M X7%L?!GMZ=S:'JW$LDMJ',GFSI7-#(J6K$BP?9=G/$6P;Q*=F0*QV,2GRB% MZUNGHV(B9*<,EZ%5RYM$>IW,F%YJTCR.TIXV.)5Q>SNDP5&M11/;W,7 R-V2 ME65=I!N?(T-%B%NJ%ZNPX&IK,!8C1$(JD*KL?:$R<*:+8 M+5H8J*154:KABJ )%7] 8D(LQD'EE^ -A#'Q))8.LH(/%+T7J#E0B'2E4$,V M/A/0N/*2"'$*7]\BRUNQI0&GUL AT88Z#>GTS-P?_K'"JR2.T*]^$;$BLW24 M;6;@@%%"KH:'#RW8+3[A"5=LKWB ]HH'7?:*15_;G6(KQ[/_ H(\1 OC,1I5 M ,,@9\GY/CCZAU?Y 4!3K& _2-Y%0"\;BRY'FKE'0W<>/3$D*$YHQK# M,*6LR<&F-:$$8QHU'6Y%919Q1B5S@TGT@'&,GTDGCA;A0$W!9JQ3_=:QFUT( M'IIJBX1S2FGZX::F"P=U&M7];71G5U9P3[XZ-FN=A=$0)ZJ%1\,S2IO!I%)& MZ*C)"#6%E!JU.)\EMK1U1*F]FJ\VCM0M[5V+'I52W.--Q5V/(37M6[ CF%2Y MIV%C@(3+$AX$3@/6J;!4(*HB>H>FRLUA;E(:?=K@1Z0$NYE=_F^CWM8AOCIB M/-3K.-D(NQHG"=D I0T+SV.Q3I+I3["SAZ^.A*X MLV1H,U-6,R&7*6H_)#6@;<.?"LY*F60\\$@?-BO-_N$EP2IWL/^SP$*:YO/B ML]8X;=_))\6L8H8Y$C'%T^YE;D["L]\BB#B/6:C4T$KV\DD1K)ICVB*[#&2> MNP29!T.Q?=-AFP1TH[^471C90&U3T5$RYCZG2#HX.B+=J&R<"3"'(M!L1S]G3='OSZA77^*E <-\#*>>S"BH8-;T6*8B,BL M0>;M2#;N[*#<9+F.PS#^,8GN\^<0^I,I&@N,9M_!_!DD:T+GEK=/UNUDM11Z M.Y)ME?4$K<^_>\D?^*5 GIQI91V5L12YKCB'FBPAVOB &[2$DEH/+"K9APY+ M%@5L#FG-N&YH3?& ]Z,1"*KPZ+'OY_.<.!PNP13ZD+;AXU>T&&7"(M_$34NZ M-3^ KNI1D._>.YSG\_%LEI">2+1M[0';RO VS4;BM=W"A@KBM1H74V\15<_5 M(MW(,>7%LW?$&9G>@1_D*^H4)E39+2 IH-W%=UH+N@M^W"?0!]4E'AIT:.4= M18L4N1H<]AT>6*7,0[\#.'M!$]WX#23>#(@"0*JN6V#H3KJ&2]G&E[>K;UU7 M[Z;7YF1ZP#.[GEO@Z4:VHKO8]>2 2^B<*;(I7.+NL%NA^H8JF?7 >2.UKN]*@1*EQQF9BC0'-$XC8I4& @Z& M;#?AT8)B1P!"S0)Q_O&$^F;,%@(UK8&*VFFC+>6,XTKS1P>47""H9^8T(E#3 M&A1TE9\$$CC4.V(\BJ23(%F0S9Q6**6' P^.4#?A(4.Q(Y 0@\+G@8"$Z(<> MO'N=)Q'$=P(1PZ[A._XM9:* 7L%A0$@2;?S6=)L#IEM*Q+9$36L0H&;IV)5R MK8%,J@)JJ:XWRFFH6*4!(8$M0U%')9-P#^ MCI/F-U7*]*+IRP.8YE'0!)..3=H%HG:B7\./#HX, EW-Y"$^+MA*AY%H70?Q MTHETK1'[!XJ 43W<%JQ05'&J"0RL\@X"0)I'UJJS!@JJE:?LUC@._S7&Z\SR,;!]OE.>2=$1[#3O5(T"A=C,*9 MT%@$D:.S4X20TY/=L[V#P_TC4U>TE+W+Q$JCI+03:\Q,2S%O6I<>^&-O4&A' MDL\_FAM@G/9J[-$Z;/8 K880A)X9/#1P-6L@UG?$A?%'(=EQ@\J:1O! M^6L8?P"\([J+(U#^M9JXEAX[*UIW(!CB2'!]&]B%>.-H4)4:II8=EGELV5C6 M-63($^O(*79'JTP[^E3=O'5X&^*BB(XW;7J@7;1M':ZU0DPY MHAE,U'JV=ZC9#=?XYK.='PG6C$G[/42+.@^_UC1W>L$_"L'D?_!<&4)U+07%5JD MS$"5)(\&@)IB.)8&:]N)%4GX,)$A2[XACH''AL5 S=GBS0%5[@2,I;C'@ M")'O&G)J*D@LL?3DM*AE+UZ,3DQL_MA[;_L^3HBLL@59#[$C( MLB',I",''#$W%UZ2?""->@"OB"$@*#P!LG"2;,4Z2'4%PR:\5'#$$8A5<5N3 M:6MS)=/$)P!79W8XU7HPQ--'B*T*($_@'OL?QYH4UF[%< MK%(WEH+UG<0G&R]-F\XNW-)ZTJ_JA8(+@#93^$(+WOUT!D!)W_]4% !%&"]NMZCE/S6VVG%'U7WB.//"WB.0[A/PZL'@ZOT51"F^ M\1>0AR?*I,(%(^0"D@XW Y+*3D95+R,O"LH'+LJ.1D5/9D.4+DMQE2DE7B$2 M"/P3O[M$AE_QIF3*@D!.%%/G5A6]G$-Z0S]\5!A9SO I@5Y82:1I.N)4LLYDR1VUH<-6TMBD;)EF+1K-E]!#5##&>G(%#/;%X0 M>KI8H8P?[.IUC.^;5W5A,3;G[VA!K;UAYOV]IV"#Y#L)L\2[H>5G + M&))$&W]800TV;H&7@IB6$\/-KV@=#/IR[K$YH/41"MN\@OV\ M,F !MEJ"00)5PFS0&BUMVS,6OR9Q*HTH4ND30HA.MZ+9K!Z@TN%!/F5O->3S M/,1*@!5,5=;$E3K.-Z.GRO:6%S-,/ZJ$1[-ROZ>ZAL)]6XE7S]"Z M P_KT0N]9#DF-@UKA:W35&$1K^\#>X@8\FXJYX!1R1!Z7D=F8GFSNSHJT1:2_Z,7 M"R?3)[2?2I'RX-,0UJT9?D6+82(BLP:9MR/95@?2=1R&\8])=)\_A]"O<@70 MGVYEE;=/UNUDM>97WB/XX(*^JIG?@!_F*:H2$*KL%) 6T M:S4S1X9P1.@N^'&?0!]43_/2H$,K[RA:I,C5&OQM""#W2>P#$*3X+6?,!YP; MKV9ZZ6%K['IN J8=V8K.T&CA2ZJ28'.)N\/K_^J;IJR";9MQ"RQ*N:#J[,W( M0^G%SL%+<>*U.0X?(0TU?WKG)8F''YJ7.X0YW3R$(>WOD Y&JSU47XT:OEKT M;CB7\8(.@I7%^!X B<,F,"$3U#,FX=[[(#?'>:F,.S6*4'ET[Q_>GAV M2(<\7>@\,-&G#D!-$O M-,+T!;X^Q5<1FK38C[])MF(=K1P-7\-XP] 29345,1^T;80 MS]H2681DXQ)5M:Y+@(_:9N9AJ!=R' $21#MRH(2O2>$S.%;6U94BULF_[V4! MEQGVYDFJAL[.J5HK9)VXN>RG2VR ,_1X3MP+XPC??LGPK@B5.9S,(_B1 MCY@%W\ JW#&Q].F\2WO60D%\:E=.OG'<*+J&0(P@._5VK8QU6.A[%N!SP][W MP-MS:$EU% A-)CJZL@Y[?"Q0COCZ8(QQ"\79>Q8O+(+RKR*L@HQ18%/*JVL= M4GJ3.F5+VXIAQA&D:/$+DFF##>5L 529G.=(B7W37_';+.V")8QMDW1\NEQ1+A<>T8S9[>\H/G. M#5L'H[YG 4TLU!I\)#WQ4#8X3^C;E#RF$/D)?EA!@.DT=MSE6(O+!M)QGKV@ MP?ZY##M:W1SUT:]]P-8#M+5ME#'6VG67@ =XM#' GE1OMG9;(L_2S(L"&,VN MXV3)0AHG4"$N=YD*T.,X/KM"F&:UUDL2IB[;=#4MXR" !1\X\T8//7X^!3'% M5*W704SEO]"\<-+6SQ;VO2R,5*:!,_XN@2K.O7DPQ'LU-*F23(N:,;_>W1;Z MO7#4KKVP80TH#[.*Q*(W47')EO6MKC7S4P-F?R6D#\V"/EG/N^>UWEW M]?X*DR)4B;"-!705[=Y3BZ6Z#YS#MUM;$.Y MSL-L VN;'=56G='5)T=[']RLSJMV[8 ]Y1)Q]=>AFX]F!"$H8U MG5#UTO'G@[EAWE:@UWQ*:T%.E/+-'=F,* >R&5&:OBK[WN9#:4B'<;I_WAP?+RW?W!@*K?;,/.A6& @-0"@80V@E7WVYD/I=,W9 G#HE5M#=#^/&?:+ MNO4U9PO$S64_76(,BHR'_ [NFK-%4&#(=6T-K)Q\X[BQXIJS!5CH>Q;@<\/> M;!?M.63A-6<+L,?'0@O_JBK&&+=0UEQSM@ IO4E];=[KQ##C"%)T@1'-^ GT MT9Q/Z&9?96PJNT53&P8Y!,2K M.12@R,XKK>AV!#"_@@@D7HBH'P=S&$'LP,8>"1'("-5U$C3M*7=D<=+] +FG MF_X6 *[OI8XF%FJ]WV-H+34.2>,@:.99J1*>P[)S*,VI=]C[*.9 @WCMR@!?CR+\(4Z8COX M]M&2 _]6L1T6@$.OW&1B.P8CZM:Q'1:(F\M^N=@.MWPLF(CML,5"61/;80%2>I.ZDM@.6Q!D MY9N>-J"IYSE/G"OVGL5;\*:G!<@1EZ0 "EK0[HA)Z?P"I(U0:"'.39 ($.T( M!@9SKFH!UOJ>L#2QT,5SU:XWOU>2%3_$87@=)_A+U=!F=F8?W/7 3R'.Y?FI M-9FZJ8,Y=>PKTGOHAWW1CSN(EP>B5BU@L%>1 KR2#!F/F9=D&VIP,DPUL"AQ MZ%85^F&PUI<#AI9^KN3=,F'E@H&:U*"AIZT:J%0#409W?37@K%"#",SPD:0K MBF#3LFAOJP6Z^:MH5UPLC*ZB3348Z++HZATD/DRQVT*K&FSTLYT+U,X%(NS5 M^J# 0+?'1>++<813>0-\'?@IQA_U-3V(=K]5%Y7JTHGKSKY1H$::OP.<&AQQ M]PTDW@R4E@G<)] '6-+3OIRO@@-Q1[,,.F:[\%KK-GV@LY(@:\TJ45V:)P/6 M'+6 -J9IC0+YQ"YAZC%MHR-1AZ*I&\%6V90IFV:A?$JW,X^G#./;SF%Z?/0#]2[R MW;4&M*[;H+;*:(^OOZV.ZCD!&.@ZMMQP& MJFV469Z^$J>QG/DHLQ4#W.JF!MW4+!ZM9P*GPUPQKIC#&\1"&*70;WI75WM_ M6X72ZV<4X/9V XU1 -4XXDNQ7YWKDYC/M5DBKWSR-(WJ / MFN5Z%T=OQ?R,V9>2E[M7O\UBD'EY-'T31EU[ZWJI.@^J8X[Q6 M][JA[ C:N%D;?/H=Q%:K^M0J<1$XZQGO,,\O.+ZV@R1A9I=> M!JX]F)")7\1=WNM W%&S5CYT\[S>)O.1#,_]'9FK=2/E M@HH\P/2/ZP1@WPY ^,L>D-7I0T&:^G5'/3JB5K/^"/->\X-D)D^$VJPIFGBY M.(C3<2C+[7"K,6R-Z8_IV^O!@BS\>XS3(H>(KKZFFN:>MZK3SV0CP7VMQZM# M'F)TXR#*.A;@U;[W>I/O_K#Y;U6)]QB!NKU[5C\P%@",?7D>^H;LK)/ MQQY)/!V['$-1BOF&[/;AV(9W0T^.CG>/=X_.CO2;5Q,*M)W^%55?_RM&X;R*D M]CD1W"1[ M!ZEI?/6OU2#JLCVS0#WTP%6A7JCCL];HO@-G=4C/.PBR M_;NC.>H ;43+&.+H(>7TT"($N7RMARWWKF7U[K=*9E;)!*2A*"S*LNO ^EA: M)/@PIE_U[K?Z95:_!*2A^=7$H67B'/0R\6!WJV$6+1,K<6C/)NW<)"9^ZV*G=+)7>.FE:[\OMT^XN=]^W M*FZ?BJN0YW;J;N\9L$_#)<>WU7#+-5R%/)U-GKI=G$O@8*@/ICFJV%UEJ=TY M9L@#K2_UYZ*EHM*Z0"C:;&P\VZE9B0;;)3^M69$,):OX[.EEM[IIG6Z*"\VN MA+24ZW"MI;LN3.H3=XV'LKWVO56I3BIE7E:E)IUHT:3%YJ4Q"\;/WS ?\"WX M__Q?4$L! A0#% @ +$5H3<_Z+>ZUD@ ,LH, !$ ( ! M 'IY;F4M,C Q.# Y,S N>&UL4$L! A0#% @ +$5H349$2'-D4$L! A0# M% @ +$5H305%@5A,"0 0'< !4 ( !X)T 'IY;F4M M,C Q.# Y,S!?8V%L+GAM;%!+ 0(4 Q0 ( "Q%:$V.N++FI1< )6Y 0 5 M " 5^G !Z>6YE+3(P,3@P.3,P7V1E9BYX;6Q02P$"% ,4 M " L16A-M%&G53Y !-QP, %0 @ $WOP >GEN92TR M,#$X,#DS,%]L86(N>&UL4$L! A0#% @ +$5H37Y6#%^B*@ 1D$# !4 M ( !J/\ 'IY;F4M,C Q.# Y,S!?<')E+GAM;%!+!08 ..!@ & (H! !]*@$ ! end

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 05, 2018
Document And Entity Information Abstract
Entity Registrant Name	Zynerba Pharmaceuticals, Inc.
Entity Central Index Key	0001621443
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		17,626,873
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 66,177,376	$ 62,510,277
Incentive and tax receivables	3,095,195	3,983,604
Prepaid expenses and other current assets	3,413,029	1,733,701
Total current assets	72,685,600	68,227,582
Property and equipment, net	248,741	164,527
Other assets		662,200
Total assets	72,934,341	69,054,309
Current liabilities:
Accounts payable	3,553,350	3,355,255
Accrued expenses	5,415,742	3,915,491
Deferred grant revenue	171,975	171,975
Total current liabilities	9,141,067	7,442,721
Deferred grant revenue, long-term		662,000
Total liabilities	9,141,067	8,104,721
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 200,000,000 shares authorized; 17,623,873 shares issued and outstanding at September 30, 2018 and 13,553,873 shares issued and outstanding at December 31, 2017	17,623	13,554
Additional paid-in capital	173,877,449	138,916,900
Accumulated deficit	(110,101,798)	(77,980,866)
Total stockholders' equity	63,793,274	60,949,588
Total liabilities and stockholders' equity	$ 72,934,341	$ 69,054,309

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	17,623,873	13,553,873
Common stock, shares outstanding	17,623,873	13,553,873

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating expenses:
Research and development	$ 4,859,902	$ 5,753,764	$ 22,368,881	$ 16,978,016
General and administrative	3,125,780	2,795,839	9,982,743	7,640,489
Total operating expenses	7,985,682	8,549,603	32,351,624	24,618,505
Loss from operations	(7,985,682)	(8,549,603)	(32,351,624)	(24,618,505)
Other income (expense):
Interest income	278,214	161,930	639,702	363,350
Foreign exchange (loss) gain	(99,897)	76,468	(409,010)	361,450
Total other income (expense)	178,317	238,398	230,692	724,800
Net loss	$ (7,807,365)	$ (8,311,205)	$ (32,120,932)	$ (23,893,705)
Net loss per share basic and diluted	$ (0.47)	$ (0.63)	$ (2.21)	$ (1.87)
Basic and diluted weighted average shares outstanding	16,587,353	13,098,914	14,531,272	12,743,332

CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (DEFICIT) - 9 months ended Sep. 30, 2018 - USD ($)	Common stock	Additional paid-capital	Accumulated deficit	Total
Balance at Dec. 31, 2017	$ 13,554	$ 138,916,900	$ (77,980,866)	$ 60,949,588
Balance (in shares) at Dec. 31, 2017	13,553,873
Increase (Decrease) in Stockholders' Equity (Deficit)
Issuance of common stock, net of issuance costs	$ 4,062	29,933,443		29,937,505
Issuance of common stock, net of issuance costs (in shares)	4,062,500
Issuance of restricted stock	$ 7	(7)
Issuance of restricted stock (in shares)	7,500
Stock-based compensation expense		5,027,113		5,027,113
Net loss			(32,120,932)	(32,120,932)
Balance at Sep. 30, 2018	$ 17,623	$ 173,877,449	$ (110,101,798)	$ 63,793,274
Balance (in shares) at Sep. 30, 2018	17,623,873

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Cash flows from operating activities:
Net loss			$ (32,120,932)	$ (23,893,705)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	$ 25,043	$ 24,773	73,195	68,368
Stock-based compensation			5,027,113	4,266,716
Changes in operating assets and liabilities:
Incentive and tax receivables			888,409	(4,013)
Prepaid expenses and other assets			(1,017,128)	(914,554)
Deferred grant revenue			(662,000)
Accounts payable			121,583	1,154,109
Accrued expenses			1,500,251	194,385
Net cash used in operating activities			(26,189,509)	(19,128,694)
Cash flows from investing activities:
Purchases of property and equipment			(157,409)	(91,070)
Net cash used in investing activities			(157,409)	(91,070)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of offering costs			30,014,017	54,245,579
Payment of financing costs				(175,011)
Proceeds from the exercise of stock options				434,691
Net cash provided by financing activities			30,014,017	54,505,259
Net increase in cash and cash equivalents			3,667,099	35,285,495
Cash and cash equivalents at beginning of period			62,510,277	30,965,791	$ 30,965,791
Cash and cash equivalents at end of period	$ 66,177,376	$ 66,251,286	66,177,376	66,251,286	$ 62,510,277
Supplemental disclosures of cash flow information:
Deferred financing costs included in accounts payable and accrued expenses			$ 76,512	89,621
Change in property and equipment acquired but not yet paid				$ 24,286

Nature of Business and Liquidity	9 Months Ended
Nature of Business and Liquidity	Sep. 30, 2018
Nature of Business and Liquidity
Nature of Business and Liquidity	(1) Nature of Business and Liquidity Zynerba Pharmaceuticals, Inc., together with its subsidiary, Zynerba Pharmaceuticals Pty Ltd (the “Company” or “we”), is a clinical stage pharmaceutical company focused on the development of pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome and refractory epilepsies. The Company was incorporated on January 31, 2007 under the laws of the State of Delaware as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $110.1 million as of September 30, 2018. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company's primary source of liquidity has been the issuance of equity securities. In June 2017, the Company entered into the Open Market Sales Agreement (the “Sales Agreement”) with Jefferies LLC, (“Jefferies”) pursuant to which the Company may sell, from time to time, up to $50.0 million of its common stock. During 2017, the Company sold and issued 296,594 shares of its common stock in the open market at a weighted average selling price of $10.74 per share, for gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018. In July 2018, the Company completed a follow-on public offering, selling 4,062,500 shares of its common stock at an offering price of $8.00 per share, resulting in gross proceeds of $32.5 million. Net proceeds received after deducting underwriting discounts and commissions and offering expenses were $29.9 million. Management believes that current cash and cash equivalents are sufficient to fund operations and capital requirements into the first half of 2020. Substantial additional financings will be needed by the Company to fund its operations, to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

Common Stock	9 Months Ended
Common Stock	Sep. 30, 2018
Common Stock
Common Stock	(7) Common Stock In June 2017, the Company entered into the Sales Agreement with Jefferies pursuant to which the Company may sell, from time to time, up to $50.0 million of its common stock. As of September 30, 2018, cumulative shares sold in the open market under the Sales Agreement were 296,594 shares, resulting in gross proceeds of $3.2 million. Net proceeds after deducting commissions and offering expenses were $3.0 million. No shares were sold under the Sales Agreement during the nine months ended September 30, 2018. In July 2018, the Company completed a follow-on public offering, selling 4,062,500 shares of its common stock at an offering price of $8.00 per share, resulting in gross proceeds of $32.5 million. Net proceeds received after deducting underwriting discounts and commissions and offering expenses were $29.9 million.

Nature of Business and Liquidity (Details) - USD ($)	1 Months Ended	9 Months Ended		12 Months Ended	16 Months Ended
Nature of Business and Liquidity (Details) - USD ($)	Jul. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Sep. 30, 2018	Jun. 30, 2017
Sales of Stock
Accumulated deficit		$ 110,101,798		$ 77,980,866	$ 110,101,798
Proceeds from the issuance of common stock, net of offering costs		$ 30,014,017	$ 54,245,579
Follow On Public Offering
Sales of Stock
Shares issued	4,062,500
Offering price per share	$ 8.00
Gross proceeds from issuance of common stock	$ 32,500,000
Proceeds from the issuance of common stock, net of offering costs	$ 29,900,000
Open Market Offering
Sales of Stock
Maximum aggregate value of common stock available for offering						$ 50,000,000
Shares issued		0		296,594	296,594
Weighted average selling price per share				$ 10.74
Gross proceeds from issuance of common stock				$ 3,200,000	$ 3,200,000
Proceeds from the issuance of common stock, net of offering costs				$ 3,000,000	$ 3,000,000

Summary of Significant Accounting Policies - Other (Details) - Australian Taxation Office $ in Millions, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2018 USD ($)	Sep. 30, 2018 AUD ($)
Incentive and Tax Receivable
Aggregate revenue maximum to be eligible to receive a cash refund		$ 20.0
Research and development tax incentive refunds	$ 3.6
Incentive and Tax Receivables Current
Incentive and Tax Receivable
Estimated incentive receivable	2.7
Estimated GST receivable	$ 0.4

Summary of Significant Accounting Policies - Anti-dilutive securities (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive securities	3,166,031	2,514,268
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive securities	3,158,531	2,369,296
Restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive securities	7,500	144,972

Fair Value Measurements (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Carrying value
Fair value on a recurring basis
Cash equivalents (money market accounts)	$ 62,316,686	$ 61,133,457
Certificate of deposit (included in prepaid expenses and other current assets)		20,171
Total	62,316,686	61,153,628
Recurring \| Fair Value Measurement \| Level 1
Fair value on a recurring basis
Cash equivalents (money market accounts)	62,316,686	61,133,457
Certificate of deposit (included in prepaid expenses and other current assets)		20,171
Total	$ 62,316,686	$ 61,153,628

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Prepaid Expenses and Other Current Assets
Prepaid development expenses	$ 2,376,965	$ 907,028
Prepaid insurance	535,722	355,838
Deferred financing costs	195,754	240,439
Other current assets	304,588	230,396
Total prepaid expenses and other current assets	$ 3,413,029	$ 1,733,701

Property and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Property, Plant and Equipment
Total cost	$ 485,024		$ 485,024		$ 327,615
Less accumulated depreciation	(236,283)		(236,283)		(163,088)
Property and equipment, net	248,741		248,741		164,527
Depreciation expense	25,043	$ 24,773	73,195	$ 68,368
Equipment
Property, Plant and Equipment
Total cost	85,417		$ 85,417		85,417
Equipment \| Minimum
Property, Plant and Equipment
Estimated useful life (in years)			P2Y
Equipment \| Maximum
Property, Plant and Equipment
Estimated useful life (in years)			P5Y
Computer equipment
Property, Plant and Equipment
Total cost	30,319		$ 30,319		30,319
Computer equipment \| Minimum
Property, Plant and Equipment
Estimated useful life (in years)			P3Y
Computer equipment \| Maximum
Property, Plant and Equipment
Estimated useful life (in years)			P5Y
Furniture and fixtures
Property, Plant and Equipment
Total cost	300,407		$ 300,407		199,016
Furniture and fixtures \| Minimum
Property, Plant and Equipment
Estimated useful life (in years)			P3Y
Furniture and fixtures \| Maximum
Property, Plant and Equipment
Estimated useful life (in years)			P5Y
Leasehold improvements
Property, Plant and Equipment
Estimated useful life (in years)			various
Total cost	$ 68,881		$ 68,881		$ 12,863

Accrued Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accrued Expenses
Accrued compensation	$ 1,786,098	$ 1,503,615
Accrued research and development	2,490,658	2,059,536
Grants payable	661,952
Other	477,034	352,340
Total accrued expenses	$ 5,415,742	3,915,491
Deferred grant revenue, long-term		$ 662,000

Common Stock (Details) - USD ($)	1 Months Ended	9 Months Ended		12 Months Ended	16 Months Ended
Common Stock (Details) - USD ($)	Jul. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Sep. 30, 2018	Jun. 30, 2017
Sales of Stock
Proceeds from the issuance of common stock, net of offering costs		$ 30,014,017	$ 54,245,579
Follow On Public Offering
Sales of Stock
Shares issued	4,062,500
Offering price per share	$ 8.00
Gross proceeds from issuance of common stock	$ 32,500,000
Proceeds from the issuance of common stock, net of offering costs	$ 29,900,000
Open Market Offering
Sales of Stock
Maximum aggregate value of common stock available for offering						$ 50,000,000
Shares issued		0		296,594	296,594
Gross proceeds from issuance of common stock				$ 3,200,000	$ 3,200,000
Proceeds from the issuance of common stock, net of offering costs				$ 3,000,000	$ 3,000,000

Stock-Based Compensation - Stock Based Compensation Narrative (Details) - 2014 Plan - USD ($)			1 Months Ended	9 Months Ended
	Jan. 01, 2018	Jan. 01, 2017	Jan. 31, 2018	Sep. 30, 2018
Stock-Based Compensation
Threshold increase of authorized shares for issuance		1,500,000
Threshold increase of authorized shares for issuance (as a percent)		10.00%
Additional number of shares authorized for issuance	1,355,387
Shares reserved for issuance	4,804,869
Shares available for issuance				1,150,545
Stock options
Stock-Based Compensation
Granted (in shares)				837,930
Contractual life (in years)				10 years
Performance-based Stock options
Stock-Based Compensation
Granted (in shares)			83,280
Contractual life (in years)			10 years
Shares options vested based upon performance-based metrics				0
Aggregate fair value			$ 663,484
Employees \| Stock options
Stock-Based Compensation
Vesting percentage				25.00%
Vesting period				3 years
Board of Directors \| Stock options
Stock-Based Compensation
Granted (in shares)				6,030
Board of Directors \| Stock options \| Maximum
Stock-Based Compensation
Vesting period				1 year

Stock-Based Compensation - Options Activity, Unrecognized Costs, Valuation (Details) - 2014 Plan - Stock options - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Options
Balance (in shares)	2,386,538
Granted (in shares)	837,930
Expired (in shares)	(65,937)
Balance (in shares)	3,158,531
Options exercisable (in shares)	1,709,384
Options vested and expected to vest (in shares)	3,114,781
Weighted average exercise price per share
Balance (in dollars per shares)	$ 12.53
Granted (in dollars per shares)	11.50
Expired (in dollars per shares)	13.76
Balance (in dollars per shares)	12.23
Options exercisable (in dollars per shares)	11.12
Options vested and expected to vest (in dollars per share)	$ 12.22
Additional disclosures
Options Outstanding Weighted Average Contractual term	7 years 9 months 4 days
Options Vested and Expected to Vest Weighted Average Contractual Life	6 years 11 months 12 days
Options Outstanding Aggregate Intrinsic Value	$ 2,290,510
Options Exercisable Aggregate Intrinsic Value	2,287,810
Expected stock based compensation expense	$ 11,100,000
Recognition period for compensation costs	2 years 5 months 9 days
Weighted Average Grant Date Fair Value
Granted (in dollars per share)	$ 7.94	$ 13.08
Assumptions and Methodology
Weighted average risk-free interest rate (as a percent)	2.51%	2.11%
Expected term of options (in years)	6 years 1 month 17 days	6 years 1 month 17 days
Expected stock price volatility (as a percent)	78.00%	77.00%
Expected dividend yield (as a percent)	0.00%	0.00%
Board of Directors
Options
Granted (in shares)	6,030

Stock-Based Compensation - Restricted Stock Activity, Unrecognized Costs (Details) - 2014 Plan - Restricted stock	9 Months Ended
	Sep. 30, 2018 USD ($) $ / shares shares
Restricted stock award activity
Unvested balance (in shares)	108,730
Granted (in shares)	7,500
Vested (in shares)	(108,730)
Unvested balance (in shares)	7,500
Weighted Average Grant Date Fair Value
Unvested balance (in dollars per share) \| $ / shares	$ 1.65
Granted (in dollars per share) \| $ / shares	12.99
Vested (in dollars per share) \| $ / shares	1.65
Unvested balance (in dollars per share) \| $ / shares	$ 12.99
Unrecognized compensation expense related to unvested awards \| $	$ 25,792
Recognition period for compensation costs	3 months
Unvested restricted stock awards expected to vest (in shares)	7,500